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ABSTRACT 
DISTRIBUTION OF IMIPRAMINE, DESIPRAMINE AND THEIR PRINCIPAL METABOLITES 
BETWEEN PLASMA, RED BLOOD CELLS AND BRAIN IN HUMANS AND ANIMAL MODELS 
Stuart Chapman Bogema, Jr. 
Medical College of Virginia - Virginia Commonwealth University, 1983. 
Major Director: Robert V. Blanke, Ph.D. 
An HPLC prodecure was developed for the simult aneous measurement of 
imipramine (IMP), desipramine (DMI), desmethyl desipramine (DMD), 
2-hydroxyimipramine (2HI) and 2-hydroxydesipramine (2HD) in human, rat 
and rabbit blood and brain Specimens. The HPLC results were validated 
by comparison to an established GC-MS method. 
DMD is a minor metabolite of IMP and DMD in humans. 2HI is a minor 
metabolite of IMP in most humans. 2HD reaches appreciable concentra-
tions in blood in humans treated with DMI and IMP. Plasma and RBC 
concentrations of IMP and DMI were compared to improvement in depression 
in patients treated with IMP. No good correlation was found. Plasma 
and RBC concentrations of DMI were compared to improvement in depression 
in patients treated with DMI. Plasma concentrations (r = -0.750, p < 
.01) and RBC concentrations (r = -0.693, p < .01) correlated with im-
provement in depression. As plasma DMI increased past 400 ng/ml, the 
degree of improvement declined. 
In autopsy specimens from an IMP overdose, IMP, DMI, DMD, 2HI and 
2HD were all measured in whole blood and brain. In autopsy specimens 
from b/0 DMI overdoses, DMI, DMD and 2HD were all measured in whole blood 
and brain. The brain to blood ratios in all cases for IMP and DMI were 
viii 
significantly higher than the brain to blood ratio of 2HD, the most 
polar.metab6lite. This finding indicates that 2HD has restricted entry 
into the brain compared to IMP and DMI. The distribution of 2HD between 
plasma and brain was studied in rats. The mean brain to plasma ratio 
for DMI was 5.87 and for 2HD it was 0.067. Therefore, in rats 2HD has 
limited access into brain from blood compared to DMI. 
In rat studies, both plasma and RBC concentrations of DMI correlated 
well with brain DMI concentrations. In humans and rats, the plasma to 
RBC ratios for IMP and DMI are significantly different. IMP has greater 
affinity for plasma than RBCs. DMI is the reverse, having greater 
affinity for RBCs than plasma. As indicated, for DMI treated patients, 
plasma DMI concentrations correlated slightly better than RBC DMI con­
centrations to patient improvement in depression. 
ix 
INTRODUCTION 
A. Current Status of Therapeutic Monitoring of Imipramine and 
Desipramine. 
During the last decade, there has been a continuous investigation 
into possible relationships between tricyclic antidepressant (TCA) 
concentrations in depressed patient's tissues, mostly blood, and the 
outcome of drug therapy. The success of therapeutic drug monitoring in 
many areas of pharmacotherapy, such as anticonvulsant and antiarrhythmic 
treatments, has been an impetus for this research. Major advances in 
three areas has allowed this investigation. First, there have been 
great improvements in the sensitivity, specificity and economy of 
quantitative analysis of drugs and their metabolites in body fluids and 
tissues so that TCA concentrations can be reliably and practically 
measured (1). Second, much has been learned about the fundamental 
pharmacology of antidepressant drugs and about different depressive 
syndromes. We now know that subtypes of depression exist and that these 
subtypes may or may not respond to a certain tricyclic antidepressant. 
For example, desipramine is efficacious in a large percentage of 
unipolar endogenous depressions but not in other subtypes (2). Third, 
the clinical diagnosis of depression has been improved so that these 
subtypes can be identified and also the extent of depression can be 
roughly quantified. The measurement of the extent of depression is 
required in order to determine the response of the patient to treatment. 
2 
Clinical response, either improvement or regression, is a parameter 
which. must ;be measured if it is going to be compared to psychiatric 
counselling and drug treatment. Global indices and rating scales have 
been developed to determine the severity of the depressive syndromes. 
For instance, the Hamilton Depression Scale is used by psychiatric 
clinicians to numerically rate the severity of the patient's depression 
(3). By combining the advances in measuring depression, in drug 
treatment of depression and in quantitation of drug concentrations, 
researchers have tried to determine what relationships exist between the 
pharmacodynamics and clinical response for tricyclic antidepressants. 
Drug concentrations should only be measured for practical purposes. 
A number of considerations should be taken into account when assessing 
the value of therapeutic drug monitoring (TDM). The clinical 
pharmacokinetics of the compounds should be understood. This knowledge 
is important for proper administration of the drug as well. The 
clinical pharmacokinetics of tricyclic antidepressants have been studied 
starting about fifteen years ago and sufficient knowledge exists for 
optimization of drug administration and for the basis of therapeutic 
drug monitoring (4). 
Tricyclic antidepressants are principally metabolized by the liver. 
Oxidative demethylation of the secondary or tertiary amine on the side 
chain and hydroxylation of the phenyl rings of the tri cyclic structure 
are the major phase one metabolic routes (5). As an example, the 
principle routes of metabolism of imipramine are given in Figure 1. 
Pharmacologic testing of metabolites to determine what activity they may 
have in relation to the parent drug is needed. For instance, it has 
long been known that N-demethylated metabolites of the tertiary amine 
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drugs amitriptyline, doxepin and imipramine have pharmacologic activity 
against depression. Hydroxylated metabolites of TCA have only recently 
been tested for pharmacological activity. The significance of hydroxy­
lated metabolites has not been completely elucidated. 
For TDM, assay procedures for the TCAs and their active metabolites 
must be developed. Assay procedures have routinely measured both the 
tertiary amine parent drugs and their secondary amine metabolites. Most 
procedures for secondary amine TCAs measure them only. The measurement 
of these drugs and metabolites must meet sensitivity, specificity, 
reproducibility and economy requirements for practical use in TDM. 
In the treatment of depression, the drug concentration must be 
maintained for a long period of time. This may be months or even years. 
This prophylatic therapy for depression, analogous to anticonvulsant 
pharmacotherapy, is benefited by periodic monitoring of drug 
concentration, especially during relapse, as variations in individual 
pharmacokinetics, or compliance, with time can increase or decrease 
steady state drug concentrations appreciably. 
It is known that the beneficial effect of TCA treatment for 
depression is not usually seen for two to six weeks (6). Therefore, no 
immediate clinical measurement of the effect is available. There are 
two ways to determine the corresponding drug concentration prior to the 
onset of this delayed therapeutic effect. First, steady-state concen-
trations for most TCAs will occur approximately one week after a fixed 
dose regimen of drug administration is initiated. Steady-state drug 
concentrations are reached about five elimination half-life time periods 
after the start of fixed dose drug therapy. The half-life of elimination 
is less than a day for most patients taking TCAs (protriptyl ine is an 
5 
exception and many elderly patients have slower rates of elimination). 
Measur.ement'of drug concentration after a week of fixed dose treatment 
gives this steady-state level and allows adjustment of the dose if a 
"therapeutic concentration" is not found. A second, better means of 
establishing a "therapeutic concentration" is the use of a test dose 
(usually 50 mg) of the TCA and the measurement of the drug in a blood 
sample drawn twenty-four hours later. This 24 hour test dose concentra­
tion is highly predictive of steady-state drug concentration (7, 8) so 
that the dose required to produce a "therapeutic concentration" can be 
calculated at the start of drug therapy. Therefore, a potentially 
therapeutic drug regimen can be initiated, although the resulting 
clinically observable outcome can not be seen for two to six weeks. 
If the same dose given to all patients resulted in the same 
steady-state drug concentration for a TCA, there would be no need to 
measure the drug concentration. There is wide inter.individual 
variability in TCA pharmacokinetics. For example, for the same dose of 
imipramine, a twelve-fold range of plasma concentrations was reported 
(9). A five-fold range of steady-state plasma concentrations was found 
for nortriptyline (10). The correlation between dose and plasma 
concentration is poor for the TCAs. The variability has been found to 
be primarily caused by differences in the rate of metabolism between 
patients (11). Metabolism is largely genetically controlled (12), but 
environmental factors such as drug interactions, disease and smoking can 
affect the metabolic rate. These environmental factors also influence 
the intrapatient, day-to-day variability of the steady-state 
concentration. This intrapatient variability was studied in patients on 
a fixed dose of certain TCAs by Ziegler et al. ( 13). They found 
6 
desipramine to have the largest coefficient of variation, 26 percent, in 
it's i;teady!-state concentration and nortri ptyl i ne to have the lowest, 13 
percent. A major axiom for therapeutic drug monitoring is that the 
plasma concentration reflects the tissue concentrations and hence, the 
relative availability of the drug at the pharmacologic receptor or site 
of action. For TCAs and most other drugs, the dose administered is a 
poor indication of the plasma concentration, so that the plasma concen­
tration must be directly measured. 
The therapeutic range of a drug is defined by a low plasma 
concentration limit and a high plasma concentration limit. The lower 
limit is a threshold value at which therapeutic effect begins and the 
upper limit is where beneficial effect dee lines or more often, where 
toxic manifestations or side effects become dangerous or unduly uncom­
fortable for the patient. If the therapeutic concentration range of a 
drug is large, variations in pharmacokinetics are of little concern and 
therapeutic drug monitoring is seldom necessary. A dose that is known 
to be large enough to produce a therapeutic concentration can be given 
without fear of adverse effects. For TCAs, this is not possible. The 
therapeutic range is small enough that interindividual variations in 
pharmacokinetics will produce a range of plasma concentrations below, 
within and a,bove the therapeutic range for the same dose in a large 
group of patients. 
The final consideration to be taken into account when assessing the 
value of therapeutic drug monitoring for TCAs is whether correlations 
between plasma concentrations and therapeutic and toxic effects have 
been established. This is the most important consideration. �Jithout 
these correlations, the plasma concentrations are meaningless. It has 
7 
also been the most difficult consideration to be addressed for a number 
of reasons.; The investigation of the relationship of plasma concentra­
tions of TCA drugs and their metabolites to clinical response has been 
underway for over a decade. During this time many advances have been 
made in the three areas that have allowed this investigation, namely in 
measuring depression quantitatively to determine clinical response to 
drugs, in diagnosing depressive subtypes and determining the drugs that 
are efficacious for each and in quantitating the drugs and active meta­
bolites in the patient tissues. Serious flaws have been discovered in 
earlier research as our understanding in each of these three areas has 
grown (14). 
The Diagnostic and Statistical Manual of Mental Disorders, Third 
Edition (DMS-111) published by the American Psychiatric Association (15) 
contains diagnostic criteria for the major affective disorders. 
Appendix I contains the diagnostic criteria used for determining the 
type and/or subtype of affective disorders. 
Patients who have depressive subtypes that are not typically 
responsive to TCAs, such as those with psychotic symptoms, atypical 
depressions or neurotic and reactive depressions (16), have been 
included in earlier clinical studies assessing plasma levels and 
response. As these subtypes which do not respond are identified and 
excluded, and patients who are identified as having major depressive 
disorder with melancholia as defined by DSM-III, are included, the 
correlation between plasma concentration of TCA and clinical improvement 
has been positive and better. On the other hand, approximately 30% of 
patients show substantial improvement with placebo treatment only (17). 
A "placebo \'lashout" period of one fo two weeks, in �,hich the patient is 
8 
treated with placebo and counselling, should be used to identify 
patien.ts who respond favorably to placebo treatment. These patients 
should be removed from clinical studies of TCA efficacy. Inclusion of 
these patients has distorted studies where there was no "placebo 
washout" period prior to initiating drug therapy. Improvement in 
patient selection for clinical studies has occurred in the last five 
years as knowledge of subtypes of depression and drug therapy are also 
improved. 
The measurement of clinical outcome is still. being assessed and 
improved. M. Asberg and F. Sjoqvist stated in 1978 (18}, "compared to 
the increasing sophistication of the chemical methods, surprisingly 
little attention has been given to development of the clinical 
methodology. Depression rating scales may be highly reliable in the 
hands of well-trained raters, but their precision is less well tested. 
Since most of the classical scales were not originally designed for 
measuring treatment induced change, it seems likely that their 
sensitivity in this respect could be increased. " A recent review (19) 
of the measurement of depression in clinical trials suggests that a 
choice from several classes of depression measures should be used 
because each class has advantages and disadvantages and a combination 
will give a much better indication of the severity of depression. 
Combinations of measures have seldom been used until recently. In fact, 
the most commonly used scale, the Hamilton Depression Scale (HOS), is 
criticized as a poor measure of clinical improvement (18). 
It is because of improvements in clinical studies of the last five 
years that reports of these studies are the most valuable. They have 
generally shown better correlations between plasma concentration and 
clinical response for tricyclic antidepressants. 
studies for; the two drugs of interest here, 
desipramine (DMI). 
1. Imipramine Studies. 
9 
I wi 11 review these 
imipramine (IMP) and 
There have been more clinical studies using IMP than there 
have been using DMI. In IMP studies the plasma concentrations of DMI, 
its major psychoactive metabolite, and IMP have been compared to clinical 
outcome. The parent compound, IMP, and metabolite, DMI, appear to have 
different central neuropharmacological activities. IMP acts to block 
the uptake of both serotonin and norepi nephri ne in centra 1 synapses, 
while DMI acts primarily as a blocker of central uptake of norepineph­
rine (20). Generally, these differences in neuropharmacological activity 
are difficult to relate to plasma TCA concentration because the mechanism 
of action of TCA is still unknown. These differences in interaction with 
biogenic amines have not been taken into account when assessing plasma 
concentration versus clinical response. 
Glassman et al. (21) reported a linear relationship be­
tween plasma concentrations of IMP and DMI and antidepressant efficacy. 
They selected a patient population suffering from endogenous depression 
and requiring hospitalization. They excluded patients with any evidence 
of schizophrenic illness, schizoaffective disease, organicity, serious 
medical illness or other preexisting diagnosable psychiatric illness. A 
one week drug-free period and one v1eek placebo treatment period were used 
to screen out patients v1hose Hamilton Depression Scale scores dropped 
below 17. The patients were then placed on 3.5 mg/kg of imipramine 
hydroch 1 ori de per day. Actua 1 doses varied from 100 to 300 mg/ day. 
Nurses verified that the drug had been ingested. Treatment lasted four 
10 
weeks. Blood specimens were drawn three times each week, prior to the 
day's .first 'dose. Plasma was analyzed by a spectrofluorometric technique 
(22) by which DMI is measured by difference following acetylation. Other 
metabolites of IMP, such as the 2-hydroxy compounds, would interfere. A 
total of sixty patients finished the study, but the investigators removed 
18 unipolar delusional patients who were less responsive to IMP therapy. 
The remaining 42 patients consisted of 30 unipolar and 12 bipolar non­
delusional endogenously depressed patients. The correlation coefficients 
for the log of the plasma IMP plus DMI concent.ration and clinical 
response (based on the Hamilton Depression Scale, a mood rating and a 
global rating but no exact definition of response is given) were 0.682 
for the bipolar group and 0.435 for the unipolar group. The combined 
plasma steady-state concentration ranged from 50 to 1050 ng/ml with an 
average of 200 ng/ml ± 137 ng/ml. They noted that patients above the 
median {180 ng/ml) do better than those below. After four weeks of 
treatment, 22 of 31 responders exceded 180 ng/ml and 21 of 29 nonre­
sponders fell below 180 ng/ml (p<0.01). Twenty-five (60%) of the 42 
non-delusional patients _responded. Thirteen of the 17 nonresponders had 
concentrations below 180 ng/ml. When dosage increases raised the 
concentrations of the nonresponders above 200 ng/ml the response rate 
increased to 84%. Again, this study is flawed by a nonpecific analytical 
method. 
Reisby et al. (23) published a study involving 66 
hospitalized depressed patients treated four weeks with 225 mg/day of 
IMP. Thirty seven patients 1•1ere classified as "endogenous" depressions 
and 29 as "non-endogenous" depressions. A one week placebo treatment 
period was used to exclude placebo responders from the study. They 
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found no statistically significant differences in response (as measured 
by HDS scores) between the two diagnostic groups. They measured IMP and 
DMI in plasma with a quantitative thin-layer chromatography method (24). 
Mean IMP concentrations for each patient during the last two weeks of 
drug treatment ranged from 6 to 268 ng/ml while mean DMI concentrations 
ranged from 20 to 675 ng/ml. The plasma level to effect relationship 
was clearest for the endogenous group as several non-endogenous patients 
responded at low plasma concentrations. They ·found all endogenous 
responders (N=l2) to have plasma IMP levels greater than 45 ng/ml and 
plasma DMI levels greater than 75 ng/ml whereas 11 of 14 endogenous 
nonresponders had one or both compounds below these limits. Ten out of 
12 responders had IMP+ DMI levels above 240 ng/ml and all nonresponders 
had IMP + DMI levels below 240 ng/ml. This study v1as flawed by the 
analytical technique, thin layer chromatography, which is semi-quanti­
tative. 
In a report by Muscettola et al. (25), fifteen patients 
in a double-blind study with a 3 week placebo washout period were 
administered IMP in daily doses of 125 to 300 mg. IMP and DMI were 
measured in plasma and spinal fluid (CSF from lumbar puncture) by a gas 
chromatography-mass spectrometry ( GC-MS) procedure �,i th stable isotope 
dilution using deuterium-labelled analogues (26). Concentrations of 
both drugs in CSF were approximately 10% of plasma concentrations and 
the concentrations in the two body fluids v1ere highly correlated (IMP r= 
.92, DMI r= .83). The mean of the ratios of IMP to DMI in plasma was 
1.1 but in CSF it was 0.8, meaning that DMI entry into CSF was greater 
than IMP entry. The number of corresponding plasma and CSF samples was 
sixteen. For patients showing a clear antidepressant response, the mean 
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plasma drug levels (IMP plus DMI, 248 ng/ml) in responders was 
significantly greater than the mean plasma drug levels (186 ng/ml) in 
nonresponders. No serious flaws are noted in this study. 
A more recent report (27) of a clinical study involved 27 
inpatients diagnosed as suffering from a major depressive disorder and 
excluding patients with schizophrenia, organic mental disorders, medical 
illnesses or active substance abuse. No placebo washout was included. 
Patients received 100 mg/day of IMP the first week and 200 mg/day the 
final three weeks of the study. Patients were rated by the Kellner 
Physician Rating Scale (28), the Zung Self-Rating Depression Scale (23) 
and the Clinical Global Impression scale on days 0, 7, 14, 21 and 28. 
Plasma IMP and DMI were analyzed by a gas chromatographic technique 
(30}. The authors state: "Our results provide 1 ittle support for a 
clinically useful relationship between blood levels of IMP or its 
metabolite, DMI and clinical improvement. Various proposed threshold 
levels of IMP and DMI failed to consistently differentiate responders 
from nonresponders. Correlations between blood levels and degree of 
clinical improvement yielded only a few weak associations between 
certain measures of outcome and certain tricyclic levels." However, 
these 27 patients were spread amongst five different treatment centers, 
no placebo washout was used and the actual drug concentrations, mean 
drug concentrations or range of drug concentrations are not given. They 
do further state: "The recent observation that the 2-hydroxy metabo-
1 i tes of IMP and DMI may make a substantial contribution to the overall 
therapeutic effects may well mean that additional measures need be 
incorporated into future studies." 
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Another recently published report concerning plasma IMP 
levels and 'response in depressed children ( 31) showed good correlations. 
Twenty prepubertal children (ages 7 to 12 years) were hospitalized with 
major depressive disorders (DSM-III criteria) with no diagnosis of 
schizophrenia, attention deficit disorder, no history of drug abuse, an 
IQ greater than 85 and no prior antidepressant drug treatment. Severity 
of depression was assessed using a Clinical Global Impression Scale, 
Children's Depression Rating Seale ( 31a) and the Childhood Depressive 
Inventory (CDI) (32) self-rating scale. The sam.e study included two 
weeks of in-huspital treatment and counselling without drugs, 3 weeks of 
treatment with 75 mg IMP at bedtime for children who did not remit after 
the initial two weeks and three weeks of additional treatment with IMP 
at an altered dose for those who did not respond to the 75 mg dose. The 
last treatment involved dosage reduction to 50 mg for children who had 
shown adverse side affects or increased dose to a maximum of 5 mg/kg if 
there were no side effects and no response. Plasma IMP and DMI concen­
trations were determined by high performance liquid chromatography (HPLC) 
with UV detection (33}. They found response to IMP to be plasma con­
centration dependent. Of the children who achieved total IMP plus DMI 
plasma levels of 125 to 225 ng/ml, 92% responded compared to 25% respond­
ing outside this range. A curvilinear relationship was found with both 
total (IMP + DMI) and DMI versus response using two-degree polynomial 
regression analysis (r = 0.72, p < .01 for total versus response and r = 
0.56, p < .05 for DMI versus response). They found no correlation 
between IMP concentrations alone and response. They determined that the 
relationship between plasma drug concentration and antidepressant 
response was determined primarily by the DMI concentration. 
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There have been good studies of the relationship of 
IMP and its demethylated metabolite, DMI, and clinical respose and other 
studies flawed by methodological problems. Still, the good studies have 
shown that a combined IMP plus DMI plasma concentration of roughly 150 
to 350 ng/ml has caused a majority of patients to improve when those 
patients are carefully se 1 ected as those for which IMP therapy is 
potentially efficacious. 
2. Desipramine Studies 
There are fewer clinical studies comparing 
Friedel et al. 
DMI 
(34) plasma concentrations and clinical response. 
reported on 26 symptomatic volunteers who met research diagnostic 
criteria for major depressive disorders according to Frighner Criteria 
(35) for Primary Unipolar Affective Disorder and had at least 2 of 5 
predictors for positive TCA response (36). Clinical response was 
determined by the Hamilton Depression Rating Sea 1 e. No p 1 acebo period 
was used. Patients received 100 mg of DMI each night in week one, 150 
mg in week two and 200 mg in week 3. Subjects were evaluated with HDS 
on days 0, 7, 14 and 21. Blood was drawn on the same days 10 to 12 
hours after the previous nights dose. Plasma DMI concentrations were 
measured by a GC-MS method (37). Sixteen of the 26 subjects (62%) were 
deemed responders (final HDS scores of less than 7 on 17 item scale) and 
10 (30%) were classified as nonresponders. The mean and median plasma 
DMI concentrations on day 21 were 173 ng/ml and 79.9 ng/ml respectively. 
In this study it was found that subjects with plasma DMI levels below 
the median (79.9 ng/ml) were more likely to show improvement than were 
those above that level. The day 21 HOS score versus day 21 plasma DMI 
concentration had a correlation coefficient (r) of 0.365 (p = 0.033). 
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The authors state: "These data suggest that clinical response in 
subjects with symptoms of major affective disorder treated with DMI is 
related to DMI plasma levels and that at DMI plasma levels above 160 
ng/ml, clinical response decreases significantly. There are not a 
sufficient number of subjects in this study with low DMI plasma levels 
to define with confidence the minimal effective plasma concentration of 
DMI needed to produce a therapeutic response, although it appears to be 
in the region of 40 ng/ml". They continue later: "Consequently, the 
data reported here on DMI support the contention that monomethylated 
tricyclics (38, 39} appear to inhibit clinical response at elevated 
plasma levels by an unknown mechanism". In this study, there was no 
s i gni fi cant difference in adverse side affects between responder and 
nonresponder groups which reduces the possibility of adverse effects at 
higher DMI plasma concentrations masking clinical improvement. The 
authors admit to two major flaws in their study, one the lack of placebo 
washout periods and two, the short ( three week} duration of the study 
which may have resulted in a lower total response rate. The correlation 
coefficient (r = 0.365) that they did find is quite low as well. 
The phenomenon of a decrease in responsiveness to mono­
methylated TCA as the plasma concentration exceeds a particular ceiling 
level has been postulated to be caused by increased adverse effects 
corresponding to these increased plasma concentrations, as well as other 
exp 1 anati ons ( 40). In a study of major adverse reactions during DMI 
treatment, Nelson et al. (41) addressed this possibility in 84 patients 
ranging in age from 20 to 80 years (mean 48 ± 18.4 years). Fifty 
received OM! a 1 one and 34 a 1 so received anti psychotic drugs. Si de 
effects were classified as major adverse reactions if they required 
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either discontinuation of DMI therapy or dosage reduction. Fifteen 
patients had major adverse reactions during the three week DMI trial. 
Symptomatic orthostatic hypotension developed in 6 patients, delirium 
developed in 5 patients, severe constipation in 2 patients, urinary 
retention in one, and one patient had periods of intense anxiety followed 
in seven days by a grand mal seizure. Major side effects developed in 
11 of the 28 patients over 60 years old in contrast to 4 of the 56 
patients under 60 years old. Plasma DMI concentrations_ were measured by 
gas chromatography with a nitrogen detector and 2-hydroxy DMI concentra­
tions by reverse phase liquid chromatography (42). DMI plasma 
concentrations ranged from 31 to 683 ng/ml. DMI plasma concentrations 
in patients having side effects did not differ significantly from those 
in patients without side effects. Steady-state DMI plasma concentrations 
did not increase with age although side effects did. All side effects 
except orthostatic hypotension occurred in patients receiving antipsycho­
tic medication as well as DMI. The concentration of 2-hydroxy DMI, the 
total concentration of 2-hydroxy DMI and DMI and the ratio of 2-hydroxy 
DMI to DMI were not higher in 11 patients having side effects than in a 
comparison group without side effects. Orthostatic hypotension occurred 
early in therapy and at low plasma DMI concentrations. 
The most recent and complete study of plasma DMI 
concentration versus clinical response was performed by the same group 
as the adverse effect investigation, namely Nelson, Jatlow, Quinlan and 
Bowers (43). They used the DSM-III criteria (15) for major depression 
with melancholia to select 30 in-patients with depression. A one week 
hospitalized placebo washout period was included and patients having HOS 
scores lower than 18 after this week were not included in the 30 
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patients. The 24 item HDS was used to assess the severity of depression. 
Drug treatm�nt lasted three weeks and responders were defined as those 
with HDS scores of 9 or less at that time. Patients received 2.5 mg/kg 
of DMI each day (range 100 to 300 mg/day). Blood samples were drawn 
prior to the first dose of the day. Plasma DMI concentrations were 
determined by GC with a nitrogen detector (34). Steady-state plasma 
levels for the 30 patients completing the 3 week treatment period ranged 
from 29 to 454 ng/ml ( mean 112 ng/ml , median 82 ng/ml). A thresho 1 d 
plasma concentration of 115 ng/ml best separated .responders and non­
responders. In contrast to the Friedel study (29), 89% of the patients 
with plasma concentrations above 115 ng/ml responded whereas only 19% 
responded who had levels below 115 ng/ml. Ten initial nonresponders 
were converted to responders when dosage increases raised DMI plasma 
concentrations to 125 ng/ml or above. The rate of response in their 
sample during the first three weeks was only 37%. Initial low plasma 
concentrations of DMI and the relatively short time period probably 
reduced the response rate. The authors state that 125 ng/ml is a good 
lower 1 imit for the therapeutic range for plasma DMI concentration. 
They do not present separate analysis of or a listing of high plasma DMI 
concentrations. This study is the best consideration of plasma DMI con­
centrations and clinical response to date. It shows a low limit of the 
therapeutic range for DMI concentrations of about 125 ng/ml. 
Finally, there is one recent case report (44) concerning 
a patient (30 year old woman) who had simultaneous plasma DMI determina­
tions (45) and HDS ratings during an emergency hospitalization. The 
plasma DMI concentration maximum was 1150 ng/ml on 200 mg/day of DMI 
and later decreased to 168 ng/ml on 50 mg/day. At high plasma DMI 
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concentrations, the patient consistently had severe depression, while 
her depression improved greatly when her p 1 asma 1 eve 1 was reduced and 
maintained· in the "therapeutic range" that the authors suggested to be 
150 to 300 ng/ml (46). 
In his review of July, 1982 (14), Friedel states: "The 
only other TCA (besides nortriptyline) for which a reasonably clear 
relationship between plasma drug and metabolite levels and clinical 
response has been demonstrated is IMP ..• with a maximal effect most 
often occurring above 200 ng/ml of IMP plus its demethylated metabolite, 
DMI." There has not been shown a clear relationship between plasma DMI 
concentrations and cl i ni ca 1 response as indicated by the contradictory 
findings of the two OMI studies sited here. Furthermore, the possible 
influence of other active metabolites, namely the 2-hydroxy metabolites 
of IMP and DMI, has not been studied in relation to clinical response. 
B. Metabolism of Imipramine and Desipramine 
Bickel and Weder (47). in 1968 published the results of an 
investigation of the total fate of IMP in male Wistar rats. They used a 
single dose administered i.p. and analyzed plasma, 18 organs and 
tissues, and 6 excreta for IMP and 18 metabolites over the course of 
seven days. Thin layer chromatography was used for the analysis, which 
must be considered semi-quantitative at best. A very large dose (50 
mg/kg) was used. In plasma, IMP, DMI, imipramine-N-oxide, 2-hydroxy IMP 
glucuronide and 2-hydroxy desipramine glucuronide were detected. No 
unconj ugated pheno 1 i c metabo 1 ites could be detected. They found that 
90% of the total drug is excreted via the urine (2/3) and feces (1/3) 
1·:ithin 24 hours. The major metabolites are DMI, IMP-N-oxide, 2-hydroxy 
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IMP(2HI}, 2-hydroxy DMI (2HD), 2HI-glucuronide and 2HD-glucuronide. 
Eight.other' metabolites are formed in minor amounts only. The percent 
of total drug as major metabolites in the first 24 hour urine collection 
were given as: IMP (0.9%), DMI (6.5%}, IMP-N-oxide {7.4%}, 2HI (3.2%}, 
2HD (10.2%}, 2HI-glucuronide (9.2%} and 2HD-glucuronide (27.6%}. 
Later Bickel and Minder (49) studied IMP and DMI metabolism and 
biliary excretion in rats with bile fistulas and in perfused rat livers 
(all male Wistar). Rats were injected i.p. with 50 mg/kg IMP. Nearly 
one third of the dose is excreted into bile during the first 3 hours, 
mostly as glucuronides of 2-hydroxy metabolites. Unchanged IMP excreted 
in bile is about 5%. In the perfused rat liver experiments, after three 
hours 88% of administered IMP is metabolized whereas for administered 
DMI, 57% is metabolised in 3 hrs. This difference in rate of metabolism 
accounts for the longer half-life and accumulation of DMI compared to 
IMP. Forty percent of DMI metabolites were hydroxy lated and 14% was 
desmethyldesipramine (DMD). A small amount of IMP was detected. Their 
experiments showed that metabolism in the liver of IMP and DMI accounted 
for almost all metabolism in these rats. 
Another study (49) with male Wistar rats demonstrated that brain 
and plasma levels of IMP and DMI and their area under the curve (AUC) 
values were much lower after oral than after i.p. administration. This 
is a first pass liver metabolism phenomenon. 
Gillette et al. (50, 51, 52) compared rat and rabbit metabolism of 
IMP and DMI. In their first report (50), they stated that rabbits 
metabolize IMP rapidly with almost complete disappearance in 6 to 8 
hours. Next (51), they compared rat and rabbit liver microsome's ability 
to metabolize IMP. Rat microsomes were half as active and demethylate 
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IMP mainly to OMI and slowly transform DMI to other metabolites. In 
contrast, r'abbit 1 i ver mi crosomes rapidly metabo 1 i ze both IMP and DMI 
and little DMI accumulates. They speculate that the main product of DMI 
metabolism is 2HD since little DMD was formed. Their in vivo 
experiments in rats and rabbits confirmed the in vitro microsome 
experiments. Rats rapidly demethyl ate IMP and DMI and s 1 owly oxidize 
the DMI. Rabbits rapidly metabolized both IMP and DMI. New Zealand 
white rabbits and Sprague-Dawley rats were used. In rabbi ts, they 
determined a plasma half-life for DMI of one hour and for IMP of two 
hours (52). 
They also incubated IMP with homogenates of rat liver, heart, lung, 
brain and kidney and found that only the liver preparation metabolized 
IMP. Microsomal and soluble liver cell fractions when combined 
metabolized IMP. DMI and 2HI were isolated as metabolites, but no 2HD 
was detected. This system metabolized DMI much more slowly. The same 
preparation from rabbit liver metabolized IMP and DMI efficiently and 
mainly by reactions other than demethylation (52). 
The metabolism of IMP has been studied by Crammer, Scott, and Rolfe 
(53, 54) in humans. About 95% of the radioactivity representing IMP and 
its metabolites after a 5 µCi oral dose of 14C-IMP was extracted from 
human urine. By thin-layer chromatography, autoradiography and various 
color tests over 20 metabolites were identified. In free plus 
conjugated forms, 2HD totalled up to 40%, 2HI up to 25% and 2-hydroxy 
iminodibenzyl up to 15% of all urinary metabolite excreted. DMD and its 
derivatives were present in only small amounts, while free iminodibenzyl 
and IO-hydroxy DMI each accounted for about 3% of the total metabolite 
excretion. About 40% of the radioactivity appears in the urine in the 
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first 24 hours and about 75% within three days. Glucuronides account 
for at least half of the urinary metabolites. 
Gram and Christiansen (55) studied the first pass metabolism of IMP 
in man by administering the same test doses of 14c-IMP by i.v. infusion 
and orally. Thin-layer chromatography was used for quantitation of IMP 
and DMI in plasma and IMP, DMI, IMP-N-oxide, 2HI, 2HD, 2HI-glucuronide 
and 2HD-glucuronide. Maximum IMP plasma concentrations were higher with 
i.v. than oral administration whereas DMI and other metabolite concen-
trations were greater following the oral route. first pass metabolism 
ranged from 23% to 71% for IMP. Non conjugated IMP, DMI, 2HI, 2HD and 
IMP-N-oxide were found in urine of all three subjects. In one subject, 
appreciable quantities of tentatively identified 2-hydroxy didesmethyl-
imipramine were found. They found first pass metabolism to be mediated 
by demethylation (DMI production) but not by hydroxylation. 
The metabolism of DMI in human fetal and adult liver microsomes was 
investigated by von Bahr et al. (56). Both adult and fetal preparations 
hydroxylated DMI to form 2HD. The hydroxylation was faster in the adult 
liver microsomes (comparison of 10 fetal versus 6 adult liver prepara­
tions). Much lower amounts of DMD were found compared to DMI and 2HD. 
Semi-quantitative thin layer chromatography was used for the analysis. 
In 1982, Potter et al. (57) reported substantial quantities of 2HD 
and 2HI in plasma and CSF of depressed patients treated with IMP and 
DMJ. In plasma of prepubescent boys and adults the concentration of 
unconjugated 2HI was 15% to 251; that of IMP and the concentration of 
unconjugated 2HD was usually about 50% that of DMI. They identified a 
subpopulation of about 5% who they classified as deficient DMI hydroxy­
lators. DMI has routinely been measured in plasma of IMP patients for 
a number of years. 
C. Pharmacological Activity of Hydroxylated Imipramine and 
Desipramine. 
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After the discovery of 2HD and 2HI as metabolites of DMI and IMP in 
rats and humans, the question of possible pharmacological activity arose. 
They were compared to their parent drugs, IMP and DMI, which are known 
to be effective antidepressants. The antidepressant activity has been 
hypothesized to result from the enhancement of central monoaminergic 
function which is regarded to be deficient in depressed patients (58). 
The relative potencies of IMP and DMI to inhibit the uptake of different 
biogenic amines are different. DMI is a more potent inhibitor of nor­
epinephrine uptake than is IMP. IMP is a more potent inhibitor of 
serotonin (5-HT). Both are relatively weak inhibitors of dopamine uptake 
(58). Javaid, Perel and Davis (58) examined the pharmacological 
potencies in the central nervous system of 2HD and 2HI, as determined by 
their relative abilities to inhibit the reuptake of biogenic amines in 
purified synaptosomes isolated from rat brain (male, Sprague-Dawley) and 
by the relative effects of spontaneous and forced motor activity in mice. 
The effect of the 2-hydroxy metabolites on motor activity of mice was of 
the same magnitude as IMP and DMI. In the biogenic amine reuptake 
experiments, 2HI had very similar inhibitory activities on norepi­
nephrine, 5-HT and dopamine as IMP. 2HD had inhibitory activities 
similar to DMI. Basically, "hydroxylation of IMP and DMI at position 2 
affected their inhibitory activities only slightly". 
Another group of investigators, Potter, Calil, Manian, Zavadil and 
Goodwin (59), also assessed the activity of hydroxylated tricycl ic anti­
depressants. They found that 2HD and 2HI inhibit the reuptake of 
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norepinephrine and serotonin into synaptosomes to the same extent as do 
their. paren't compounds. They also employed a classic test for anti­
depressant screening, the reversa 1 or prevention of reserpine-induced 
syndrome in rats, and found 2HD and 2HI to be active. They further 
suggested that 2HD will contribute to the central nervous system (CNS) 
activity of administered IMP because the ratios of 2HD to DMI in plasma 
and CSF of rats were the same. Quantitation was performed by thin-layer 
chromatography and GC-MS. All evidence to date indicates that. 2HD and 
2HI are pharmacologically active and at the approximate potency of DMI 
and IMP, respectively. 
D. Plasma Concentrations and Pharmacokinetics of IMP, DMI, 2HI and 2HD. 
There are several recent reviews of TCA plasma concentrations and 
pharmacokinetics (4, 60). Very little information concerning hydroxy­
lated metabolites was available when they were written. The pharmaco­
k i net i cs of the tertiary amines and secondary amines, such as IMP and 
DMI, are well studied. The drugs are highly bound to tissue and protein 
so that they have a large apparent volume of distribution (V0). Their 
metabolism, as noted, occurs almost entirely in the liver with high 
clearance rates and large interindividual variations in elimination 
half-life, clearance and steady-state concentrations. Peak parent drug 
concentrations are reached within 2 to 10 hours after oral doses and the 
drugs are rapidly distributed to most tissues, including the brain. 
Absorption of TCA can vary markedly and the amount of first pass meta­
bolism, as noted earlier, varies widely. Only a small percentage of the 
drugs will be excreted into urine unchanged. In humans, the metabolic 
pathways are demethylation, dealkylation, N-oxidation and ring hydroxy-
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lation with glucuronide coupling. 
A bi-exponential equat_i on, i ndi cati ve of a two compartment 
pharmacokinetic model, can be used to describe plasma concentration 
versus time plot following a single i .v. administration. Drug 
concentrations in tissues such as liver, heart and brain are much higher 
than plasma concentrations. The elimination rate is low even though 
hepatic metabolism is efficient (30% to 70% extracted and excreted 
during each pass through the liver) because relatively little of the 
total drug in the body is in the blood. There is a_ large percentage of 
plasma protein binding of drug (usually greater than 80%) with albumin, 
a1-acid-glycoprotein and lipoproteins (very low density and low density) 
being the principle components which bind. The mean post steady-state 
half-life for IMP is about 15 hours and for DMI is about 20 hours. 
Reisby et al. (23) administered 225 mg/day of IMP orally to 66 
depressed patients for 31 days each and found a range of 6 to 300 ng/ml 
for IMP and 15 to 700 ng/ml for DMI in their plasma samples. In the DMI 
study of Nelson et al. (43), oral doses of DMI ranging from 100 to 300 
mg/day resulted in steady state plasma concentrations of DMI from 29 to 
454 ng/ml. In both these studies, substantial improvement in depression 
was noted and the doses correspond to accepted pharmacotherapy. The 
accepted practice is to draw blood samples 10 to 12 hours after the last 
dose or just prior to a first dose in the morning. This practice is 
required due to variations in absorption (2 to 10 hours to peak 
concentration) of oral doses and equilibrium of distribution is "a 
prerequisite for obtaining a reproducible relationship bet1�een plasma 
and receptor level of a drug (61)." 
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Potter et al. (57) have studied steady-state concentrations of 
hydroxyl ate'd metabolites of IMP and DMI. IMP, DMI, 2HI and 2HD were 
analyzed using a HPLC assay (62) in plasma and CSF. In 32 males (ages 7 
to 13 years) treated with 75 mg/day of IMP the mean steady-state plasma 
2HI/IMP ratio was 0.23 and the 2HD/DMI ratio was 0.38. In 7 males (also 
ages 7 to 13 years) treated with 75 mg/day DMI the mean steady-state 
plasma 2HD/DMI ratio was found to be 0.43. Adults had similar ratios. 
They found that within an individual the ratio of 2HD/DMI in plasma was 
fairly consistent for multiple time points but there was great variation 
among different patients. They found a high positive correlation 
between plasma and CSF concentrations of 2HD and DMI and postulate that 
"under steady-state conditions patients who have a significant plasma 
concentration of 2HD relative to DMI will have an even greater relative 
concentration in the CNS." 
Devane, Savett and Jusko (63) looked at DMI and 2HD pharmacokinetics 
in four normal volunteers. A single oral dose of 50 mg of DMI was taken 
after an overnight fast. Timed blood specimens were taken over three 
days. An HPLC procedure (62) was used to measure plasma DMI and 2HD 
concentrations. For three subjects, 2HD appeared in plasma simul­
taneously with DMI and with greater concentration than DMI for the first 
two hours following administration. Peak concentrations of DMI appeared 
between 3 and 6 hours and of 2HD between 2 and 4 hours. The maximum 
plasma concentration of 2HD was 76% to 144% of that of DMI for the four 
subjects. The mean AUC of 2HD was 79% of the AUC for DMI. The decline 
in plasma concentrations were apparently parallel for 2HD- and DMI in all 
subjects. The authors suggest that pre-systemic elimination (that is, 
first pass liver metabolism) of orally administered DMI occurs, at least 
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in part, through formation of 2HD. 
Kitanah et al. (64) investigated the relationship of steady-state 
plasma concentrations of 2HD and DMI in elderly depressed patients com­
pared to younger patients. The ratios of 2HD to DMI were higher in 
elderly ( 67 to 85 years) patients than in younger patients due to 
increased plasma concentrations of 2HD in the elderly. The urinary 
clearance of 2HD decreased with age. "The known decrease in glomerular 
filtration with age may explain the selective increase of 2HD concentra­
tion in the elderly." They postulate that a primary means of elimination 
of 2HD is through renal excretion because urinary clearance of 2HD 
decreased with age and 2HD reached higher concentrations in the elderly. 
E. Imipramine and Metabolites in Brain. 
The so-called "blood-brain barrier" at the cerebral vasculature is 
made up of a continuous layer of endothelial cells which are connected 
by tight junctions as opposed to typical endothelial cell junctions 
which are not tight. Close intercellular connections prevent inter­
cellular diffusion of water-soluble non-electrolytes, ions and proteins. 
Vascular transport is minimal at the cerebrovascular endothelium. These 
three properties, tight endothelial cell junctions, minimal endothelial 
cell vesicular transport and close intercellular connections, provide 
the "blood-brain barrier" which as a whole has properties of an extended 
lipoid cell membrane and is selectively permeable for lipid-soluble as 
opposed to water-soluble substances (65). Lipid-soluble agents equili­
brate rapidly between brain and blood while less lipid-soluble drugs may 
be restricted in blood-brain exchange and have 1 imited intracerebral 
distribution (66). 
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Rapoport, Ohno and Pettigrew (67) determined that cerebral 
capil lary 'permeability was related linearly to the octanol-water 
partition coefficient for a wide variety of compounds. Deviations from 
their linear-regression line, although small, could be affected by other 
factors such as size, steric and electronic parameters and specific 
interactions with cell membranes. From knowledge of the octanol-water 
partition coefficient they were able to predict brain uptake of a drug 
from the history of the plasma concentration in experi�ents with rats. 
Bickel and Weder (68) studied the partitioni.ng of IMP, DMI, DMD, 
2HI and 2HD between organic solvents and isotonic buffer solutions. The 
partition values were presented as the percent of the compound in the 
organic phase after equilibration with isotonic phosphate buffer, pH 7.4. 
Com12ound Chloroform Hexane Dieth,llether Dichloroethane 
IMP 99.8±0.8 99.4±1.4 99. 3±1. 2 98.5±1.4 
DMI 98.5±1.6 65.1±2.1 88.4±1.5 97 .8±1.8 
DMD 99.1±1.8 70.5±2.3 
2HI 97.4±1.5 25.2±2.0 84.2±1.7 71.0±1.9 
2HD 55.2±2.1 6.3±2.0 55.6±2.6 50.2±3.1 
Although octanol-water partitioning was not studied, these data 
indicate that 2HD, in particular, should have limited entry into brain. 
Bickel and Weder also qualitatively studied these compounds passage 
through the blood-brain barrier in male Wistar rats. The compounds were 
administered in high doses (generally 50 mg) i.p. and the rats 
scarificed after various t1mes. Thin layer chromatography was used to 
detect IMP or DMI in homogenized brain extracts. After administration 
of 2HI and 2HD, rats were sacrificed 5 and 15 minutes, respectively, 
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after administration by i.v. and i.p. routes, respectively. They stated 
that 2HI was detected in brain while 2HD was not. 
The question of the extent of entry of IMP and metabolites into the 
brain is important because these are centrally acting compounds (69). 
Specific high affinity binding sites for IMP have been found in both rat 
(70) and human (71) brain and for DMI in rat brain (72). In the rat 
brain study, the specific binding of 3H-IMP was of high affinity (Kd=4.0 
nM), rapid and reversible. It was inhibited by TCAs at nanomolar 
concentrations and by atypical antidepressants (i_prendol, viloxazine, 
mianserin, and pirazidol) at micromolar concentrations. These binding 
sites were not detected in the heart and vas deferens and were unequally 
distributed between various brain regions (higher in cortex and 
hypothalamus than corpus striatum and lowest in cerebellum). Rats 
chronically treated with DMI for three weeks had significantly less 
specific 3H-IMP binding sites in cortex than did control animals. They 
concluded that these binding sites may be important in the study of 
depression and of the mechanism of action of antidepressant drugs. 
In membranes prepared from human brain_ (71), the high affinity 
binding sites (Kd=l.7 nM) were found. The binding of 3H-IMP was 
saturable, reversible and inhibited by pharmacologically active TCAs but 
not by other psychoactive compounds or most neurotransmitter substances 
in concentrations up to 10 1JM. They found the hypothalamus to have 
greater density of sites than the cerebral and cerebellar cortex. 
Tertiary TCAs had Ic50 values (IMP, 6.5 nM; amitriptyline, 22 nM; 
chlorimipramine, 10 nM; doxepin, 120 nM) generally lower than secondary 
TCAs (DMI, 130 nM; nortriptyline, 170 nM). The rc50 is the concentration 
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necessary to inhibit 50% of specifically bound 3H-IMP (2 nM) to human 
hypothalamit membranes. 2HI had an IC50 value of 50 nM. 
Desipramine binding was studied in rat cerebral cortex membranes by 
Hrdina (72). He found a high affinity component (Kd=4.5 nM) and a low 
affinity component (Kd=80 nM). He found a different order of potency in 
displacing the high affinity DMI and IMP binding by various compounds 
tested. Nortri ptyl i ne and ni soxeti ne were the most potent DMI dis­
placers and chlorimipramine and amitriptyline showed highest potency in 
competing for IMP binding sites. He suggested that the high affinity 
binding of DMI is distinct from that of IMP and most likely associated 
with sites involved in neuronal up-take of norepinephrine. 
Practically a 11 theories of TCA mechanism of action i nvo 1 ve the 
brain as their site of action (69). The discovery of these high 
affinity binding sites reinforces that premise. If the site of action 
of IMP and DMI is in the brain, the distribution of drug to the brain is 
important. In humans, the concentration of the drug has been measured 
most often in the plasma. The relationship between plasma 
concentrations and brain concentrations of CNS active drugs should be of 
importance. 
A quantitative study in the rat of the relationship between IMP 
levels in brain and serum was performed by Van Wijk and Kort (73). They 
used male Wistar rats treated for one day or 17 days with 10 mg/kg IMP 
i.p. twice daily. Radioactive IMP (
3H-IMP) in combination with 
unlabelled IMP was administered in various doses i .v. and rats were 
sacrificed at different time intervals post injection. Rats were 
decapitated and blood collected from the trunk. The brains were 
dissected into frontal cortex, left and right striatum, occipital 
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cortex, cerebellum and brain stem. Radioactivity was measured by 
scinti.ll ati o'n counting and HPLC was used to quantitate some specimens. 
They found a virtually constant ratio between serum and brain levels of 
IMP. They found a ratio of 25 for brain to serum concentrations at 
steady-state. Equilibrium between serum and brain occurred in 30 
minutes or less after i.v. administration. 
There was little difference in concentration of IMP in the various 
brain areas in either subacute or subchronic administration. They found 
the uptake into the brain to be nonsaturable and s�rum protein binding 
did not limit the accumulation of IMP in the brain. 
In an earlier study (74), Nagy investigated blood and brain con­
centrations of IMP and it's metabolite DMI after oral and intramuscular 
administration in male Sprague-Dawley rats. IMP and DMI were estimated 
by thin layer chromatography with direct densitometry. Doses were a 
single injection of 15 mg/kg or 10 mg/kg twice daily for 8 days. They 
found DMI concentrations to be about ten times higher in brain than blood 
and IMP concentrations to be about eight times higher in brain. The IMP 
concentration in red blood cells was an average 26% higher than in 
plasma. The DMI concentration in red blood cells was on average 47% 
higher than in plasma. The route of administration (oral or i .m.) did 
not affect the brain to blood concentration ratios. 
Biegon and Samuel (75) compared brain concentrations of DMI after 
i .p. injection in male and female Wistar rats. They found the total 
amount of DMI in the brains of females to be 2 to 4 times that found in 
the brains of males after the same dose. In females the amount of DMI 
was highest on the day of estrus and lo�1est on proestrus. They also 
found only small differences in regional distribution for DMI in brain 
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(both male and female). Maximal brain concentrations were reached 30 
minutes following i.p. injection. They did not measure blood concentra­
tions and stated that sex-dependent liver metabolism may have caused the 
sexual differences in brain concentrations. Hrdina and Dubas (76) 
studied the pharmacokinetics and regional and subcellular brain distri­
bution of DMI in male Sprague-Dawley rats after single and repeated i.p. 
admi ni strati on. They found twenty times the plasma concentration in 
brain. "No significant regional differences were found in brain distri­
bution or disappearance half-lives of the drug." DMI concentrations in 
cortex, striatum, hypothalamus and cerebellum were measured. The ratio 
of brain to p 1 asma concentration remained steady between one and 48 
hours after the last dose. 
In 1973, Christiansen and Gram (77) reported the qualitative and 
quantitative study of the distribution of IMP and its metabolites in 13 
different regions of the brain in a fatal case of IMP intoxication. 
Only IMP and DMI were quantitated using a thin layer chromatographic 
technique. Qualitative identification of 8 identified and 8 unidentified 
metabolites was made. A 23 year old man committed suicide by ingestion 
of an unknown amount of IMP and was found dead 12 to 24 hours 1 ater. 
Whether IMP had been taken regularly prior to suicide was not known. 
The blood concentration of IMP was 39 µg/ml. A trained neuropathologist 
removed the various brain tissues. IMP concentrations in brain ranged 
from 4 to 36 µg/g and were lowest in the white substance of the frontal 
lobe (4 µg/g) and cortex cerebelli (5 µg/g). Much less variation 
occurred in the other regions: frontal cortex (18 µg/g), temporal cortex 
(18 µg/g), thalamus (25 JJg/g), caudate (23 to 28 µg/g), stria tum 
(25 µg/g), mesencephalon (20 µg/g), pons (13 µg/g), nucleus amygdalae 
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(36 µg/g) and medulla oblongata (20 µg/g). DMI concentrations were 
one-third tci one-fourth lower than IMP concentrations. Qualitative 
identification of 2HI was made in most regions. 2HD was found only in 
heart tissue and they state "this could be due to the difference in the 
concentration in the tissues". 
A recent report by Pentel, Bullock and Devane (78) of an IMP 
overdose included postmortem concentrations of IMP, DMI, 2HI and 2HD in 
brain and liver. Unfortunately, postmortem blood concentrations are not 
reported. Serum concentrations during hemoperfusion treatment prior to 
death were measured. A 25 year old male was brought to the hospital 1 
hour after ingesting an estimated 5000 mg of IMP. At the time of 
admission, the serum IMP concentration was 1440 ng/ml and the metabolites 
DMI, 2HI and 2HD were all present in concentrations exceeding 100 ng/ml. 
Hemoperfusion was initiated and continued twenty six hours until the 
patient was declared dead. Final concentrations in serum are estimated 
as IMP (150 ng/ml), DMI (300 ng/ml), 2HI (50 ng/ml) and 2HD (140 ng/ml). 
The authors calculated that 1.8% of the total dose was removed by hemo-
perfusion. Postmortem tissue concentrations (96 hours after IMP 
ingestion and almost three days after declared death) were reported in 
ng/g as follows: 
Compound 
IMP 
DMI 
2HI 
2HD 
Brain 
91 
407 
23 
97 
Liver 
338 
640 
85 
384 
It is unfortunate that no postmortem blood concentrations were 
determined and that three days elapsed before tissue samples were 
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removed for analysis. However, positive identification of 2HD was made 
in human brain. Quantitation was made in serum and tissues of IMP, DMI, 
2HI and 2HD using hexane extraction at alkaline pH and HPLC with 
fluorescence detection (62). 
Tricyclic antidepressants are centrally acting drugs. It has been 
demonstrated that drug entry into brain is determined by lipid 
solubility of the drug. It stands to reason that more polar metabolites 
of drugs may be restricted to some degree from entry into the brain. 
The hydroxylated metabolite of DMI, that is 2HD, has been shown to have 
a smaller portion partition into organic solvents from water than IMP, 
DMI, DMD and 2HI. This is an indication that entry of 2HD into brain 
may be restricted compared to IMP and DMI. 
F. Red Blood Cell Versus Plasma Drug Concentration 
1. Antipsychotic Studies 
In 1977, Garver, Dekirmenjian, Davis, Casper and Ericksen (79) 
reported that red blood cell concentrations of butaperazine, a 
piperazine phenothiazine used as an antipsychotic, were more strongly 
correlated with therapeutic response than were plasma butaperazine 
concentrations. RBC butaperazine concentrations could be used to define 
a "therapeutic window" above and below which favorable response 
diminished. The data were preliminary in nature and consisted of the 
study of ten patients who met Research Diagnostic criteria (15) for 
schizophrenia. All were maintained drug-free for 2 to 3 weeks after 
admission. Various doses of butaperazine were administered orally to 
each patient for 15 days or more. Patients were rated by the New Haven 
Schizophrenic Indices conducted daily. The percentage change in score 
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between day O and day 12 was used to determine clinical outcome. Blooa 
samples were taken on days 5, 7, 9 and 12 and separated into plasma and 
RBCs by centrifugation. Butaperazine was quantitated in both specimens 
by a fluorometric method (80). Plasma butaperazine concentrations 
ranged between 40 and 321 ng/ml at steady-state. RBC butaperazine 
concentrations ranged between 10.8 and 124 ng/ml. The ratios of RBC to 
plasma concentrations varied considerably from patient to patient (0.11 
to 0.66). A quadratic polynomial nonlinear equation derived by least 
squares showed that RBC levels fit better (r = 0.90) than did plasma 
concentrations (r = 0.58) versus therapeutic improvement. The authors 
remark: 
"Since physicochemical distribution factors such as affinity, 
capacity, lipid solubility and transport govern passage of drug across 
the blood-brain barrier and the localization of neuroleptic at critical 
central nervous system sites, it would be of considerable interest if 
similar distribution factors governing the accumulation of neuroleptic 
in or on the RBC were operative. Although such distribution factors 
have not been studied systematically, there is now clinical evidence 
indicating that RBC and functional central nervous system butaperazine 
levels may parallel one another". They later add: "although clinical 
pharmacology has generally focused on plasma levels of drugs, we suggest 
that RBC levels of neuroleptics may provide better correlates of 
therapeutic response". 
These researchers later reported a more extensive study involving 
24 hospitalized schizophrenic patients (81). Again, butaperazine con­
centrations in RBC correlated significantly with clinical improvement in 
an inverted U-shaped pattern (similar to the nortriptyline therapeutic 
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window), whereas plasma levels of butaperazine were not significantly 
related to clinical response. There were large interpatient variations 
in both plasma and RBC butaperazine concentrations. This more complete 
study substantiated the preliminary report. 
In 1982, Dahl, Bratlid and Lingjaerde (82) reported a study of 
plasma and erythrocyte levels of another antipsychotic drug, 
methotrimeprazine and two of its nonpolar metabolites. Heparinized 
blood samples were separated by immediate centrifugation for 10 minutes 
at 1500 x g. Drug and metabolite concentrations were quantitated by gas 
chromatography with a nitrogen detector. The plasma/erythrocyte ratio 
for drug and metabolites varied widely (approximately three fold for 
methotrimeprazine) among five patients and five volunteers. No clinical 
response data were included in this study. 
2. Antidepressant Study 
There is one limited study comparing plasma and 
erythrocyte TCA concentrations in depressed patients (83). Linnoila, 
Dorrity and Jobson studied steady-state drug concentrations in 59 
depressed inpatients. Plasma and RBC drug levels were measured by 
extraction and gas chromatography (84). They found the ratio of OMI to 
IMP to be similar in plasma and RBC (n=ll). The authors stated that 
patients administered DMI had similar plasma versus RBC correlations for 
DMI as did patients administered IMP although the number of DMI treated 
patients was small (n=4}. Independent analysis of the DMI treated 
patients RBC vs. plasma correlations would seem to indicate a difference 
from IMP treated patients for plasma DMI versus RBC DMI concentrations. 
There was poor correlation (r = .38, n=ll) between plasma IMP and RBC 
IMP concentrations. The authors conclude: "The interindividual 
variation in the RBC-plasma tricyclic level ratios was large enough to 
warrant further clinical studies on the relationship between efficacy 
and pharmacokinetics of tricyclic antidepressants". 
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However, since this initial study of the variation in 
plasma and RBC drug concentrations variation there has been no further 
investigation. The only related report was published in December, 1982 
by Schulz and Luttrell (85). They measured the plasma to whole blood 
ratio (P/B) and the plasma to erythrocyte ratio (P/E), as well as the 
free fraction in plasma of IMP and the concentration of a1-acid 
glycoprotein in four normal subjects and five cancer patients. It has 
been reported that the binding of IMP in plasma increases in parallel 
with the concentration of a1-acid glycoprotein (86), which is often 
elevated in subjects who have cancer or inflammatory diseases. Only one 
blood sample from each subject was analyzed. 3H-IMP was added to the 
heparinized blood samples. The free IMP fraction in cancer patients 
(range 1.8% to 5.3%) was lower than in normal subjects (range 5.3% to 
7.0%). The free IMP fraction was negatively correlated (r = -0.90) to 
the a1-acid glycoprotein concentration. The P/E ratio for all nine 
subjects ranged from 0.80 to 2.03 (mean = 1.17) and was only slightly 
correlated to hematocrit (r = -0.82). 
There is some evidence for antipsychotic medications that 
RBC drug concentrations may better correlate with clinical response than 
plasma concentrations. Interindividual variation exists in TCA 
distribution between plasma and RBC. Investigation of plasma and RBC 
TCA concentrations versus clinical response has not been investigated. 
It is not known whether RBC TCA concentrations may correlate better to 
clinical response than do plasma TCA concentrations. 
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G. Quantitation of Imipramine and Metabolites in Plasma and Tissues. 
The tertiary and secondary amine tricyclic antidepressants have 
been quantitated in the plasma of depressed patients for over ten years. 
There have been several recent reviews of the methodologies employed 
(87, 88, 89). Analytical techniques that have been utilized include gas 
chromatography with nitrogen detector, gas chromatography-mass 
spectrometry and high performance liquid chromatography with various 
detectors. In the last several years, these analytical procedures have 
been improved so that gas chromatography-mass spectrometry (GC-MS) (90) 
and HPLC (91) procedures are available that are specific, sensitive and 
reproducible. 
Interest in the quantitation of the 2-hydroxy metabolites of IMP 
has increased tremendously in the last three years. In early animal 
metabolism studies thin layer chromatographic methods were used that 
could be described as semi-quantitative at best. The first good 
quantitative method was published by Weder and Bickel in 1968 (92). For 
separation and quantitation, they used a gas chromatograph equipped with 
a flame ionization detector and an SE-30 six foot column. Metabolites 
of IMP were acetylated with acetic anhydride prior to injection. The 
real beauty of the paper is the description of blood and tissue 
extractions. They determined the partition coefficients of IMP and its 
metabolites (including DMI, DMD, 2HI and 2HD) between various organic 
solvents and aqueous buffers. Optimum pH values of the aqueous phases 
were determined for each compound. IMP and DMI were extracted at 
virtually 100% yield from aqueous buffers with pH above 8.5 by diethyl 
ether, 1,2-dichloroethane or n-heptane. 2HD had a narrow pH range for 
optimum extraction by both diethyl ether and 1,2-dichloroethane: 9.0 to 
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11.5. In this pH range these two solvents would extract 93% and 91%, 
respectively, of 2HD in 5 ml of aqueous phase using two 5 ml portions of 
solvent. Under identical conditions, a much more nonpolar solvent, 
n-heptane, would extract only 14% of the 2HD in the aqueous phase. 
These data compare favorably with the partition values between pH 7,4, 
isotonic, phosphate buffer and n-hexane or chloroform for IMP and 
metabolites given previously {68) as the percentage of compound in the 
organic phase: 
Compound 
IMP 
DMI 
DMD 
2HI 
2HD 
n-Hexane 
99.4 
65.1 
70.5 
25.2 
6.3 
Chloroform 
99.9 
98.5 
99.1 
97.4 
55.2 
Chloroform is a more polar solvent than is n-hexane. It is noted 
that more polar solvents (diethyl ether, 1,2-dichloroethane) extract the 
2-hydroxy metabolites, especially 2HD, much more efficiently than do 
very non-polar solvents (n-heptane, n-hexane). 
A GC-MS procedure using solvent extraction was reported in 1981 by 
Narasimhachari, Saady and Friedel for quantitating IMP, DMI and 
2-hydroxy metabolites (93). A very polar solvent, ethylacetate, was 
used at pH 9.0 for an initial extraction of plasma, followed by hexane: 
isopropanol (9:1) extraction at pH above 11. The d4-derivatives of IMP, 
OM!, 2HI and 2HD were used as internal standards. N-methyl-bis­
(trifluoroacetamide) was used to derivatize OM!, 2HI and 2HD prior to 
injection into the GC-MS system (90). Either a 3% OV-101 or 3% OV-17 
(90 cm) column was used for separation, and selected ion monitoring of 
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fragment ions of d4 and d0 compounds was used for quantitation. This 
procedure is' the most specific and. accurate method for quantitation of 
IMP and it's metabolites published. The use of deuterated internal 
standards is especially effective. 
The first report of an HPLC assay of IMP, DMI, 2HI and 2HD was that 
of Sutfin and Jusko (62). The chromatography was performed with 5 µm 
particle size, silica column (0.46 x 25 cm) and mobile phase of 
methanol-acetonitrile (1:5) with 4 ml per liter of ammonium hydroxide. 
A fluorescence detector (excitation at 240 nm, emission filter of 370 
nm) was utilized for detection and quantitation. They used N-desmethyl 
chlorimipramine as an internal standard and extracted plasma samples 
which were made alkaline with ammonium hydroxide. The extraction 
solvent was 20% n-butanol in hexane. The HPLC retention times were: 
IMP (6 minutes), 2HI (6.9 minutes), DMI (14.4 minutes) and 2HD (17.4 
minutes). The stated sensitivity of the procedure is 1 ng per ml of 
plasma for each compound. There are three problems with this HPLC assay. 
First, silica columns are not stable at alkaline pH with low molecular 
weight alcohols in the mobile phase without another source of silica such 
as a precolumn to saturate the mobile phase. Second, the extraction of 
2HD by a nonpolar solvent mixture (20% n-butanol in hexane) is in-
efficient. Third, one of the compounds expected in low concentrations, 
2HD, eluted last from the HPLC column (17.4 minutes) so that its peak 
height per amount injected will be lowest and, therefore, its sensitivity 
will be poorest. 
This procedure was later improved (64) in several ways. First, 
carbonate buffer, pH 10.2, was substituted for ammonium hydroxide as the 
plasma alkalinizer. This change brings the pH for extraction closer to 
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the pH optimum for the extraction of the 2-hydroxy metabolites, as found 
by Hect.er and Bickel (92). Second, they substituted a more polar extrac­
tion solvent, hexane:ether (1:1) with 5% isobutanol, for the 20% 
n-butanol in hexane. This more polar solvent should increase the 
extraction efficiency for 2HD. They also doubled the solvent to aqueous 
phase volume ratio to increase the extraction efficiency. The HPLC 
mobile phase was also modified. The methanol content was reduced and 
butylamine (0.5%) was substituted for ammonium hydroxide (0.4%). The 
solubility of the silica stationary phase is reduced in this mobile 
phase. 
Wong, McCauley and Kramer (94) developed an HPLC procedure for the 
quantitation of 2HD. This procedure required 2 ml of plasma and 2HI was 
used as internal standard. Carbonate buffer, pH 11, was used to adjust 
the aqueous phase pH before extraction with 10 ml of methylene chloride: 
isomyl alcohol (98:2). The organic phase was back extracted into 400 µl 
of pH 2.5 phosphate buffer. 350 µl was injected into the HPLC system. 
A 10 µm particle size c18 column (0.46 x 25 cm) and a mobile phase of 
phosphate buffer, pH 4.7: acetonitrile (75:25) were the separation 
system. A UV absorbance detector set at 254 nm was used to detect 2HD 
and the internal standard, 2HI. The flow rate was 2.7 ml/min and the 
column was heated to 43°C. The retention time for 2HD was about 8 
minutes. They reported a percentage recovery of 2HD of 68% with their 
extraction procedure. Their procedure did not measure DMI or IMP, how-
ever. 
Sackow and Cooper (95) developed an HPLC procedure using ampero­
metric detection for IMP, DMI, 2HI, and 2HD. Plasma v1as extracted at pH 
9.7 into ether, back extracted into O.lN HCl and re-extracted into ether 
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following alkalinization. An ion-pairing reagent, heptane sulfonate, 
was used in' a mobile phase of acetonitrile:acetate buffer, pH 4.2 
(40:60) with a 10 µm c18 column (30 x 0.39 cm). A model TL-4A electro­
chemical detector (Bioanalytical Systems, West Lafayette, Ind.) was used 
at a potential of+ 1.05 volts versus the silver-silver chloride 
reference electrode. 8-hydroxyclomipramine was the internal standard. 
The elution order was 2HD, 2HI,. internal standard, DMI and IMP. The 
detection limit for each was 5 ng/ml using 1 ml of plasma. The extrac­
tion procedure they employed was a significant improvement over those 
used previously because the initial pH for extraction was near optimum 
and a polar solvent, ether, was used. 
Quantitation of IMP, DMI and metabolites has steadily improved. 
However, a simple, accurate procedure for simultaneous quantitation of 
these compounds can be improved still. High performance liquid 
chromatography (HPLC) is a promising analytical method for this purpose 
when it is validated by a more specific method, i.e. gas 
chromatography-mass spectrometry (GC-MS). 
H. Statement of Purpose 
The first objective of this research is to develop a procedure for 
the simultaneous extraction and chromatography of IMP, DMI, DMD, 2HI and 
2HD. High performance liquid chromatography is to be used routinely and 
the results produced are to be validated by an established GC-MS method. 
The HPLC procedure must be shown to be practical, accurate and precise. 
IMP, DMI, DMD, 2HI and 2HD are to be quantitated in patient plasma 
and red blood cell specimens. It is to be determined which compounds 
accumulate in these specimens to significant concentrations. The plasma 
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and RBC concentrations are to be compared statistically to the degree of 
improvement' in the patient's depression as measured by the Hamilton 
Depression Ratings. 
Blood concentrations of the compounds will be compared to brain 
concentrations in autopsy specimens from human overdose fatalities and 
in animal models. The relative entry into the brain of significant 
metabolites found in blood will be compared to the parent drugs. The 
relative entry into brain of metabolites should help determine the 
significance of these metabolites because IMP and DMI are generally 
considered to have their site of action in the brain. 
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MATERIALS 
A. Standards 
Reference standards of imipramine, desipramine, 
2-hydroxyimipramine, 2-hydroxydesipramine and desmethyldesipramine.were 
gifts from Dr. A. A. Manian of the National Institute of Mental Health. 
Chl orimipramine was manufactured by Ciba-Geigy and obtained from the 
Medical College of Virginia Hospitals Toxicology Laboratory. Stock 
standards equivalent to 10 mg/1 iter of free base were prepared in 
methanol. Various working standards were prepared by dilution of stock 
standards with deionized water. Horki ng plasma based standards were 
prepared by diluting stock standards in salvage blood bank plasma 
obtained from the MCV Hospitals Blood Bank. 
B. Reagents 
1. Buffers 
Carbonate buffer, 10% and pH 9.7 was prepared by dissolving 10 
grams of sodium carbonate and 10 grams of sodium bicarbonate in about 
150 ml of deionized water. The pH was raised to 9.7 with 10 N sodium 
hydroxide. The volume was then brought to 200 ml with additional 
deionized water. 
Phosphate buffer, 0.6 M and pH 6.5 was prepared by dissolving 
16.6 grams of sodium phosphate, monobasic, monohydrate in about 180 ml 
of deionized water. The pH was lowered to 6.5 with concentrated 
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phosphoric acid. The volume was brought to 200 ml with deionized water. 
2. demicals 
Acetonitrile, methanol, hexane, ethyl acetate, isopropanol and 
methylene ch 1 ori de were a 11 either Waters Associates, Fi sher or Baker 
HPLC grades or Burdick and Jackson distilled in glass grade. 
Isoall\Yl alcohol was obtained from Fisher Scientific (A-393). 
Triethylamine 99% was obtained from Aldrich Chemical. 
Concentrated phosphoric acid, hydrochloric acid and 10 N 
sodium hydroxide were obtained from Fisher Scientific. 
N-methyl-bis-(trithioroacetamide) was obtained from Regis 
Chemical Co. (270091). 
Salts were all ACS reagent grade. 
Sodium heparin was obtained from Riker Labs, Inc. (Lot 80862, 
expiration date Jan. 83) and was 10,000 units/ml. 
C. Instrumentation 
1. HPLC 
The HPLC pump was either a Waters Model 6000A or a BIO-RAD 
Model 1330. The HPLC detector was either a Waters 440 Absorbance 
Detector or a Kratos Spectrofl ow 773 Absorbance Detector. The strip 
chart recorder was Houston Instruments D5217-2. A Waters Model U6K 
injector was used. The HPLC column was either a Waters RCM cyanopropyl 
cartridge ( 84636) with a RCSS Guard-PAK insert ( 85826) in a RCM 100 
module or a Altex 5 µm cyanopropyl column (Ultrasphere, 242950) 15 cm x 
4.6 mm. 
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2. GC-MS 
Either a Finnigan model 4000 or a Hewlett-Packard Model 5985 
GC-MS system was used. 
3. Miscellaneous 
Tissue homogenization was performed with a TRI-R STIR-R Model 
K43 (TRI-R Instruments). 
The centrifuge was a Damon/IEC HN-SII model. 
The pH meter was a Corning Digital 109 equipped with an A. H. 
Thomas Co. electrode (#4094 L15). 
A Meyer N-Evap Analytical Evaporator (Organomation Associates) 
was used for solvent evaporation. 
D. IMP and DMI Autopsy Specimens 
All blood was drawn by cardiac puncture. 
IMP Fata 1 i ty: A 46 year old white ma 1 e was found dead. Numerous 
{approx. 20) empty bottles of IMP were found at the scene. Decedent 
last seen four days prior to discovery of body. A note dated one day 
prior to discovery was found at the scene. The brain specimen analyzed 
consisted of approximately equal portions of cortex and midbrain. 
DMI Fatility-I: A 23 year old white female was found dead. She had 
a history of mental illness. No other information was available. The 
brain specimen was cortex. 
DMI Fatality-II: A 38 year old woman was taken to an emergency 
room after ingesting approximately 100 DMI tablets (50 mg) and 100 
Ativane tablets. She died 36 hours after arrival. The brain specimen 
consisted of cerebellum and brain stem. 
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METHODS 
A. HVMAN STUDIES 
1. Depressed patients treated with imipramine 
This study was conducted by the Department of Psychiatry, 
MCV-VCU in conjunction with the Upjohn Company. Dr. R. O. Friedel was 
the Chief Investigator. Patients were "symptomatic volunteers" who 
responded to a newspaper ad in which a self-rated version of the 
Hamilton Depression Scale (HDS) was included. Inclusion criteria (96) 
were: 
a. Age 18 to 65 inclusive. 
b. A Raskin Depression Scale score of 8, a HDS score of 18 
and a Cori Anxiety Scale score equal to or less than the Raskin score. 
These three scales are standard psychiatric tools for assessing depres­
sion and anxiety. 
c. At least 3 of the 5 positive indicators of tricyclic 
response defined by Bielski and Friedel (36): insidious onset, anorexia, 
weight loss, middle and/or late insomnia, and psychomotor retardation or 
agitation. 
d. Depressive diagnosis. 
e. Voluntary participation and informed consent. 
Exclusion criteria were: 
a. Patients who are psychopathic, sociopathic or psychotic. 
b. Patients ·with any form of bipolar depression, or 
schizo-affective depression or "involutional" depre�sion. 
c. Significant liver or kidney disorder. 
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d. Patients with uncontrolled cardiovascular, pulmonary, 
endocri no 1 ogi ca 1 or co 11 a gen diseases or glaucoma or conditions ,where 
IMP is contraindicated. 
e. Patients with a history of urinary retention, paralytic 
ileus and convulsive disorders. 
f. Indi vi dua 1 s known to be sensitive to benzodi azepi nes or 
TCAs or actively abusing alcohol or other drugs. 
g. Patients requiring other psychotropic medication, 
hypnotics or analgesics containing narcotics. 
h. Patients receiving anticholinergic drugs or preparations 
containing sympathomimetic amines. 
i. Patients receiving guanethidine, propanolol, methyldopa or 
thyroid medications. 
1 i st. 
j. Patients who cannot read and understand the symptoms check 
k. Females of child-bearing potential. 
Patients in this study received IMP or alprazolam. The 
IMP dose was gradually raised to 225 mg per day over a two week period. 
They remained at that dose for another four weeks unless side effects 
required dosage reduction to the last well-tolerated dose. Prior to 
the start of medication, a one week placebo period was used to determine 
p 1 acebo responders. If the patient's HDS dropped be 1 ow 18, they were 
considered placebo responders and were removed from the study. At the 
end of the weeks 1, 2, 4 and 6, most of the patients treated with IMP 
finished the entire six weeks of the study. Only plasma was analyzed 
for IMP and metabolites in some patients. All blood samples for drug 
analysis were drawn in the morning prior to the first dose of the day. 
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Patients were evaluated by HOS and other ratings and had blood drawn for 
drug analysis 
Name 
J-1 
A-1 
M-1 
J-1 
H-1 
D-1 
C-1 
J-3 
H-2 
H-3 
H-4 
E-1 
D-2 
B-2 
B-3 
B-3 
W-1 
R-1 
K-1 
H-5 
C-2 
C-3 
T-1 
A-2 
N=24 
Patients Treated with Imipramine 
Steady State 
IMP Dose Sex � 
(mg/day) 
225 F 32 
225 F 36 
225 F 27 
225 F 51 
225 F 44 
225 M 31 
200 M 56 
200 M 22 
225 F 40 
225 F 34 
225 M 47 
225 F 41 
225 M 24 
225 F 23 
200 F 46 
225 M 51 
200 F 38 
100 F 45 
225 M 33 
200 F 47 
225 M 32 
225 M 32 
200 M 45 
200 F 29 
M=9 Mean 37.7 
F=15 ± 9.4 
2. Depressed patients treated with desipramine 
RBC analysis 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
N=12 
This study was conducted by the Department of Psychiatry, 
MCV-VCU in conjunction with the National Institute of Mental Health. 
Dr. R. 0. Friedel was the Chief Investigator. Again, "symptomatic 
volunteers" recruited via a newspaper ad were the subjects. Inclusion 
criteria (97) were: 
a. Age 18 to 60 inclusive. 
b. Patient must sign informed consent form. 
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c. Patient must fulfill the Research Diagnostic Criteria for 
depression (15) and the Bielski and Friedel criteria (36) for response 
to tricyclic antidepressants. 
Exclusion criteria were: 
illness. 
trophy. 
a. Reported heart, kidney, liver, metabolic or other medical 
b. Narrow angle glaucoma or symptomatic prostatic hyper-
c. Patient taking thyroid medication. 
d. Patient taking MAO inhibitors within 14 days, TCAs or 
antipsychotic drugs within 7 days, benzodiazepines, barbiturates, opiates 
or psychostimulants within 3 days or meprobamate or sedative/hypnotic 
medications within one day of entering study. 
months. 
e. Patient having received electroconvulsive therapy within 2 
f. Patient is a female who is pregnant, nursing, or without 
reliable birth control. 
g. Patient is receiving psychotherapy. 
h. Patient is an alcoholic who has been dry less than 2 
years. 
i. Patient has had one or more distinct periods with pre­
dominantly elevated, expansive or irritable mood (mania) and patient has 
had one �,eek duration during which, for most of the time, at least 3 of 
the following have persisted (4 if mood is only irritable) and have been 
present to a significant degree: 
50 
1. increase in activity (either socially, at work, or 
sexually) or physical restlessness. 
2. more talkative than usual or pressure to keep 
talking. 
3. flight of ideas or subjective experience that 
thoughts are racing. 
4. inflated self esteem (grandiosity, which may be 
delusional). 
5. decreased need for sleep. 
6. distractibility. 
7. excessive involvement in activities that have a high 
potential for painful consequences which are not 
recognized, e.g. buying sprees, sexual 
indiscretions, foolish business investments, 
reckless driving. 
The 21 item Hamilton Depression Scale (HOS) was used to rate 
severity of depression. Subjects chosen to begin the study were treated 
one week with placebo. Those whose HOS scores dropped below 18 or 
dropped dramatically (for example, from 42 to 22) were removed from the 
study and referred for further treatment. All patient's doses were 
raised up to 300 mg per day of des i prami ne over a one week period and 
continued with 300 mg per day for another four weeks. At this point, 
one-half of the patients, chosen randomly, had their dosage reduced to 
an amount predicted to result in a 100 ng/ml plasma concentration of 
DMI. This dose was calculated by the following equation: 
New Daily Dose (mg) = 300 mg X 100 ng/ml 
Vis 6 (ng/ml) 
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Where Vis 6 (ng/ml) is the plasma DMI concentration of the blood sample 
drawn on vis'it 6 (visit 6 occurs after three weeks of DMI treatment) of 
the patient. This new dose is continued for three additional weeks. 
The other one-half of the patient population were continued on 300 
mg/day for those three weeks. Each week after iniation of DMI therapy, 
the patients were evaluated with the HOS and other rating systems to 
determine clinical status and they had a blood sample drawn into a green 
top Venoject™ 10 ml tube containing 143 units of sodium heparin. These 
blood samples were drawn for drug analysis. The visits to the clinic 
were timed so that the blood sample could be taken 12 hours after the 
previous nights dose of DMI. All patients except EW #10 and WK #11 had 
drug analysis of RBC samples as well as plasma. 
Initials and Number 
EW #10 
WK #11 
MJ #16 
CA #18 
JB #19 
GW #21 
MO #23 
SJ #24 
BB #27 
EM #28 
DB #29 
EW #32 
N=12 
Patients Treated with Desipramine 
New Daily Dose (mg) 
Sex � If A[![!licable 
M 38 
F 34 
F 51 150 mg 
F 32 
F 30 125 mg 
M 40 100 mg 
F 34 100 mg 
F 23 
F 37 250 mg 
F 41 
F 35 75 mg 
F 29 100 mg 
M=2 Mean 35.3 
F=lO ± 6.7 
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The patient blood specimens were labelled with the visit number, 
date and pa
i
tient initials and number. The visits correspond to weeks 
after start of DMI therapy as follows: 
Number of Weeks After 
Initiation of DMI Treatment 
1 
2 
3 
4 
5 
6 
7 
8 
Vis it Number 
Vi sit 4 
Visit 5 
Vi sit 6 
Visit 7 
Visit 8 
Visit 9 
Visit 10 
Visit 11 
Patients in both the IMP and DMI studies were allowed to smoke and 
to drink alcohol in moderation. 
3. Clinical status versus drug concentrations 
Patients were evaluated for severity of depression by ex-
peri enced psychiatric cl i ni ci ans using the 21 item Hamil ton Depression 
Scale (HOS; see Appendix II). For each patient, the HOS scores prior to 
placebo treatment and after one week of placebo treatment were averaged 
to determine the Severity Index. For IMP treated patients, the HOS 
score from week 6 of treatment was subtracted from the Severity Index to 
determine the Raw Improvement score. For DMI treated patients, the HOS 
scores from visits 7 and 8 (weeks 4 and 5 of treatment with DMI) were 
averaged and substracted from the Severity Index to produce the Raw 
Improvement score for each subject. 
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For the DMI treated subjects the following Pearson correlations 
(98) were determined: 
1. Severity Index vs. Raw Improvement 
2. Raw Improvement vs. Plasma DMI, Plasma DMI + 2HD, RBC DMI 
and RBC DMI + 2HD. 
In addition, Partial correlations (99) between Raw Improvement and 
each of plasma DMI, plasma DMI + 2HD, RBC DMI and RBC DMI + 2HD were 
made controlling for The Severity Index. Spearman' s rank difference 
correlations (.100) were calculated for Raw Improvement vs. plasma DMI 
and RBC DMI. 
For IMP treated patients, Pearson correlations were made for: 
1. Severity Index vs. Raw Improvement. 
2. Raw Improvement vs. plasma IMP, plasma DMI, plasma IMP+ 
DMI, plasma IMP/DMI, RBC IMP, RBC DMI, RBC IMP+ DMI and 
RBC IMP /DMI. 
Human blood specimens were collected via venopuncture by trained 
medical personnel. Blood was drawn by evacuated Venoject™, 10 ml blood 
collection tubes containing 143 units of sodium heparin and immediately 
mixed by repeated inversion. The tubes were labelled with the patients 
name, the date, the study name and visit number when applicable. The 
blood samples were then immediately transported to the Clinical 
Psychopharmacology Laboratory (CPL). The time interval between blood 
drawing and receipt at the CPL was generally less than one hour. 
Immediately upon receipt at the CPL, the plasma and red blood cells 
were separated. The conditions of separation were consistent. The 
blood tubes were spun in the outer slots (mid point radius of 4 inches) 
of the Damon/IEC model HN-SII centrifuge for 10 minutes at 3/4 full 
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speed (3000 x g). The plasma was removed with a 5 inch pasteur pi pet 
and placed 'in a clean 16 x 100 mm borosilicate glass test tube and 
tightly sealed with a double layer of Parafilm™ . The upper layer 
(approximately one quarter inch) which consisted of the left-over 
plasma, the white cells and the upper red cell layer was removed with 
the pasteur pipet and discarded. The packed red blood cells were left 
in the original Venoject tube and recapped with the original green 
rubber stopper. The plasma and RBC specimens were stored at -20°C until 
analyzed. 
4. Overdose Fatality Studies 
Whole blood and brain tissues from the overdose fatalities 
were removed during autopsy at the Chief Medi ca 1 Examiner's office in 
Richmond, Virginia. All whole blood was obtained by cardiac puncture 
and placed in 16 x 150 mm glass tubes and capped with a cork. Brain was 
placed in waxed cardboard containers which were not air or liquid tight. 
Both specimens were stored frozen in the Bureau of Forensic Sciences 
laboratory specimen freezers. They were labelled with the deceased's 
name, the case number and type of specimen. Portions of the brain 
samples (see Materials) were dissected away and transferred to clean 
polyethylene tubes and transported to the CPL. 
B. ANIMAL STUDIES 
1. Rat 
a. Chronic IMP and DMI treatment 
A tot a 1 of twenty male Sprague-Dawley rats ( 175 to 200 
grams each) were used in this study. Each rat was injected i.p. with a 
five milliliter syringe and 20 gauge needle twice each day for five 
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days. The rats were divided into four groups of five animals each. For 
the four gro'ups, each injection contained: 
Group 
Group I I 
Group III 
Group IV 
5 mg/kg IMP 
10 mg/kg IMP 
5 mg/kg DMI 
10 mg/kg DMI 
.The dosing solutions were 1 milligram of drug per 
milliliter of deionized water. All rats were considered to be 200 grams 
so that 5 mg/kg injections were 1.0 milliliter and 10 mg/kg injections 
were 2.0 milliliters. The rats were dosed each day between 8:30 to 9:30 
a.m. and 8:30 to 9:30 p.m. The last dose was at 8:30 a.m. and the 
animals were sacrificed that day between 5:30 and 8:00 p.m. Blood was 
collected with sodium heparin (143 units in green top Venoject tubes) to 
reduce clotting and brains were removed within three minutes of decapi­
tation. Plasma, RBCs and whole brains were analyzed for IMP, DMI, 
DMD, 2HI and 2HD for the IMP treated rats and DMI, DMD and 2HD for the 
DMI treated rats. 
b. 2HD and DMI rat distribution study 
Ten male Sprague-Dawley rats, each weighing 175 to 200 
grams, were injected i.p. with 7.5 mg/kg of 2HD and 12.5 mg/kg of DMI in 
2.0 ml of deionized water using a 5 ml syringe with a 20 gauge needle. 
Five rats 1-1ere sacrificed by decapitation exactly 30 minutes after 
injection and the other five exactly 60 minutes after injection. 
Immediately, whole blood \'las collected in sodium heparin (143 units) 
containing tubes and the brains were removed. Plasma and brains were 
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analyzed for 2HD and DMI. 
c. Specimen collection 
Rats were sacrificed by decapitation and blood collected 
immediately from the torso through a funnel into uncapped 10 ml Venoject 
blood collection tubes containing 143 units of sodium heparin. The 
tubes were shaken during collection, then immediately capped and more 
vigorously shaken to mix the b 1 ood and heparin to prevent c 1 otti ng. 
Approximately 2 to 4 milliliters of blood was collected from each.rat. 
The entire collection time from decapitation to capping the tube was ten. 
seconds or less. 
The rat skull was then opened with scalpel and scissors 
and the entire brain removed and placed in a standard glass scintilla­
tion counting vial and the cap screwed on. The brain sample was then 
placed on ice. The entire process from decapitation to placing the 
brain sample on ice took approximately two minutes for each rat. Speci­
mens were collected from a group of ten animals and transported to the 
CPL. Brains were stored in the scintillation vials at -20° C. Blood 
tubes were centrifuged exactly the same as described for human blood. 
Plasma was transferred to 10 mm x 50 mm borosilicate glass tubes, sealed 
tightly with a double layer of Parafilm and labelled with the animal 
identification number (as were the original Venoject tubes and the brain 
containers). The residual plasma layer (approximately 2 millimeters) 
was removed from packed red blood cell specimens and discarded. To each 
RBC sample was added 2.0 ml of deionized water for dilution and 
hemolysis and the tubes vortexed. The original green rubber cap was 
replaced. The rat plasma and diluted RBC samples were then immediately 
p 1 aced upright in a -20°C freezer. The 1 onges t period of ti me from 
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sacrifice to placement of plasma and diluted RBC samples in the freezer 
for any ani�al was 70 minutes. 
2. Rabbit 
a. Chronic DMI treatment 
Five male New Zealand white rabbits, each weighing 
between 4 and 5 pounds, were injected twice a day with 5 mg/kg of DMI. 
Each injection was 2.5 ml of a 5 mg/ml solution of DMI in deionized 
water. The rabbits were injected i.p. with a 5 ml syringe and 20 gauge 
needle. They were dosed four days with the last .injection at 8 a.m. 
Blood was drawn at 2 p.m. by cardiac puncture into a 10 ml syringe (with 
21 gauge needle) containing 150 USP units of sodium heparin ( 15 µ l of 
10,000 U/ml). Brains were removed between 4:00 and 8:00 p.m. after 
anesthesia with methoxyflurane and CSF sample procurement. Plasma, RBC 
and brain samples were analyzed for DMI, and 2HD. 
b. Expired rabbit studies 
Three male New Zealand white rabbits, each weighing 
between 4 and 5 pounds, died within 24 hours of receiving a 10 mg/kg 
injection of DMI. The first rabbit that died on 12-15-82 had blood 
collected by cardiac puncture when he was discovered dead. No brain 
tissue was removed. The subsequent two rabbits that were found dead on 
12-16-82 and on 12-20-82 had whole blood and brain specimens taken. All 
whole blood and brain samples were analyzed by HPLC for DMI and 2HD. 
c. 2HD and DMI distribution study 
Two male New Zealand white rabbits, each weighing 
approximately five pounds, were injected i .p. with 1 ml of deionized 
water containing 7 mg of 2HD and 12.5 mg of DMI with a 5 ml syringe and 
19 gauge needle. Exactly 20 minutes after each injection, 10 ml of 
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blood was drawn by cardiac puncture into a 10 ml syringe containing 150 
USP units ot sodium heparin. Immediately after each blood sample, the 
rabbits were killed by air injection (40 ml) into the lateral ear vein. 
Approximately one minute of time elapsed between blood sampling and 
death. Immediately after the rabbits died, their brains were removed 
surgically. Approximately twenty minutes elapsed between death and 
complete brain removal. Plasma, RBC and brain specimens were analyzed 
for 2HD and DMI by the HPLC method. 
d. Specimen collection 
All rabbits were sacrificed by the injection of at least 
30 milliliters of air into a lateral ear vein with a 20 milliliter 
plastic syringe and a 21 gauge needle. Blood specimens from live 
rabbits were obtained by cardiac puncture with alt inch long, 19 gauge 
needle connected to a 10-milliliter plastic syringe containing 150 units 
of sodium heparin (15 µl of 10,000 units per milliliter). Ten milli-
1 iters of blood were drawn into the syringe. Within one hour the 
syringe was transported to the CPL. The needle was removed and the 
blood transferred to a 10 x 100 mm borosilicate glass test tube. All 
blood samples were centrifuged and plasma and RBC specimens separated. 
Post mortem blood specimens were obtained by cardiac 
puncture after the chest was surgically opened. Three milliliter 
sterile syringes with 19 gauge needles were used. Approximately 1 to 
1.5 milliliters of blood were obtained. After transport to the CPL, the 
blood was transferred to 10 mm x 50 mm borosilicate glass test tubes, 
sealed with a double layer of Parafilm, labelled �1ith the date and 
rabbit identification number and stored at -20°C. 
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Brain samples were obtained as follows: immediately 
following de'ath, the skin covering the top of the skull was slit from 
the nose to the back of the neck and then pulled to the sides. A bone 
saw was used to cut through the skull from between the eyes to the base 
of the neck and between the ears. The skull was then chipped away with 
a small pair of surgical pliers to expose the brain. The brain stem and 
larger nerves were cut where they entered the skull and the entire brain 
removed in one intact piece to a sterile six ounce polyethylene specimen 
container. The container was labelled with the rabbit's identification 
number and placed on ice. The brain removal process took approximately 
5 to 10 minutes for each rabbit. The brains were stored in the specimen 
containers at -20°C in the CPL. 
The first group of five rabbits for the desipramine 
metabolism and distribution study were anesthetized after the cardiac 
puncture for blood specimen and before sacrifice so that cerebrospinal 
fluid could be obtained by puncture of the cisterna magna and removal by 
syringe. Methoxyflurane was used as the inhalation anesthetic by spray­
ing 5 ml of the solution on the walls of the glass chamber in which the 
rabbit was enclosed. The rabbits were killed while still anesthetized. 
The time between cardiac puncture and sacrifice ranged between 2 and 4 
hours for this group of rabbits. 
For all other rabbit studies, the time between cardiac 
puncture and sacrifice was less than one minute. Post mortem blood 
samples were obtained within 5 minutes of brain removal. 
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C. IN VJTRO STUDIES 
1. Pla�ma-RBC equilibration 
Four 10 ml Venoject tubes containing 143 units of sodium 
heparin were filled consecutively by venopuncture from one human 
volunteer. By injection with a 50 µ 1 Hamilton syringe through the 
rubber stopper was added 25 µl of aqueous DMI-DMD-2HD working standard 
(100 ng/µl DMI, 40 ng/µl each of DMD and 2HD) for a total of 2500 ng 
DMI, 1000 ng DMD and 1000 ng 2HD. The test tubes were placed in a 37°C 
water bath-shaker and shaken throughout the incubation. One tube was 
incubated 5 minutes, another 10 minutes, another 20 minutes and the last 
60 minutes. Each tube was immediately placed in the centrifuge after 
removal from the water bath and spun 10 minutes at 3000 x g. The plasma 
and red blood cells were separated as described earlier. To the RBC 
fraction of each tube was added 5.0 ml of deionized water to hemolyze 
the cells and the tubes restoppered and vortexed 10 seconds. All plasma 
and RBC samples were labelled by the incubation time (5, 10, 20 or 60 
minutes) and stored at 4°C overnight. The following day they were 
analyzed for DMI, DMD and 2HD. 
2. Equilibration from RBC to plasma 
Three 10 ml Venoject tubes con ta i ni ng 143 units of sodium 
heparin were filled consecutively by venopuncture from one human 
volunteer. Plasma �,as separated from the RBC as before. To each RBC 
fraction was added 25 µl of the DMI-DMD-2HD working standard (total 2500 
ng DMI, 1000 ng DMD and 1000 ng 2HD), the tubes were restoppered and 
thoroughly mixed by repeated gentle inversion. The RBC fractions were 
then incubated 15 minutes at 37 °C and remixed each 5 minutes. After 
this incubation, the plasma was returned to its original RBC fraction 
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and the blood mixed by repeated inversion. Each blood tube was 
incubated in' a 37 °C water bath-shaker for 20 minutes. The plasma and 
RBC were then reseparated and 5.0 ml of deionized water added to each 
RBCs fraction. The tubes were labelled as either 1,2 or 3 to identify 
the corresponding plasma and RBC samples. All were stored overnight at 
4°C. The following day each sample was analyzed for DMI, DMD and 2HD. 
3. Plasma-RSC distribution over time 
One 10 ml tube of heparinized blood was drawn from the same 
volunteer one week, two weeks, three weeks, five weeks and eight weeks 
after the pl asma-RBC equilibration study above. The same quantity of 
DMI-DMD-2HD working standard was added to each tube as in the 
equilibration study. The blood samples were incubated at 37 °C with 
shaking for 20 minutes. Then, the plasma and RBCs were separated, 5.0 
ml of deionized water added to the RBCs and the tubes labelled. The 
samples were stored at -20°C. After the eighth week sample, all were 
thawed as was the 20 minute equilibration sample. Each was analyzed for 
DMI, DMD and 2HD. 
4. Saturation study 
Five 10 ml tubes of heparinized blood were drawn consecutively 
by venopuncture from the same volunteer as in the previous studies. The 
tubes were labelled as 250, 500, 1000, 2000 and 3000 and were injected 
by syringe through the stopper with 25, 50, 100, 200 and 300 µl of 
DMI-DMD-2HD working standard solution respectively. All were incubated 
together for 20 minutes in a 37 °C water bath with shaking. They were 
immediately removed and the plasma and RBC fractions separated. 5.0 ml 
of deionized water was added to each RBC sample. The samples were 
stored at 4°C overnight and analyzed for DMI the next day. 
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5. Normal population plasma-RBC distribution study 
F'ifteen vo 1 unteers had one 10 ml tube of hepari ni zed b 1 ood 
drawn by venopuncture. There were eight males and seven females, five 
persons age 40 or over and 10 below age 40 and all appeared healthy. 
Each tube of blood was injected with 30 µl of DMI-DMD-2HD working 
standard solution. The blood samples were incubated 20 minutes in the 
37 °C water bath with constant shaking. They were then removed and 
centrifuged 10 minutes at 3000 x g. For each sample, the RBC volume 
height and total blood height were measured from the bottom of the tube. 
The plasma and RBCs were then separated and stored at 4°C overnight. 
All samples were analyzed the next day for DMI, DMD and 2HD and then 
re-frozen. Plasma was analyzed about a week later for total protein, 
albumin, cholesterol and electrolytes by the Technicon SMAC continuous 
flow analyzer by a qualified medical technologist at MCV Hospital 
Clinical Chemistry Laboratories. 
6. Drug and metabolite stability 
To 2 ml aliquots of heparinized whole blood from a normal 
volunteer were added IMP, DMI, DMD, 2HI or 2HD to make concentrations of 
200 ng per milliliter. The blood aliquots were mixed by vortexing five 
seconds and then incubated at 37 °C for one hour with shaking. All 
samples were then stored overnight at 4°C. One aliquot containing each 
drug or metabolite was analyzed the next day by the HPLC procedure. 
Another aliquot of each was stored at -20°C for eight weeks, then thawed 
and analyzed in the same manner. 
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D. ANALYTICAL METHODS 
1. Pl a'sma Extractions 
a. SEP-PAK 
All solutions were manually forced through the 
c18 
SEP-PAK cartridges with a 10 ml glass syringe (101). The long end of 
the SEP-PAK is connected to the syringe according to the package insert. 
The solution flow rate through the SEP-PAK was approximately one drop 
per second (3 ml per minute) or slower. SEP-PAKs were activated by 
pushing 4 ml of methanol and then 5 ml of deionized water through them. 
For each solvent to be tested, 1.0 ml of blood-bank, 
drug-free plasma containing 100 ng per ml each of IMP, DMI, 2HI and 2HD 
was placed in a clean 16 x 100 mm test tube. 200 ng of chlorimipramine 
tube. 0.5 ml of carbonate buffer, pH 9.7, was then added to each and 
all tubes were vortexed 5 seconds. The plasma solution was transferred 
to the 10 ml syringe with a 9 inch Pasteur pipet. Each sample mixture 
was then pushed through a new, activated c18 SEP-PAK cartridge. Each 
SEP-PAK was then rinsed with 2 ml of deionized water. The Pasteur 
pipet and 10 ml syringe were rinsed with deionized water between each 
sample. After all the plasma samples were eluted, the 10 ml syringe was 
rinsed with 10 ml of deionized water and 10 ml of methanol. The 
following solvent combinations were used to extract separate SEP-PAKs: 
A. Ethyl Acetate 
B. Hexane:Isopropanol (9:1) 
C. Hexane:Isoamyl Alcohol (98.5:1.5) 
D. Methylene Chloride 
E. Hexane:Ethyl Acetate (2:1) 
F. Acetonitrile 
G. Methylene Chloride:Isopropanol (9:1) 
H;. Methylene Chloride:Ethyl Acetate (1:1) 
I. Methylene Chloride:Hexane (1:1) 
J. Methylene Chloride:Ethyl Acetate: Isopropanol (5:4:1) 
K. Hexane:Ethyl Acetate:Isopropanol (5:4:1) 
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Each contained 1% isoamylalcohol except C. 4 ml of the 
solvent were transferred with a 9 inch Pasteur pipet to the 10 ml 
syringe connected to the SEP-PAK. The syringe plunger.was inserted and 
the solvent slowly pushed through. The first five drops of liquid from 
the SEP-PAK were discarded. The rest of the solvent was collected in 
clean 5 ml conical glass tubes, one for each SEP-PAK. All extracts were 
then centrifuged for 5 minutes at 3000 x g. If any aqueous phase was 
noted on the bottom or top of the solvent, it was carefully removed and 
discarded with a clean Pasteur pipet. Tube F had no aqueous phase. All 
extracts were dried under a stream of nitrogen nitrogen in a 40°C water 
bath. All SEP-PAKs were then re-eluted with 4 ml of the same extraction 
solvent that was originally used for that SEP-PAK. These extracts were 
added to the first extract and were then evaporated under a stream of 
nitrogen in the 40°C water bath until they contained approximately 0.5 
to 1 ml of solvent. They were vortexed several seconds to rinse the wall 
of the tube and evaporated completely. For each sample, the second 
extract was evaporated just prior to injection into the HPLC. They were 
redissolved in 50 µ l of methanol , vortexed 15 seconds and 25 µl was 
injected. Prior to any sample injection and interspersed in the sample 
injections were 5 µl injections of a solution of IMP, DMI, 2HI, 2HD 
(each 2 ng/µl) and CMP (4 ng/µl). These standard injections were used 
to determine the absorbance {by peak height) of standard amounts of the 
65 
compounds and the retention times. The Waters Radial Compression Module 
with .10 µm' cyanopropyl cartridge was used with a flow of 1.5 ml per 
minute of mobile phase (acetonitrile:methanol; water: 0.6 M Na H2 P04: 
triethylamine, 400:300:300:6:1.2, pH 7.43). The detector was always set 
at 254 nm and 0.005 absorbance units full scale. 
The extraction efficiences were determined by calculating 
the peak height in millimeters per ng of standard compound, then 
determining the amount of each compound injected from the extractions by 
their peak height. This amount was doubled because 50% of each extract 
was injected (25 of 50 µl) and then divided by 100 ng for the drug or 
metabolite (100 ng/ml plasma) or 200 ng for the internal standard. This 
ratio was multiplied by 100 to determine the extraction efficiency in 
percent. 
b. SEP-PAK with back extraction 
Plasma based standards containing IMP, DMI, DMD, 2HI and 
2HD were made with each compound in concentrations of 20, 50, 100, 200 
and 400 ng per milliliter. 1.0 ml of plasma standard, 500 ng of CMP (25 
µl of 20 ng per µl of deionized water) and 0.5 ml of carbonate buffer 
were mixed by vortexing 5 seconds in a 16 x 100 mm test tube. Each was 
eluted through a new activated c18 SEP-PAK which was then rinsed with 2 
ml of deionized water. Each SEP-PAK was extracted with 4 ml of 
hexane:ethyl acetate:isopropanol:isoamyl alcohol (5:4:1:0.1) as 
described in the previous section. The solvent was evaporated and the 
SEP-PAK was extracted with another 4 ml of the same solvent. The tubes 
were evaporated to 0.5 to 1 ml remaining, vortexed several seconds and 
evaporated completely. 100 pl of 0.1 N hydrochloric acid:acetonitrile 
(50:50) were added to each tube, �1hich 1·1ere then vortexed 10 seconds. 
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100 µl of hexane:isoamyl alcohol (98.5:1.5) were added to each and all 
were vortex'ed 30 seconds and centrifuged 5 minutes. The upper hexane 
layer was carefully and completely removed with a 100 µl Hamilton 
syringe and discarded. 50 µl of 0.6 M NaH2 P04, pH 6.5, were added to 
each tube and they were mixed by vortexing 5 seconds. 50 or 100 µl of 
this solution was then injected into the HPLC. The Waters Radial 
Compression Module with 10 µm cyanopropyl cartridge was used. The flow 
rate was 1.5 ml/min. The mobile phase was acetonitrile:water:0.6 M NaH2 
P04:triethylamine (425:375:10:2, pH 6.50). 
The peak heights measured at 254 nm and 0.005 AUFS were 
used for quantitation. Each drug or metabolite peak height was divided 
by the CMP peak height to obtain the peak height ratio (PHR). A 
standard curve for each compound was produced by plotting the PHRs 
versus standard concentrations on linear graph paper. Linear regression 
was used to determine the best line and the correlation coefficient (r) 
for each drug and metabolite. 
Nine patient serum samples (six DMI treated and three IMP 
treated) and a control serum sample were received from the Clinical 
Toxicology Laboratory of the MCV Hospitals after they �1ere analyzed 
there by a gas chromatography-mass spectrometry procedure using a 
solvent extraction (90). They were analyzed in the CPL the same day by 
the back extraction SEP-PAK procedure detailed above. A total of 
fourteen IMP and DMI values were compared by the two separate 
procedures. No 2HI, 2HD or DMD concentrations were available from the 
GC-MS analysis. 
Plasma based standards were extracted and chromatographed 
with all unknown plasma samples. Each run of 4 to 8 unknowns included 
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at least three standards. Comparison of the PHRs for each drug and 
metabolite 'from one run to the next was made. The mean PHR, standard 
deviation and relative standard deviation (S.D. -; mean PHR x 100) was 
calculated for each compound at each standard concentration (20, 50, 
100, 200 and 400 ng/ml). The composite slope, y intercept and 
correlation coefficient were calculated by linear regression for each 
compound. 
c. Solvent extraction 
Solvent extractions were done in 16 x 150 mm glass tubes 
with screw-on Teflon lined caps. The final extracts were evaporated in 
5 ml conical bottom glass tubes. All glassware was washed with labora­
tory detergent, rinsed three times with tap water and three times with 
deionized water. It was dried overnight in an 80°C oven. All tubes 
used for extractions were rinsed with extraction solvent prior to use. 
All mixing of aqueous solutions and organic solvents was performed by 
tightly capping the extraction tubes and vortexing each tube twice for 
15 seconds. The tubes were then centrifuged six minutes at 3000 x g. 
The organic solvent phase was then transferred with a 9 inch Pasteur 
pipet to the evaporation tube. 
The evaporation of organic extracts was done under a 
stream of nitrogen in a 40 to 50°C water bath. They were always dried 
to about 0.5 ml of volume, vortexed several seconds and then evaporated 
completely. They were removed from the water bath and redissolved in 
the HPLC mobile phase. 
The Waters RCM with cyanopropyl cartridge (10 µm) was 
used with a mobile phase of water:acetonitrile:methanol: 0.6M NaH2 
P04:triethylamine (200:150:150:8:1), pH 6.5. The flow rate was 1.4 ml 
per minute. The detector was set at 254 nm and 0.005 AUFS. 
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1.0 ml each of blood bank plasma standards containing 20, 
50, 200, 400 or 800 ng/ml of IMP, DMI, DMD, 2HI and 2HD was placed in 
extraction tubes. 200 ng of CMP (10 µl of 20 ng/µl) and 0.5 ml of 
carbonate buffer were added to each. Each was extracted twice with 4 ml 
of ethyl acetate:hexane:isopropanol:isoamyl alcohol (10:9:1:0.2) 
(extraction so 1 vent, ES). These extracts were transferred to appro­
priately labelled extraction tubes containing 2 ml of 0.5N HCl and 
vortexed. The organic upper phase was discarded. 1 ml of 2N NaOH and 4 
ml of the extraction solvent (ES) were added to the acid and the tubes 
reextracted. The solvent was transferred to 5 ml conical tubes and 
evaporated. 50 µl of mobile phase were used to redissolve the extracts 
for HPLC injection. A DMI study patient plasma sample was analyzed in 
triplicate along with the standards. 
Extraction efficiency for the standards was determined by 
comparison to injected unextracted standards. A standard curve was 
determined by linear regression from these standards and the peak height 
ratios to the internal standard peak. The concentration of DMI, DMD and 
2HD was determined from the standard curves for the unknown plasma. 
The HPLC system was the 5 µm Altex cyanopropyl column and 
mobile phase of water:acetonitrile: 0.6 M NaH2 P04:triethylamine 
(600:400:20:2, pH 6.5). The flow rate was 1.0 ml per minute. The 
detector was set at 254 nM and 0.005 AUFS. 
This procedure was used to assay most of the plasma 
unkno�m samples. 1.0 ml of plasma was used for analysis. At least 
three plasma based standards were analyzed with each batch of 3 to 9 
unknowns. 
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Within-run precision was tested using plasma from DMI 
study .patient MO #23 visit 10). This sample was analyzed six times in 
one batch for DMI, DMD and 2HD. Day to day precision was checked in 
three assays on separate days using DMI study plasma samples for a total 
of ten replications. In addition, the concentrations of 2HD, DMD and 
DMI in two plasma standards were calculated from linear regression 
derived standard curves in eleven consecutive DMI study assays. For 
each group, the mean, standard deviation and relative standard deviation 
were calculated. 
Nine DMI study plasma specimens and three standards were 
analyzed for DMI and 2HD by gas chromatography-mass spectrometry to 
compare with the HPLC analysis. D4 DMI and 2HD were used as internal 
standards. The samples were extracted identically as for HPLC analysis. 
After evaporation, 4 µl of N-methyl-bis-(trifluoroacetamide) was added 
to each tube for derivatization. The tubes were capped, vortexed 20 
seconds and placed in an 80°C oven for 15 minutes. 2 µl of this 
solution were used for each GC-MS injection. The ions with mass to 
charge ratios of 208.1 (DMI}, 212.1 (d4DMI}, 320.1 (2HD) and 324.1 
(d42HD) were monitored. The retention time for DMI was 1.85 minutes and 
for 2HD was 2.67 minutes. The peak areas of the four ions were measured 
and used to calculate the peak area ratios (PARs) of d
0 
compound to d4 
compound for DMI and 2HD. The PARs of standards versus the standard 
concentrations graph was used to determine unknown plasma sample DMI and 
2HD concentrations. The HPLC and GC-MS results for DMI and 2HD were 
compared by graph and linear regression. The mean coefficient of varia­
tion was calculated for both DMI and ZHD. 
70 
2. Red blood cell extractions 
R�d blood cell fractions from 10 ml of heparinized blood were 
diluted with 5.0 ml of deionized water. The total volume was measured 
prior to analysis to determine the RBC volume. The total volume minus 
the 5.0 ml of water equals the RBC volume. The RBC volume divided by 
total volume is the RBC fraction. Diluting the RBC allowed easier 
pipetting and hemolyzed the cells. 
The RBC fractions from 10 ml heparinized blood specimens from 
patients on placebo treatment were used to prepare standards. The 
DMI-DMD-2HD working standard solution (100 ng/µl of DMI and 40 ng/µl of 
DMD and 2HD) was added to clean, rinsed extraction tubes in 2.5 or 5.0 
µl amounts. 2.0 ml of the placebo diluted RBC was added to each to make 
250-100 ng/µl and 500-200 ng/µl RBC standards, respectively. For IMP 
patient samples, the IMP-DMI-DMD-2HI-2HD working standard (100 ng/µl IMP 
and DMI and 40 ng/µl 2HI, 2HD and DMD) was used in the same way. Four 
standards were used for each set of eight unknown RBC determinations. 
To 2.0 ml of diluted RBC standard or unknown sample was added 
1.0 ml of carbonate buffer and 250 ng of CMP (50 µl of 5 ng/µl in 
deionized �later). This mixture was extracted twice with the ES. The 
extracts were combined with 2 ml of 0.5N HCl and extracted. The solvent 
was discarded and 1 ml of 2N NaOH and 4 ml of ES added to the acid. 
This mixture was extracted and the solvent transferred to an evaporation 
tube. After evaporation, the extract was redissolved in 50 µl of mobile 
phase (water:acetonitrile: 0.6M NaH2 P04:triethylamine, 550:450:20:2, pH 
6.5) which was acidified to pH 4.0 with 0.5N HCl. 25 µl were injected 
into the HPLC system. 
All RBC assays were analyzed with the 5µm Altex cyanopropyl 
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column. The mobile phase flow rate was generally 0.8 to 1.2 µl/min. 
The ·detector was always set at 254 nm and 0.005 AUFS. Peak height 
ratios and linear regression were used to calculate unknown sample 
concentrations. 
Within-run precision was determined by analyzing a spiked 
placebo RBC sample. It contained 500 ng/ml DMI, 200 ng/ml DMD and 200 
ng/ml 2HD. Four replicates were analyzed along with two standards. 
Eight RBC specimens were analyzed for DMI and 2HD by the HPLC 
procedure and by a gas chromatography-mass spectrometry method. The 
GC-MS method substituted d4 DMI and d4 2HD as the internal standards 
instead of CMP. D4 DMI and d4 2HD were prepared according to the method 
of Narasimhachari (93). 
The samples for GC-MS analysis were extracted just as the HPLC 
samples. After evaporation, the GC-MS samples were dissolved in 40 µl 
of the N-methyl-bis- (trifluoroacetomide) by vortexing 20 seconds. They 
were capped and heated in the 80°C oven 15 minutes. 2 µl were injected 
in the GC-MS. Peak area ratios of d
0 
compound to d4 compound were used 
in the calculations. PAR versus standard concentration graphs were used 
to determine the unknown sample DMI and 2HD concentrations. HPLC values 
and GC-MS va 1 ues were compared by graphing and by ca 1 cul ati ng the 
coefficient of variation for each pair of values. A mean coefficient of 
variation {C.V.) was determined for OM! and 2HO values. 
Day to day variations in the HPLC procedure was calculated by 
assaying six samples on two separate days. These were DMI study samples 
and were analyzed for DMI, DMD and 2HD. All RBC drug and metabolite 
concentrations were adjusted to ng/ml of RBC by dividing by the RBC 
fraction. 
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3. Brain extraction 
All_ brain specimens were thawed prior to homogenization. Rat 
brains were transferred completely to a Wheaton 15 ml glass homogeniza­
tion tube. For rabbit brains, sections from cortex and midbrain were 
combined in roughly equal proportions to yield approximately 1.5 to 2.0 
grams. Human brain samples were taken from whatever brain region was 
available (see Materials section) to yield approximately 2 grams of 
tissue. All brain samples were transferred to a clean homogenization 
tube that was placed on a Mettler model PB300 pan balance. The weight 
of brain in grams was multiplied by four to determine the volume in 
mil 1 il iters of deionized water which was added to the sample in the 
homogenization tube. This resulted in a one to five dilution of the 
brain sample with water. The tissues were homogenized with a TRI-R 
Instruments Model K43 homogenizing apparatus by setting the motor at 
1000 RPM and repeatedly grinding the tissue against the bottom of the 
tube with the spinning Teflon rod until no sign of intact tissue remained 
and the solution appeared homogenous. The entire mixture was then trans­
ferred to an extraction tube, which was labelled, capped and stored at 
4° C if to be analyzed within t1�0 days or at -20°C if not to be analyzed 
in the next two days. 
For the first analysis of all brain specimens, 1.0 ml of the 
mixture was extracted. The mixture was mixed by vortexi ng prior to 
pipeting the aliquot to be analyzed. For those samples that required 
repeat analysis due to very high drug or metabolite concentrations (over 
5000 ng per gram of brain), the mixture was remixed and a portion was 
diluted with three parts deionized water (a further one to four 
dilution) and one milliliter of this mixture was used for analysis. 
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Standards were made in the identical dilution (one to five or 
one to twenty) as those of the brain specimens. Brain tissue from drug 
free rats was used for standards for all brain (rat, rabbit or man) 
assays. The same working standards as those described in the RBC 
extraction section were added to clean extraction tubes and ml of 
blank rat brain dilution was added. Working standards were chosen 
according to the drug and metabolites to be analyzed in the brain 
specimens. Standard concentrations were chosen to approximate the range 
of compound concentration expected in the specimens. For example, rats 
treated with DMI had their brains analyzed in conjunction with 
DMI-DMD-2HD working standard (100 ng DMI/µl and 40 ng each DMD and 
2HD/µl). A wide range of standard concentrations was used to cover the 
expected brain specimen concentrations. For example, assay of brains 
from 5 mg/kg DMI treated rats included seven brain based standards. The 
two brain specimens from rats treated with 2HD and 2HI were analyzed 
with standards made with the 10 ng/µl solutions of 2HD and 2MI. Rabbit 
and rat brains from 2HD and DMI treated animals were assayed with 
standards made from the DMI-DMD-2HD working standard. 
Tei 1.0 ml of each diluted brain specimen and standard was 
added 1 ml of carbonate buffer and 250 ng of CMP. These mixtures were 
each extracted twice with 4 ml of ES. The extracts were combined in 
another extraction tube with 2 ml of 0.5N HCl. These tubes were 
extracted and the solvent phase discarded. The acid phase had 1 ml of 
2N NaOH added to it and was then extracted with 4 ml of ES. The solvent 
extract was evaporated and redissolved in 50 µl of HPLC mobile phase. 
25 µl was then injected into the HPLC system. 
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All brain specimens were analyzed on the 5 µm Altex 
cyanopropyl H_PLC column. The mobile phase was water:acetonitril e :0. 6M 
NaH2 P04:triethylamine (550:450:20:2, pH 6.50) with a flow rate of 1.0 
ml/minute. The detector was set at 254 nm and 0.005 or 0.010 AUFS. 
Peak heights were used for quantitation. Peak height ratios (PHRs) of 
drugs or metabolites to the internal standard were compared to standard 
curves to calculate the unknown concentrations. 
Two brain specimens, one from a rat treated with 10 mg IMP/kg 
(Number 10-4) and one from the rabbit treated with DMI and 2HD and 
sacrificed 12-22-82 and designated #3, were analyzed for 2HD by GC-MS. 
1.0 ml of 1 to 5 diluted homogenized brain specimen or standard (made 
with DMI-DMD-2HD working standard) or blank was transferred to 
appropriately labelled extraction tubes. A solution of d4 2HD prepared 
by the method of Narasimhachari (93) was checked for d
0 
2HD contamina­
tion and d4 2HD concentration as follows: 10 µl of unknown concentration 
d4 2HD were transferred to an extraction tube. 1 ml of deionized water, 
1 ml of carbonate buffer and 2 ml of ES were added and the tube 
extracted. The so 1 vent was removed to an evaporation tube and dried. 
40 µl of N-methyl-bis- (trifluoroacetamide) was added and the tube vor­
texed 20 seconds, capped and placed in an 80 °C oven for 15 minutes. 2 
µl were injected into the Finnigan GC-MS system. The ions for d4 2HD 
(324.1) and d
0 
2HD (320.1) were monitored and the peak areas determined. 
The same 10 µl quantity of the d4 2HD solution was added to each brain 
samp 1 e aliquot and 1 ml of carbonate buffer was added to each. They 
were extracted identically as in the HPLC method. Evaporated samples 
were derivatized with N-methyl-bis- (trifluoroacetamide). Again 2 µl 
injections were used for GC-MS analysis. The same ions were monitored 
and peak areas measured. 
4. Overdose fatality whole blood and brain by GC-MS 
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Whole blood and brain specimens from the three overdose cases 
were analyzed by solvent extraction and gas chromatography-mass spectro­
metry. One to five brain dilutions and one to ten diluted and undiluted 
blood specimens were the samples used. 1.0 ml of each was extracted. 
The DMI overdose samples were analyzed for DMI, DMD and 2HD. The IMP 
overdose samples were, in addition, analyzed for IMP and 2HI. Appro­
priate quantities of d4 DMI, d4 2HI and d4 2HD were used as internal 
standards. One to five diluted, homogenized blank rat brain was used 
to prepare standards for brain assays. Whole blood and one to ten 
diluted, whole blood from placebo treated patients were used to prepare 
standards for the blood assays. The extractions were identical to those 
described in the diluted RBC and brain extraction sections. Evaporated 
extracts �1ere redissolved in 40 µl of N-methyl-bis- (trifluoroacetamide), 
vortexed 20 seconds, capped and heated fifteen minutes in the 80°C oven. 
Two injections of 2 µl of each sample were required to monitor all the 
ions required for analysis. The ions and the retention times for the 
compounds in question were: 
Com�ound Ion Retention Time (minutes) 
IMP 234.1 1.65 
d4 IMP 238.1 1.65 
DMI 208.1 3.48 
d4 DMI 212.1 3.48 
DMD 208.1 2.73 
d4 2HI 350.1 1. 72 
2HI 346.1 1.72 
d4 2HD 324.1 3.95 
2HD 320.1 3.95 
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The area of each peak was measured. The ratio of the area of 
the d0.compound to its corresponding d4 compound area was the peak area 
ratio for each drug or metabolite in each sample. The peak area ratio 
for DMD was obtained by dividing the DMD area by the d4 DMI area. The 
PARs of standards versus the standard concentration graph were used to 
determine drug and metabolite concentrations in the brain and whole 
blood overdose specimens. Concentrations were then adjusted for the 
dilution factor. For example, brain samples diluted one to five with 
deionized water had their concentrations multiplied by five to yield 
nanograms per gram of brain. 
5. HPLC quantitation 
Initially, a Waters Associates Radial Compression Module™ 
containing a Waters Associates 10 µm particle size 10 cm diameter cyano­
propyl cartridge (No. 84636 Radial-PAK) was used for the separation of 
the drugs, metabolites and internal standard. A variety of mobile phase 
solutions were tested for their separation characteristics. These 
solutions contained varying proportions of methanol, acetonitrile and 
deionized water. They also contained 1 to 2 milliliters of triethyla­
mine and 20 milliliters of 0.6M NaH2 P04 per liter of solution. The 
mixtures were adjusted to pH 7.0 with 10% phosphoric acid or 2N NaOH. 
A mobile phase solution containing acetonitrile:methanol: 
water:0.6M NaH2 P04:triethylamine (400:300:300:20:1.2) was adjusted to 
pH 7 .0 with 10% phosphoric acid using a combination electrode and pH 
meter. While using this mobile phase, a standard solution containing 
CMP, IMP, DMI, 2HI and 2HD (2 ng per µl each except CMP, 4ng per ul) was 
injected into the system on day 1 and day 4. The retention time and peak 
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height for each compound were determined. 
One liter of mobile phase solution was adjusted to pH 7.52 
with 10% phosphoric acid and 150 ml removed. The pH was adjusted to 
7 .07 with several drops of 10% phosphoric acid and again 150 ml was 
removed. This procedure was repeated to produce 150 ml portions of 
mobile phase of pHs 6.98, 6.67 and 5.82. Each aliquot of different pH 
was then divided into 50 ml portions. For each different pH solution, a 
1.0 µg per ml solution of CMP, DMI and 2HI was made by �dding 50 µl of 1 
mg/ml stock standard in methanol. A Cary Model 118 UV-visible spectro-
photometer was then used to measure the absorbance of each solution at 
254 nm with a slit width of .24 nm. The absorbance versus the pH of 
solution for each compound was graphed. 
A mobile phase containing acetonitrile:water:0.6M NaH2 P04: 
triethylamine (530:450:20:2) and adjusted to pH 6.50 was used because of 
good separation of the compounds of interest. The flow rate used was 
generally 1.5 ml per minute. Retention times and K' values were deter­
mined for each compound using this mobile phase and the 10 µm cyanopropyl 
radial compression cartridge. This high performance liquid chromato­
graphy system was used almost every day for several months. Slight 
variations in the proportion of acetonitrile to water and the concen­
tration of triethylamine were made during this time as the efficiency of 
the cartridge decreased. A standard mixture containing 5 ng per µl each 
of IMP, DMI, DMD, 2HI and 2HD and 10 ng per µl of CMP was injected before 
each days samples. The amount injected was either 5, 7.5 or 10 µl using 
a 25 µl HPLC syringe. The peak height ratios of each drug and metabo­
lite to the internal standard, CMP, were determined for thirteen 
injections of this mixture over a period of two weeks. The mean, 
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standard deviation and relative standard deviation of the peak height 
ratios. for each drug and metabolite were calculated. 
An Altex Ultrasphere™ cyanopropyl HPLC column (5 µm particle 
sixe, 150 x 4.6 mm, Beckman Instruments No. 242950) replaced the radial 
compression module several months after the study was initiated. The 
mobile phase which was found to produce good separation of the compounds 
of interest contained acetonitrile:water:0.6M NaH2 P04:triethylamine 
(420:580:20:2) and was always adjusted to pH 6.5 ± 0.05. Again, slight 
variations in the acetonitrile and the triethylamine concentrations were 
made during the six months this column was utilized. The flow rate was 
0.8 to 1.2 ml per minute. The retention times and K' values of IMP, 
DMI, DMD, 2HI, 2HD and CMP were determined at a flow rate of 0.8 ml per 
minute. 
6. Gas Chromatography-Mass Spectrometry 
The gas chromatography-mass spectrometry was performed on a 
Finnigan Model 4000 or a Hewlett-Packard Model 5985 system by Dr. N. 
Narasimhachari or Mr. J. Saady, respectively. The extraction and 
derivatization of samples are described in a previous section. The 
complete description of the GC/MS parameters has been published by 
Narashimhachari, Friedel and Saady (90, 93). 
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RESULTS 
A. Analytical Procedures 
High performance liquid chromatography (HPLC) was used to separate 
and quantitate imipramine, desipramine, desmethyldesipramine, 2-hydroxy­
imipramine and 2-hydroxydesipramine. Silica, c18 reverse phase and 
cyanopropyl reverse phase HPLC columns were evaluated for the separation 
of the compounds of interest. Cyanopropyl reverse phase columns gave 
the best resolution and the sharpest peaks for these compounds. Chlor­
imipramine was chosen as the internal standard because of its structural 
similarity to imipramine and metabolites and its separation on the HPLC 
system from imipramine and metabolites. UV detection at 254 nm was 
chosen because the instrumentation was readily available and the detec­
tion limit of 2 ng of compound injected was adequate for these studies. 
Gas chromatography- mass spectrometry (GC-MS) was used as necessary to 
validate the HPLC procedures because of its specificity and its accuracy 
when deuterated analogs of the compounds of interest are used as in­
ternal standards. 
The extraction of the compounds from biological fluids and tissues 
was first performed using c18 SEP-PAK
™ cartridges from Waters Associ­
ates. Table 1 shows the extraction efficiencies determined for a number 
of different elution solvent mixtures. As shown in the far right column, 
some mixtures yielded more interfering substances than others when the 
extracts were chromatographed. From these data, the mixture of hexane: 
TABLE 1 
Extraction Efficiencies from c18 SEP-PAKs for Drugs and 
Metabolites Using Different Elution Solvents 
Extraction Efficiencies (%) 
Elution Solvent 2HD 2HI DMI IMP 
Ethyl Acetate 40.4 85.5 33.3 65.0 
Hexane : Isopropanol (9:1) 67.0 74.6 48.3 68.3 
Hexane : Isoamyl Alcohol (98.5:1.5) 3.2 25.4 38.3 74.9 
Methylene Chloride 46.3 75.1 95 88.3 
Hexane : Ethyl Acetate (2:1) 20.2 6.4 16.7 68.3 
Acetonitri 1 e 16.0 74.0 16.7 58.3 
Methylene Chloride : Isopropanol (9:1) 107 79.3 60.8 87.0 
Methylene Chloride : Ethyl Acetate (1:1) 12.7 32.2 51.2 89.1 
Methylene Chloride : Hexane (1:1) 0 50.6 60.8 91.3 
MeCl : Ethyl Acetate : Isopropanol (5:4:1) 59.8 64.2 68.1 90.4 
Hexane : Ethyl Acetate : Isopropanol (5:4:1) 68.4 78.2 75.3 91.1 
Retention Time (minutes) on HPLC 8.8 9.7 12.9 14.8 
K' Value (V0 = 1.3 min) 5.7 6.3 9.1 10.2 
lscale of zero to+++, with+++ most chromatography interferences. 
Interferences 
+ 
++ 
+ 
+++ 
0 
+ 
+++ 
+++ 
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++ 
0 
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ethyl acetate: isopropanol (5:4:1) was chosen for further c18 SEP-PAK
™ 
extractions 1 because of good extraction efficiencies for the compounds of 
interest and the absence of interfering peaks in the chromatograms. 
The chromatography of evaporated residues of direct SEP-PAK extracts 
caused deterioration of the HPLC column and a marked loss in its 
efficiency. This may have been due to some elution of packing material 
from the SEP-PAK which would then be injected into the HPLC or from non­
polar plasma constituents which would be extracted and injected into the 
column. To remedy this situation, a back extraction procedure· was 
developed. Table 2 shows the extraction efficiency, chromatography data 
and parameters of the standard curve for 2HD, 2HI, DMD, DMI, IMP and CMP 
using this SEP-PAK extraction with back extraction procedure. The 
extraction efficiencies are slightly lower with the back extraction than 
without it. For ex amp 1 e, the extraction efficiency for 2HD with back 
extraction (Table 2) is 63.0% and without back extraction (Table 1 
elution solvent hexane : ethyl acetate : isopropanol [5:4:1]) is 68.4%. 
Similar decreases were found for each compound. Table 2 also shows the 
standard curve slopes, y intercepts and correlation coefficients for 
2HD, 2HI, DMD, DMI and IMP using five standards for each. All 
correlation coefficients (r) were greater than 0.99. The acid back 
extract had to be buffered with phosphate buffer because injection of an 
acidic sample into the buffered HPLC mobile phase changed the chromato­
graphy of the compounds. Table 3 shows the effect of the HPLC injection 
sample acidity on the chromatography. The stronger the acidity (the 
greater the number of mEq of HCl per injection) the shorter the reten­
tion ti mes of the compounds and the 1 a rger the PHR to CMP. The pH 
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TABLE 2 
c18 SEP-PAK and Back Extraction Procedure 
2HD 2HI DMD DMI IMP CMP 
Extraction 
Efficiency (%) 63.0 76.9 79.2 70.6 83.9 82.8 
Retention Time (min) 7.8 8.7 9.7 11. 7 14.3 16.8 
K' (V0 = 2.4) 5.9 6.7 7.5 9.3 11.6 13.8 
Linear Regression Analysis of each compound's standard. curve: 
y intercept -0.02 -0.02 0.03 0.03 0.01 
Slope 0.0039 0.0040 0.0044 0.0028 0.0030 
Correlation 
Coefficient ( r) 0.999 0.999 0.999 0.997 0.9999 
Number of Standards 5 5 5 5 5 
(20, 50, 100, 200 and 400 ng/ml) 
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TABLE 3 
Effect of HPLC Injection Sample Acidity on Chromatography 
Sample Acidity 
in mEq HCl injected 2HD 2HI DMI IMP CMP 
A. 0 mEq 
Retention Time 9.3 10.8 15.7 18.8 23.3 
Peak Height 83 72 41.5 34 39 
PHR to CMP 2.13 1.85 1.06 0.87 
B. 0.001 mEq 
Retention Time 9.2 10.4 15.0 17.5 22.8 
Peak Height 94 85.5 50 38.5 45.5 
PHR to CMP 2.07 1.88 1.10 0.85 
C. 0.005 mEq 
Retention Time 8.8 9.9 14.2 16.3 20.7 
Peak Height 86 78 44.5 36.5 38.5 
PHR to CMP 2.23 2.03 1.16 0.95 
D. 0.01 mEq 
Retention Time 8.3 9.3 13.4 15.3 19.3 
Peak Height 106 105 56.5 45.5 42 
PHR to CMP 2.52 2.50 1.35 1.08 
Retention Time in m.m. from injection point on chart 
(chart speed 127 m.m./min). Peak height in m.m. 
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of the back extract was buffered to pH 6.5 by the addition of phosphate 
buffer. 0.2 'M and pH 6.5 as described in Methods. This solution was 
then injected into the HPLC without changes in retention of the compounds 
when compared to aqueous standards. 
The apparent acidity of the mobile phase was also important. The 
absorbance of the compounds changed with the pH of the mobile phase as 
indicated in Figure 2. The original mobile phase apparent pH was 7 .0. 
The absorbance of a 11 compounds tested (2HI, OMI and CMP_) changes as the 
pH changes at 7.0. This effect was noticed in the variation in compound 
absorbance over a three day period as shown iri Table 4. For these 
reasons, a more stable portion of the absorbance versus mobile phase 
apparent pH curve was chosen_ for chromatography, that is, mobile phase 
pH 6.50. 
The SEP-PAK HPLC procedure was compared to an established GC-MS 
procedure for the quantitation of IMP and OMI in patient samples. Table 
5 contains this comparison data. When HPLC data was plotted on the X 
axis and GC-MS data on the Y axis, the Y intercept of the best fit 
linear regression line was 4.9, the slope of the line was 0.986 and the 
correlation coefficient (r) was 0.976 for the 14 data points. Table 6 
consists of data showing the day to day variation in this c18 SEP-PAK 
back extraction HPLC procedure. Five standards of varying concentra­
tions (20 to 400 ng/ml) which were extracted and chromatographed over 
several weeks ti me were used to determine a composite standard curve. 
The mean peak height ratio (PHR) and relative standard deviation were 
calculated for each compound in each standard mixture. The slopes and y 
intercepts for the composite standard curves are given at the bottom of 
Table 6. The correlation coefficients for all compounds are shown to be 
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Figure 2. The Effect of Mobile Phase pH on the 
Absorbance at 254nm of 2HI, DMI, and CMP 
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TABLE 4 
Absorbance (254 nm) Variation of Standards with 
pH 7.0 Mobile Phase of Acetonitrile: Methanol: Water: 
0.6M NaH2Po4: Triethylamine (400:300:300:20:1.2). 
2HD 2HI DMI IMP 
DAY 1 
Retention Time (min) 8.3 9.1 12.3 13.7 
Peak height (mm)/ng 2.37 2.17 1.52 1.39 
DAY 4 
Retention Time (min) 8.2 9.0 12.0 13.8 
Peak height (mm)/ng 2.25 2.10 1.25 1.225 
Per Cent Change in Absorbance 5.1% 3.2% 17.8% 11.9% 
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CMP 
16.0 
1.82 
15.7 
1.19 
34.6% 
TABLE 5 
SEP-PAK HPLC Versus GC-MS Quantitation of IMP and DMI 
in Patient Plasma Samples. All ng/ml Plasma 
SEP-PAK HPLC 
Sample IMP DMI 
Cl in. Tox. #157 137 306 
Cin. Tox. #149 66 
Clin. Tox. #759 165 
c.c.c. 3/8/82 39 62 
TCA Control 103 92 
Clin. Tox. #758 49 
Props 95 
Clin. Tox. #442 210 281 
Clin. Tox. #393 121 
Cl in. Tox. #339 64 
Correlation Coefficient 
(r) for IMP and DMI (N = 14) 0.976 
y intercept (GC-MS data as y axis) 4.9 
slope 0.986 
GC-MS 
IMP 
126 
44 
100 
188 
87 
DMI 
334 
60 
182 
99 
90 
65 
121 
270 
180 
47 
TABLE 6 
Day to Day Variation in c18 SEP-PAK Back Extraction HPLC Procedure 
2HD 2HI DMD DMI IMP 
20 ng/ml std. (N) 9 9 9 9 9 
Mean PHR .044 .065 .080 .081 .071 
Relative S.D. (%) 37% 35% 21% 31% 27% 
50 ng/ml std. (N) 12 12 12 12 12 
Mean PHR .153 .172 .238 .180 .172 
R. S.D. (%) 43% 30% 24% 28% 15% 
100 ng/ml std. (N) 12 12 12 12 12 
Mean PHR .316 .400 .496 .347 .349 
R.S.D. (%) 38% 40% 20% 23% 19% 
200 ng/ml std. (N) 13 13 13 13 13 
Mean PHR .669 .759 .928 .664 .639 
R.S.D. (%) 27% 21% 11% 14% 10% 
400 ng/ml std. (N) 8 8 8 8 8 
Mean PHR 1.37 1.56 1. 73 1.19 1.21 
R.S.D. (%) 14% 14% 8% 13% 7% 
LINEAR REGRESSION 
Std. curve data 
y intercept -.02 -.01 .02 .03 .02 
slope .0035 .0039 .0043 .0030 .0030 
Correlation coefficient (r) .9998 .9998 .9988 .9982 .9992 
CD 
CD 
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greater than 0.99. There were problems in the c
18 
SEP-PAK back extrac­
tion procedure. The cartridges are expensive and the extraction of 
chlorimipramine was variable, especially with a later lot number of car­
tridges. Several procedures were attempted to improve CMP extraction 
reproducibility, including double extraction at two buffer pHs, without 
total success. At this point, a three step solvent extraction procedure 
was developed. Plasma samples were made alkaline with 10% carbonate 
buffer, pH 9.7 and extracted twice with 4 ml of ethyl acetate : hexane : 
isopropanol : isoamyl alcohol (10:9:1:0.2). These extracts were backed 
extracted into 2 ml of 0.5 N hydrochloric acid. The acid portion was 
made alkaline with 1 ml of 2 N sodium hydroxide and then extracted with 
4 ml of the extraction solvent. The solvent extract was then evaporated. 
The residue was redissolved in HPLC mobile phase for injection into the 
HPLC system. 
Table 7 shows the HPLC retention times for the compounds on the 5 
µm Altex cyanopropyl column with the mobile phase listed, the extraction 
efficiency for each compound using the 3 step so 1 vent extraction, the 
slopes and y intercepts for the standard curves for each compound and 
the mean concentration with relative standard deviation (S.D.) of the 
compounds assayed in triplicate in a patient sample. The standard curve 
data are comparable to that found using the c
18 SEP-PAK back extraction 
procedure. Again, all r values exceed 0.99. The patient sample assayed 
in triplicate was reproducible for 2HD (relative S.D. of 7.6%) and DMI 
(relative S.D. of 4.1%). The reproducibility of the DMD value (relative 
S.D. of 26.6%) was poor due to the low concentration of DMD (13 ng/ml). 
This analysis procedure on HPLC was the basic method used to analyze 
fluids and tissues in the studies documented here. 
TABLE 7 
Three Step Solvent Extraction and Chromatography on 5 µm Altex 
Ultrasphere Cyanopropyl Column. 
Extraction Solvent: Ethyl Acetate : Hexane : Isopropanol : Isoamyl Alcohol (10:9:1:0.2) 
2HD 2HI DMD DMI IMP 
Retention Time (min) 5.9 7.1 8.0 9.6 11.8 
Extraction Efficiencies (%) 
50 ng/ml plasma std. 56 70 66 85 86 
200 ng/ml plasma std. 78 85 86 94 89 
400 ng/ml plasma std. 79 80 83 94 81 
Mean 71 78 78 91 85 
Linear Regression Data 
for these standards 
y intercept -.074 -.008 -.034 -.028 .027 
slope .0103 .0093 .0102 .0098 .0068 
Correlation Coefficient (r) .9989 .998 .9985 .9996 .9976 
CA #18 5-27-78 Plasma 
Sample analyzed in triplicate 
Mean (ng/ml) 80 Not 13 321 Not 
Relative S.D. (%) 7.6% Detected 26.6% 4.1% Detected 
CMP 
15.6 
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95 
97 
99 
<D 
0 
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Table 8 contains the precision data (intra-run and inter-run) for 
plasma analtsis. The Methods section describes the studies in detail. 
The intra-run precision for 2HD and DMI (C.V. values of 8.7% and 11.9% 
respectively) was approximately equal to the inter-run precision (C.V. 
values of 10.8% and 10.0%, respectively). Standard curves were run with 
every assay. The mean values for two of the plasma based standard 
mixtures are presented in Table 8 also. Table 9 compares HPLC and GC-MS 
results for DMI and 2HD. The comparison of DMI results (C.V. of 5.55% 
and r = 0.980) is better than that for 2HD results {C.V. of 14.2% and r 
= 0.941). It was found that the quantitation of 2HD, 2HI and DMD was 
not as precise as that of IMP and DMI. Lower concentrations and lower 
extraction efficiencies of 2HD, 2HI and DMD may cause this phenomenon. 
The same 3 step solvent extraction and chromatography on the Altex 
5 µm cyanopropyl column were used for RBC analysis as we 11 . Table 10 
contains the precision data and standard curve data for RBC analysis. 
Table 11 contains the HPLC versus GC-MS quantitation results comparison 
of DMI and 2HD in RBC specimens. The precision data is good, with all 
coefficient of variations below 6% for 2HD and DMI. HPLC and GC-MS 
compared very well as the correlation coefficients for DMI and 2HD were 
0.972 and 0.969, respectively. 
The chromatography system reproducibility was checked over a two 
week time period by injection of a standard mixture. The peak height 
ratio of each compound to the internal standard (CMP) was calculated. 
Tab 1 e 12 consists of these data. The chromatography was found to be 
consistent as indicated by the low relative standard deviations. The 
Altex 5 µm column was used instead of the Waters radial compression 
module (RCM) because it was more efficient as indicated in Table 13. 
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TABLE 8 
Precision Data: 3 Step Solvent Extraction and 
HPLC Analysis with 5 µm Altex Ultrasphere Cyanopropyl Column 
2HD DMD DMI 
Intra-Run Precision 52 0 48 
MO #23 Visit 10 (N = 6} 54 6 74 
ng/ml 51 5.5 66 
38 3.4 54 
47 4 64 
51 8 67 
Mean 4a.""8 CT 62.°"2 
Standard Deviation 5.8 2.5 8.6 
Coefficient of Variation 8. 7% 11. 9% 
Inter-Run Precision 
DMI Study Plasma (N = 10) 
Coefficient of Variation 10.8% 10.0% 
DMI Study Assays (N = 10) 
100-40 ng/ml STD Mean 37.6 41.8 106.6 
Standard Deviation 4.5 5.5 8.1 
Relative S.D. (%) 12% 13.2% 7.6% 
400-160 ng/ml STD Mean 156.1 160.8 401. 7 
Standard Deviation 8.8 14.0 19.9 
Relative S.D. (%} 5.6% 8.7% 5.0% 
TABLE 9 
Comparison of HPLC and GC-MS Results for DMI and 2HD. 
Both Three Step Solvent Extractions. All ng/ml Plasma. 
DESIPRAMINE 2-HYDROXYDESIPRAMINE 
S A M P L E HPLC GC-MS HPLC GC-MS 
MO Visit 7 198 224 62 65 
BB Visit 5 227 197 119 Bl 
GW Vis it 9 570 555 10 13 
EM Vis it 5 290 263 108 119 
SJ Visit 10 399 340 141 160 
SJ Visit 9 372 308 208 180 
MO Visit 6 283 253 140 107 
MO Visit 11 67 66 28 37 
SJ Visit 11 338 341 Not measured 
Coefficient of 
Variation (%) 5.55% 14.2% 
Correlation 
Coefficient (r) 0.980 0.941 
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TABLE 10 
HPLC Quantitation of RBC Samples from 
DMI Study: Precision Data. 
2HD DMD 
Inter-run Variation 
DMI Study Samples (N=l2) 
(Coefficient of Variation (%) 5.72% 10.8% 
Intra-run Variation 
DMI Study Control 
Coefficient of Variation (%) 2.65% 2.15% 
Mean Linear Regression 
Data for Standard Curves 
for all RBC DMI Assays (N=20) 
y intercept -.007±.040 .0036±.0034 
slope of regression 1 ine .0031±.0012 .0043±.0009 
Correlation Coefficient (r) .9924±.0081 .9975±.0031 
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DMI 
5.54% 
3.04% 
.0318±.0578 
.0050±.0009 
.9977±.0042 
TABLE 11 
Comparison of HPLC and GC-MS Results for OM! and 2HD 
in RBC Specimens (ng/ml) 
DESIPRAMINE 2-HYDROXYDESIPRAMINE 
S A M P L E HPLC GC-MS HPLC GC-MS 
SJ Visit 3 53 48 16 15 
SJ Visit 4 103 114 61 54 
SJ Visit 5 299 287 371 341 
SJ Visit 6 302 278 126 138 
SJ Visit 7 402 380 192 287 
SJ Visit 8 394 462 398 384 
SJ Visit 9 424 369 382 376 
SJ Visit 10 448 449 339 365 
Coefficient of 
Variation (%) 4.25% 5.52% 
Correlation 
Coefficient (r) 0.972 0.969 
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Mean 
s.o. 
R.SO % 
TABLE 12 
Peak Height Ratios (PHRs) of Standard Mixture Injections 
into HPLC Over Two Week Period 
2HO 2HI OMO OMI 
.687 .540 .632 .531 
.645 .544 .560 .520 
.677 .567 .589 .521 
.629 .510 .609 .500 
.707 .610 .638 .568 
.644 .537 .660 .534 
.673 .572 .644 .557 
.645 .555 .632 .529 
.665 .567 .629 .545 
.654 .560 .626 .526 
.637 .541 .619 .513 
.630 .536 .607 .509 
.626 .526 .607 .493 
.6553 .5512 .6194 .5266 
.0249 .0250 .0257 .0213 
3.80% 4.54% 4.15% 4.05% 
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IMP 
.436 
.446 
.440 
.406 
.477 
.430 
.456 
.439 
.455 
.438 
.421 
.421 
.404 
.4361 
.0204 
4.67% 
RCM 
V1 
w 
N 
HETP 
Altex 
V1 
vJ 
N 
HETP 
TABLE 13 
Comparison of Column Efficiency : Radial Compression 
Module (RCM) Versus 5 µm Altex Column 
2HD 2HI DMD DMI IMP 
12.4 14.8 17.0 19.8 24.2 
2.3 3.3 3.5 3.8 4.0 
465 322 377 434 586 
0.215 0.311 0.265 0.230 0.171 
12.7 14.2 17.4 20.8 24.6 
1.4 1.5 1.5 1.5 1.5 
1317 1434 2153 3077 4303 
0.114 0.105 0.070 0.049 0.035 
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CMP 
28.7 
5.0 
527 
0.190 
33 
1.8 
5370 
0.028 
v1 = Peak retention in mm; W = peak width in mm; N = number of theoretical 
plates; HETP = height equivalent of a theoretical plate. 
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The number of theoretical plates (N) was substantially higher with the 
Altex.columh for the compounds of interest. For example, N was 586 for 
IMP on the Waters RCM and 4303 on the Altex column. 
B. In Vitro Studies 
These in vitro studies were performed to standardize techniques to 
be performed on patient samples and to investigate the distribution of 
DMI, DMD and 2HD between plasma and RBC. The first study, as documented 
in Table 14, investigated the time necessary for DMI, DMD and 2HD to 
equilibrate between plasma and RBC after their addition to blood. It is 
evident that equilibrium is reached quickly and that 10 minute incuba­
tion is sufficient. All other distribution studies used 20 minute 
incubations. 
It was then investigated whether equilibration from RBC into plasma 
differed from equilibration from plasma to RBC. The compounds were add­
ed to RBC first and then the plasma was returned to the RBC. Table 15 
shows the distribution in RBC and plasma in this study. The mean 
recovery in percent expresses the amount of compound found in the RBC 
and plasma specimens compared to the total added to the blood originally. 
The ratio of plasma to RBC concentrations (P/RBC) is given in Tables 14, 
15 and 16 to allow direct comparison of the data. Comparison of the 
mean P/RBC values in Tables 14 and 15 show that little difference was 
found for DMI (0,664 and 0.691) and DMD (0.554 and 0.591). There was a 
greater difference for 2HD when 2HD was added to whole blood (0.569) or 
to RBCs alone first (0.410). It appears that more 2HD associates with 
RBCs when it is added to the RBCs first. 
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TABLE 14 
Equilibration of DMI, DMD and 2HD Between Plasma 
and RBC with Time. 
DMI DMD 2HD 
Specimen ng/ml P/RBC ng/ml P/RBC ng/ml P/RBC 
5 minute plasma 202 65 54.5 
5 minute RBC 269.5 0.750 102 0.637 115 0.474 
10 minute plasma 182 52 65 
10 minute RBC 296 0.615 104 0.500 105 0.619 
20 minute plasma 190 55 64 
20 minute RBC 285 0.667 90 0.611 99 0.647 
60 minute plasma 185 49 59 
60 minute RBC 297.5 0.622 105 0.467 110 0.536 
Mean P/RBC 0.664 0.554 0.569 
Mean Recovery (%) 96.9± 1.1 79.5±3.9 85 .8±1. 7 
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TABLE 15 
Distribution of DMI, DMD and 2HD from RBC 
to Plasma 
DMI DMD 2HD 
Specimen ng/ml P/RBC ng/ml P/RBC ng/ml P/RBC 
Tube 1 Plasma 202 49 52 
Tube 1 RBC 273 0.740 86 0.570 115 0.452 
Tube 2 Plasma 187 47 44 
Rube 2 RBC 287 0.652 72 0.653 117 0.376 
Tube 3 Plasma 194 49 49 
Tube 3 RBC 283 0.686 87 0.563 121 0.405 
Mean Plasma 194.3 48.3 48.3 
Mean RBC 281.0 0.691 81. 7 0.591 117. 7 0.410 
Mean Recovery{%) 96.4 66.3 85.8 
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Next, the equilibrium of DMI, DMD and 2HD between plasma and RBC 
was studied_ in blood samples drawn from the same individual over an 
eight week period. The purpose was to obtain an indication of the 
variability in distribution over a time period equal to that used in the 
clinical trials. DMI, DMD and 2HD were incubated in whole blood for 20 
minutes prior to separation of RBCs and plasma. As noted in Table 16, 
there are some weekly variations. Week two DMI concentrations had a 
P/RBC of 0.827 which is substantially higher than the other weeks. 
As rather large variations in drug and metabolite concentrations 
occur in different patients taking the same dose of TCA, the dis­
tribution between RBC and plasma of a range of concentration of DMI from 
250 to 3000 ng/ml in whole blood was studied. Table 17 shows that the 
plasma to RBC ration of DMI concentration was consistent throughout this 
concentration range. This ratio ranged from 0.598 to 0.613. 
The distribution of DMI, DMD and 2HD beh1een plasma and RBC of 
blood samples from 15 "normal" persons was investigated to determine the 
variability in a population of these distributions. In all samples used 
for in vitro studies, the hematocrit is an estimation calculated by 
measuring the height of the RBC volume in the Venoject tube and dividing 
it by the total blood volume height after the sample has been centrifuged 
under standard conditions noted in the methods section. Tables 18 and 
19 contain the normal population plasma - RBC distribution data. The 
plasma to RBC ratios are included. The DMI ratio ranged from 0.390 to 
0.732 with a mean of 0.526. No significant difference was found between 
males and females or those over 40 and under 40. No correlation to the 
hematocrit was found either. The mean ratio for ZHD was higher (0.619) 
than for DMI (0.526) while the ratio for DMD was lower (0.429). Again, 
Specimen 
Week one 
Week one 
Week two 
Week two 
Week three 
Week three 
Week five 
Week five 
Week eight 
Week eight 
TABLE 16 
Eight Week Plasma-RBC Distribution Study 
of DMI, DMD and 2HD. (Equilibration Time 
of 20 Minutes) 
DMI DMD 
ng/ml P/RBC ng/ml P/RBC 
Plasma 190 55 
RBC 285 0.667 90 0.611 
Plasma 215 61 
RBC 260 0.827 125 0.488 
Plasma 198 60 
RBC 296 0.669 109 0.480 
Plasma 181 48 
RBC 288 0.628 90 0.533 
Plasma 185 62 
RBC 291 0.636 112 0.554 
Mean Plasma ± S.D. 193.8±12.0 57.2± 5.2 
Mean RBC ± S.D. 284.0±12.5 105.2±13.5 
Mean P/RBC 0.682 0.544 
Mean Recovery (%) 97.0 83.1 
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2HD 
ng/ml P/RBC 
64 
99 0.646 
64 
101 0.634 
67 
105 0.638 
57 
112 0.509 
57 
116 0.491 
61.8±4.1 
106.6±6.5 
0.580 
86.0 
TABLE 17 
Plasma - RBC Distribution Saturation Study. 
All Concentrations are ng/ml 
Concentration Plasma RBC Total DMI Plasma to 
In Blood DMI DMI Recovered RBC Ratio 
250 164.5 273 90.1% 0.603 
500 293 480 79.5% 0.610 
1000 629 1051 86.5% 0.598 
2000 1247.5 2035 84.4% 0.613 
3000 1855 3041 84.0% 0.610 
Mean Recovery 84.9% ± 3.5% 
Mean Plasma to RBC DMI Concentration 0.607 ± 0.005 
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TABLE 18 
Normal Population Plasma - RBC Distribution 
of DMI. All Concentrations ng/ml 
Plasma RBC Plasma to 
Subject Sex Hematocrit DMI DMI RBC Ratio 
PH F 0.394 203 473 0.429 
CM M 0.490 173 433 0.400 
RB M 0.455 160 355 0.451 
SB M 0.496 240 407 0.590 
SC F 0.479 212 380 0.558 
FF F 0.465 190 325 0.585 
PB F 0.433 193 393 0.491 
LF M 0.503 147 377 0.390 
GJ M 0.468 180 371 0.485 
JL F 0.414 205 351 0.584 
DM M 0.559 203 352.5 0.576 
LT M 0.528 227 310 0.732 
NL F 0.426 155 347 0.447 
RG M 0.519 189 297.5 0.635 
BV F 0.423 206 381.5 0.540 
All mean ± S.D. 0.526 ± 0.092 
Male mean ± S.D. 0. 532 ± 0. 113 
Female mean± S.D. 0.519 ± 0.059 
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TABLE 19 
Normal Population Plasma - RBC Distribution 
of 2HD and DMD. All Concentrations ng/ml 
Plasma RBC Plasma to Plasma RBC Plasma to 
Subject 2HD 2HD RBC Ratio DMD DMD RBC Ratio 
PH 54 78 0.692 70 178 0.393 
CM 48 100 0.480 57 152 0.375 
RB 53 95 0.558 53 147.5 0.359 
SB 70 95 0.737 86 199 0.432 
SC 39 102 0.382 64.5 150 0.430 
FF 60 81.5 0.736 61 137 0.445 
PB 61 77 0.792 63 194 0.325 
LF 46 102 0.451 47.5 151 0.315 
GJ 54 85 0.635 58 173 0.335 
JL 66 80 0.825 63 164 0.384 
DM 71 88 0.807 63 130 0.485 
LT 85.5 98 0.872 73 104 0.702 
NL 49 123 0.398 47 133 0.353 
RG 57.5 101 0.569 62 103 0.602 
BV 51 146 0.349 66 130 0.508 
Mean± S.D. 0.619 ± 0.171 0.429 ± 0.104 
Compound 
IMP 
DMI 
DMD 
2HI 
2HD 
TABLE 20 
Drug and Metabolite Stability in Whole Blood Stored 
at -20°C for Eight Weeks. 
All Concentrations are ng/ml 
24 Hour 8 Week Per Cent 
Concentration Concentration Change 
215 197 -8.4% 
189 201 +6.3% 
168 181 +7.7% 
206 185 -10.2% 
195 180 -7.7% 
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there was a wide range in the distribution ratio (plasma to RBC) for 2HD 
(0.349 _to 0.872) and for DMD (0.315 to 0.702). There were no good cor­
relations found between the plasma to RBC ratios of these compounds and 
plasma total protein, albumin, cholesterol and triglycerides. 
The final in vit:t'o study performed investigated the stability of 
the compounds of interest (IMP, DMI, DMD, 2HI and 2HD) in whole blood 
when stored at -20°C for eight weeks. Table 20 indicates that the 
concentrations at 24 hours and 8 weeks did not differ significantly, 
especially when the overall precision of the assay is considered. The 
largest change was a decrease of 10.2% in the 2HI concentration. 
C. Human Studies 
1. Imipramine clinical study. 
The patients in the imipramine clinical study had their daily 
dose raised during the first two weeks of the study to 225 mg. If this 
dose was not we 11 tolerated, the dose was decreased to the 1 ast we 11 
tolerated amount. This was an outpatient study so that compliance could 
not be completely verified. For the most part, a daily dose of 200 to 
225 mg was achieved and continued through the end of the six week study. 
Blood samples were drawn at the end of the first, second, fourth and 
sixth weeks but there were exceptions. Some patients did not finish the 
study and week four was their last blood sample. Others missed week six 
but came in a week later. The steady state drug and metabolite con­
centrations for imipramine clinical study patients were considered to be 
week four and week six. If patients came in and had blood drawn both 
weeks, the average of the two values was considered their steady state 
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concentrations. If one or the other blood sample was drawn, its concen­
trations were considered steady state. All IMP, DMI, DMD, 2HI and 2HD 
concentrations were measured by HPLC. Table 21 contains this steady 
state concentration data. One patient, R-1, had a maximum daily dose of 
100 mg. All others had maximum daily doses of 200 to 225 mg. Only the 
23 patients with daily doses of 200 to 225 mg were included in the mean 
data analysis. Table 21 includes the IMP and DMI steady state plasma 
concentrations in ng per ml and the total of IMP plus DMI. Also in 
Table 21 is the DMI to IMP ratio and the ratios of ·DMD, 2HI and 2HD to 
the total (IMP plus DMI). 
The ratios of DMD, 2HI and 2HD to the total of IMP plus DMI 
show the relative amounts of these metabolites (DMD, 2HI and 2HD) that 
are found in the plasma in relation to the parent drug, IMP, and princi­
ple metabolite, DMI. IMP and DMI plasma concentrations have been 
measured at MCV for several years and the total of the two concentra­
tions is what is generally used clinically (16). Total means the IMP 
concentration plus DMI concentration sum. The mean DMD to total ratio 
in the 23 patients is 0.051 (± 0.047) with a range from zero to 0.15. 
Five of 23 patients had ratios over 0.10. The mean 2HI to total ratio 
is 0.091(± 0.090) with a range from zero to 0.43. Only one patient's 
2Hl/total ratio was over 0.20 while 7 of 23 (30%} had ratios greater 
than 0.10. The mean 2HD to total ratio was 0.20 (± 0.12). The range of 
2HD/total ratios was from zero to 0.43. Twelve of 23 patients had 
ratios over 0.20 and 16 of 23 patients' ratios exceeded 0.10. 2HD was 
the most significant metabolite of the three. 
Figure 3 shov1s the percent of all IMP treated patients with 
particular values for the ratio of both 2HI and 2HD to their total IMP 
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TABLE 21 
Imipramine Treated Patients Steady State Plasma Drug Contentrations 
at 200 to 225 mg/day of IMP. IMP and DMI Concentrations are ng/ml. 
Patient IMP DMI OM I/IMP Total DMD/T 2HI/T 2HD/T 
M-1 58 39 0.67 96 0.066 0.070 0.380 
A-1 43 37 0.86 80 0.150 0.100 0.125 
J-2 110 89.5 0.81 200 0.135 0.185 0.430 
C-2 311 220 0.70 531 0.020 0.080 0.094 
J-2 97 126 1.30 223 0.022 0.180 0.305 
W-1 64 580 9.06 644 0.110 0.014 0.062 
C-1 169 124 0.73 293 0.046 0.034 0.246 
R-1 (100 mg) 70 38 0.54 108 0.092 0.079 0.167 
K-1 35 223 6.37 258 0.039 0.300 
H-5 395 84 0.21 479 0.125 0.019 0.097 
0-1 34 103 3.04 137 0.073 0.383 
A-2 54 29 0.54 83 0.430 0.230 
H-1 161 76 0.47 237 0.140 0.156 
J-3 24 67 2.79 91 0.027 0.406 
E-1 171 285 1.67 456 0.015 0.061 0.207 
H-4 49 83 1.69 132 0.038 0.136 
H-2 266 388 1.46 654 0.000 0.035 
0-2 151 133 0.88 284 0.025 0.077 
B-3 145 155 1.07 300 0.027 0.077 0.093 
C-3 279 154 0.55 433 0.053 0.140 0.225 
H-3 78 895 11.50 973 0.121 0.000 0.000 
B-2 72 158 2.19 230 0.017 0.104 0.230 
T-1 111 148 1.33 259 0.008 0.127 0.260 
B-1 165 131 0.79 296 0.014 0.094 0.074 
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Figure 3. Distribution of 2-Hydroxy Metabolites 
Relative to Total IMP Plus DMI Concentration in Plasma 
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plus DMI concentration. The 2HI to total ratios are low (most less than 
0.20) while the 2HD to total ratios are spread more evenly from zero to 
0.45. Again, these ratios of metabolites 2HD, 2HI and DMD to IMP plus 
DMI show the relative amounts of these metabolites in the plasma. A low 
ratio indicates that little metabolite is present in plasma compared to 
the amount of IMP plus DMI. 
Table 21, as noted, contains the DMI/IMP ratio. The value of 
this ratio ranges from 0.21 to 11.5. This indicates that there is a 
large variation in the relative proportions of DMI and IMP in these pa­
tients plasma at steady state. Figure 4 displays the distribution of 
all 24 patients plasma DMI to IMP ratios. Most patient DMI/IMP ratios 
are below three and half are below one. 
DMI is the demethylated metabolite of IMP. The degree of 
demethylation may be seen in the relative proportions of IMP and DMI 
measured in the plasma at steady state. Arbitrarily, slow demethylators 
have been designated as those patients with DMI/IMP ratios less than 
one. Fast demethylators are designated as those with DMI/IMP ratios 
greater than one, that is, with more DMI than IMP in the plasma. In 
this study, there are twelve each of fast and slow demethylators. 
Again, arbitrarily, these patients can be divided into fast 
and slow hydroxylators on the basis of their plasma drug and metabolite 
concentrations. 2HI and 2HD are the hydroxylated metabolites of IMP. 
If the patients 2HI/total plus 2HD/total sum is greater than 0.20 they 
are designated as fast hydroxylators. This means that the hydroxy meta­
bolites in plasma reach 20% of the value of the IMP plus DMI concentra­
tion. Slow hydroxylators have a 2Hl/total plus 2HD/total ratio less 
than 0.20. Of these 24 patients, nine v1ere considered slow hydroxylators 
1
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and fifteen .as fast hydroxylators. Table 22 helps illustrate the hydro­
xylator and demethylator designations. The steady state plasma IMP plus 
DMI concentrations are divided up first into slow or fast demethylator 
categories. Within demethylator category, the concentrations are 
separated into their hydroxylator type, either fast or slow. The number 
of patients in each group and the mean plasma IMP plus DMI concentration 
with the standard deviation of each group are included in Table 22. It 
can be seen that within both demethylator categories the slow hydroxy­
lators have a mean steady state plasma IMP plus DMI concentration double 
that of the fast hydroxylators. Fast demethylators have mean IMP plus 
DMI concentrations greater than slow demethylators in both hydroxylation 
groups. 
The concentrations of drug and metabolites in the plasma dur­
ing the course of the six week study in two patients are shown in Fig­
ures 5 and 6. These graphs help to show the relative amounts of meta­
bolites in these two examples. In Figure 5 the data for· patient K-1 is 
given. This patient is designated as a fast demethylator and the DMI 
concentrations are greater than IMP concentrations during the entire 
study. Patient C-1 in Figure 6 is an example of a slow demethylator. 
In both cases, the concentration of 2HD is greater than 2HI at all time 
points. 
For twelve imipramine patients, drug and metabolite concentra­
tions were measured in red blood cells (RBCs) as well as plasma. The 
IMP and DMI concentrations in plasma and RBCs are compared in Table 23. 
The data for all samples is included and the IMP plus DMI and the DMI to 
IMP ratio for both plasma and RBCs are listed. 
concentration in plasma is 234.5 (± 175}. 
The mean IMP plus DMI 
The mean IMP plus DMI 
N 
Mean 
Standard 
Deviation 
% S.D. 
TABLE 22 
Steady-State Plasma IMP Plus DMI 
Concentrations (ng/ml) of Metabolism Groups 
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SLOW DEMETHYLATORS FAST DEMETHYLATORS 
Slow Fast Slow Fast 
Hydroxyl a tors Hydroxyl a tors Hydroxyl a tors Hydroxyl a tors 
531 96 644 223 
479 200 132 258 
284 80 654 137 
296 293 300 91 
108 973 456 
83 230 
237 259 
433 
4 8 5 7 
397.5 191.2 540.6 236.2 
109 118 295 107 
27% 52% 55% 45% 
Figure 5. Time Course of IMP and Metabolites 
Plasma Concentrations in PATIENT K-1 
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TABLE 23 
Comparison of Plasma and RBC Concentrations of IMP Plus 
DMI (ng/ml) and DMI/IMP 
P L A S M A R B C 
Patient Week IMP+ DMI DMI/IMP IMP+ DMI DMI/IMP 
J-1 1 77 0.54 85 1.08 
2 166 0.73 185 1.56 
4 233 0.88 205 1.59 
M-1 1 47 0.34 43 0.95 
2 100 0.67 101 1.15 
A-1 1 44 1.45 63 0.85 
C-2 4 650 0.81 437 1.64 
6 408 0.84 179 1.43 
J-2 1 68 0.89 81 2.70 
2 199 0.92 246 5.56 
4 198 1.35 230 4.76 
6 280 1.59 265 4.55 
W-1 1 336 3.33 518 9.09 
2 383 6.25 1074 16.7 
4 676 8.33 964 14.3 
6 542 9.09 523 14.3 
C-1 2 257 0.83 370 4.35 
4 329 0.66 259 1. 79 
6 188 1.02 182 3.85 
R-1 1 138 0.41 261 2.38 
2 79 0.88 115 3.25 
4 51 1.04 59 5.00 
K-1 1 116 3.33 233 12.5 
2 257 6.25 512 20.0 
4 132 4.55 422 5.88 
6 135 4.00 369 5.26 
H-5 1 195 0.26 190 0.16 
2 423 0.20 234 0.71 
4 448 0.27 419 1. 92 
6 602 0.21 220 0.44 
D-1 2 138 4.17 333 10.0 
4 125 2.13 305 10.0 
6 148 3.33 322 7.14 
A-2 1 145 0.83 90 3.70 
2 74 0.40 44 1.92 
6 55 0.37 43 2.56 
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·concentration in RBCs is 283 (± 226). The DMI to IMP ratio diffe"rs 
considerably between plasma and RBCs. For these 36 blood samples, the 
mean ratio in plasma was 2.03 (± 2.30) and the mean ratio in RBCs was 
5.14 (± 4.97). Figure 7 illustrates this difference in the DMI/IMP 
ratio. It is a plot of the plasma ratios versus RBC ratios. If the 
DMI/IMP was the same for plasma and RBCs the line slope would be near 1. 
The actual slope is 1.90. These data indicate DMI and IMP distribute 
differently between plasma and RBCs. The correlation coefficient is 
0.878, meaning that there is a significant (p <; .005) relationship 
between DMI/IMP in plasma and RBCs for these patients. 
The plasma and RBC IMP and DMI steady state concentrations 
were compared to the Severity Index and Raw Improvement derived from 
Hamilton Depression Rating scores. The Methods sec ti on describes how 
the Severity Index (S.I.) and Raw Improvement (R.I.) values were cal­
culated for each patient. Table 24 is a compilation of this data with 
plasma drug concentrations for 24 patients. Table 25 contains RBC drug 
concentrations, S.I.s, and R.I.s for the twelve patients whose RBC con­
centrations were measured. All of these data were compared in order to 
ascertain the degree of correlation, if any, between drug concentration 
and clinical response. The Pearson correlation (98) was used to compare 
these factors. Tab 1 e 26 contains the results of these corre 1 at ions. 
The parameter used on the X axis and the parameter used on the Y axis 
are given with the line parameters for each correlation. The best 
correlation was between Raw Improvement and the Severity Index. That 
correlation coefficient (r) was 0.653 (p<.01). The best correlation of 
drug concentration to improvement was for RBC DMI to IMP ratio versus 
Raw Improvement. However, its correlation coefficient of -0.395 was not 
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TABLE 24 
i 
IMP fatient Depression Ratings and Plasma Drug Concentrations (ng/ml) 
Patient s. I. R. I. IMP DMI IMP+ DMI DMI/IMP 
M-1 32 22 58 39 96 0.67 
A-1 22 16 43 37 80 0.86 
J-1 20.5 13.5 110 90 200 0.81 
H-1 32.5 22.5 161 76 237 0.47 
J-2 20.5 4.5 97 126 223 1.30 
D-1 25 19 34 103 137 3.04 
C-1 30.5 16.5 169 124 293 0.73 
D-2 27 8 151 133 284 0.88 
J-3 27 0 24 67 91 2.79 
H-2 36 22 266 388 654 1.46 
H-3 33.5 25.5 78 895 973 11. 5 
H-4 30.5 15.5 49 83 132 1.69 
E-1 19.5 7.5 171 285 456 1.67 
B-1 33 28 165 131 296 0.79 
B-2 24 5 72 158 230 2.19 
B-3 28 18 145 155 300 1.07 
W-1 18.5 3.5 64 580 644 9.06 
R-1 23 1 70 38 108 0.54 
K-1 31.5 15.5 35 223 258 6.37 
H-5 19.5 6.5 395 84 479 0.21 
C-Z 25 23 311 220 531 0.71 
C-3 26.5 18.5 279 154 433 0.55 
T-1 23 20 111 148 259 1.33 
A-2 27.5 21.5 54 29 83 0.54 
s. I. Severity Index 
R. I. Raw Improvement 
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TABLE 25 
IMP Patient Depression Ratings and RBC Drug Concentrations ( ng/ml) 
Patient s. I. R. I. IMP DMI IMP+ DMI DMI/ IMP 
J-1 20.5 13.5 79 126 205 1.59 
M-1 32 22 47 54 101 1.15 
C-2 25 23 165 272 437 1.65 
J-2 20.5 4.5 47 218 265 4.64 
W-1 18.5 3.5 64 900 964 14.1 
C-1 30.5 16.5 93 166 259 1.78 
R-1 23 1 27 88 115 3.26 
K-1 31.5 15.5 62 360 422 5.81 
H-5 19.5 6.5 148 147 295 0.99 
D-1 25 19 40 282 322 7.05 
A-2 27.5 21.5 15 30 45 2.00 
s. I. Severity Index 
R. I. Raw Improvement 
TABLE 26 
IMP Patient Pearson Correlations 
X Axis Y Axis y s r 
Raw Improvement Severity Index 20.5 0.406 0.653 
Plasma [IMP] Raw Improvement 13.0 0.013 0.160 
Plasma [DMI] Raw Improvement 15.8 0.001 0.016 
Plasma [IMP + DMI] Raw Improvement 12.4 0.007 0.200 
Plasma [DMI/IMP] Raw Improvement 14.8 -0.039 -0.014 
RBC [IMP] Raw Improvement 12.0 0.018 0.108 
RBC [DMI] Raw Improvement 16.0 -0.011 -0.336 
RBC [ IMP + DMI] Raw Improvement 16.4 -0.009 -0.304 
RBC [DMI/IMP] Raw Improvement 16.6 -0.819 -0.395 
y y intercept of correlation line 
s = line slope 
r = correlation coefficient 
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significant. Other r values approached zero, indicating that there is 
no significAnt correlation between that data. 
2. Desipramine clinical studies. 
In the desipramine clinical study, the patients were adjusted 
upward to a maximum daily dose of 300 mg during the first week of drug 
therapy. The blood samples drawn at visits 5, 6, 7 and 8 (corresponding 
to 2, 3, 4 and 5 weeks after initiation of DMI therapy) were considered 
to contain steady state concentrations of DMI, DMD and 2HD. All DMI, 
DMD and 2HD concentrations were measured by HPLC. 
Table 27 contains the plasma steady state concentrations. 
Drug and metabolite concentrations from visits 5, 6, 7 and 8 were 
averaged to obtain these values. In several cases a visit was missed so 
that it could not be included. Table 27 also contains the plasma DMD to 
DMI ratio and plasma 2HD to DMI ratio. Figure 8 shows the distribution 
of plasma DMI steady state concentrations for the twelve patients. The 
mean value is 408 (± 278) ng/ml. Patient EW #32 had the highest steady 
state plasma DMI concentration, 1123 ng/ml� and WK #11 had the lowest, 
165 ng/ml. 
The variation in the steady state DMI concentrations for each 
patient was determined by calculating the relative standard deviation of 
each mean steady state concentration. The relative standard deviation 
is the standard deviation divided by the mean and multiplied by 100 to 
yield a percent standard deviation. The overall relative standard de­
viation for DMI for all 12 patients was 18.2% (± 5.1%). It ranged from 
8.8% to 29.3%. 
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TABLE 27 
DMI Treated Patients (3DO mg per day): Steady-state Plasma Concentrations 
of DMI, DMD and 2HD (Mean of Visits 5, 6, 7 and 8). 
All Concentrations in ng/ml. 
Patient DMI DMD DMD/DMI 2HD 2HD/DMI 
EW #10 424 9.5 0.022 136 0.321 
WK #11 165 11 0.067 15 0.091 
MJ #16 608 56 0.092 190 0.312 
CA #18 291 15 0.052 96 0.330 
JB #19 289 31 0.107 88 0.304 
GW #21 786 46 0.059 19 0.024 
MO #23 254 22 0.087 104 0.409 
SJ #24 300 22 0.073 200 0.667 
BB #27 180 8 0.044 99 0.550 
EM #28 224 13 0.058 98 0.438 
DB #29 249 13 0.052 81 0.325 
EW #32 1123 101 0.090 88 0.078 
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The relative standard deviation in the steady state 2HD con­
centrations'was 36.7% (± 22.1%). It ranged from 20.7% to 102%. The 2HD 
concentration therefore varied more from week to week than did the DMI 
concentration. 
The DMD/DMI ratio for plasma steady state concentrations was 
low. The mean was 0.067 (± 0.023) and it ranged from 0.022 to 0.107. 
That means that in only one patient did the DMD concentration reach 10% 
of the DMI concentration. 
The mean 2HD/DMI ratio for plasma steady .state concentrations 
was 0.321 (± 0.181). It ranged from 0.024 to 0.667. In 8 of the 12 
patients this ratio was greater than 0.300, meaning that in those 
patients the 2HD concentration was at least 30% of the DMI concentration. 
The 2HD plasma concentration at steady state never exceeded the DMI 
plasma concentration. 
For 10 of the 12 desipramine patients, red blood cell (RBC) 
drug and metabolite concentrations were measured. Table 28 contains the 
RBC steady state DMI, DMD and 2HD concentrations. Again, DMD to DMI and 
2HD to DMI ratios are included. As can be seen, the DMD/DMI ratio is 
low (mean of 0.099 ± 0.017) and the 2HD/DMI ratio is significantly high­
er (mean of 0.478 ± 0.307). In both RBCs and plasma, 2HD reaches 
significantly greater concentrations than does DMD. 
A comp a ri.son of plasma and RBC drug and metabolite concentra­
tions is made in Table 29. For DMI, DMD and 2HD, the ratio of plasma to 
RBC concentrations at steady state are shown. The mean value, the stan­
dard deviation and relative standard deviation were calculated and in­
cluded as well. For DMI and its t�/0 metabolites, the mean plasma con­
centration is less than the RBC concentration. That is, the mean plasma 
U/ 
TABLE 28 
DMI Treated Patients (300 mg per day): Steady-State RBC 
Concentrations of DMI, DMD and 2HD (mean of Visits 5, 6, 7 and 8). 
All Concentrations in ng/ml. 
Patient DMI DMD DMD/DMI 2HD 2HD/DMI 
MJ #16 368 36.5 0.099 79 0.215 
CA #18 352.5 30.5 0.087 258.5 0.733 
JB #19 393 38 0.097 97.5 0.248 
GW #21 1738 174 0.100 96 0.055 
MO #23 434 43 0.099 284 0.654 
SJ #24 349 36 0.103 272 0. 779 
BB #27 298.5 42 0.141 257 0.861 
EM #28 294 28 0.095 245 0.833 
DB #29 483 34 0.070 157 0.325 
EW #32 2655 251.5 0.095 204 0.077 
1.::0 
TABLE 29 
Steady State Plasma Concentration to RBC 
Concentration Ratios for DMI, DMD and 2HD 
Patient DMI DMD 2HD 
MJ #16 1.65 1. 53 2.41 
CA #18 0.83 0.49 0.37 
JB #19 0.74 0.82 0.90 
OW #21 0.45 0.26 0.20 
MO #23 0.59 0.51 0.37 
SJ #24 0.86 0.61 0.74 
BB #27 0.60 0.19 0.39 
EM #28 0.76 0.46 0.40 
DB #29 0.52 0.38 0.52 
EW #32 0.42 0.40 0.43 
Mean 0.742 0.565 0.673 
SD 0.336 0.362 0.610 
% S.D. 45% 64% 91% 
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to RBC ratio for all three is less than one. However, the variation as 
expressed by the relative standard deviation is high for all three. 
For comparison to clinical response, only drug and metabolite 
concentrations at visit 7 and 8 were used. The visit 7 and 8 Hamilton 
Depression Rating scores were used to calculate the patient's Raw Im­
provement values (R.I.s). Visits 7 and 8 are 4 and 5 weeks after the 
initiation of drug therapy and should allow time for DMI treatment to 
take effect (6). The DMI and DMI plus 2HD concentrations were compared 
to the Severity Index (S.I.) and Raw Improvement (R.I.). All the plasma 
data used is in Table 30 and all the RBC data used is in Table 31. The 
visit 7 and 8 average Hamilton Depression Rating scores (HDS) are also 
included. The Methods section describes S.I. and R.I. value calcula­
tions. 
Table 32 contains the DMI patient Pearson correlations derived 
from the data in Tables 30 and 31. Both plasma DMI and RBC DMI concen­
trations give good correlations versus Raw Improvement. (r = -0.750 and 
r = -0.693, both p<0.01). The combined DMI plus 2HD concentrations in 
both plasma and RBCs also correlated well with Raw Improvement (r = 
-0.752 and r = -0.655). These correlations are all negative and indi­
cate an inverse relationship between drug concentrations in this range 
and Raw Improvement. Figure 9 is a plot of the plasma DMI concentration 
versus Raw Improvement which illustrates this relationship. 
Rank order correlations and partial correlations are statisti­
cal manipulations which may increase the correlation coefficients for 
some data sets. Rank order correlations often are helpful when some 
extreme values or outliers are in the data. Partial correlations are 
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TABLE 30 
DMI Patient Depression Ratings and Plasma Drug Concentrations ( ng/ml) 
Vis 7+8 R. I. DMI 
Patient s. I. Ave HOS R. I. Rank DMI Rank DMI+2HD 
EW #10 36.5 28.5 8 10 399 9 523.5 
WK #11 30 12.5 17.5 4 201.5 4 232 
MJ #16 28 15 13 7.5 582.5 10 707.5 
CA #18 25 10 15 6 286 6 401 
JB #19 39 19.5 19.5 3 291.5 7 395.5 
GW #21 31 30 1 12 906.5 11 931.5 
MO #23 32.5 8 24.5 1 198 3 272 
SJ #24 35.5 22.5 13 7.5 324 8 568.5 
BB #27 35 18.5 16.5 5 148.5 1 230.5 
EM #28 30 6.5 23.5 2 172.5 2 251.5 
DB #29 34.5 24 10.5 9 246 5 316 
EW #32 44 36.5 7.5 11 1062 12 1125.5 
s. I. Severity Index 
HOS Hamilton Depression Score 
R. I. Raw Improvement 
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TABLE 31 
DMI Patient Depression Ratings and RBC Drug Concentrations (ng/ml) 
Vis 7+8 R. I. DMI 
Patient s. I. Ave HOS R. I. Rank DMI Rank DMI+2HD 
MJ #16 28 15 13 6.5 394.5 4 492.5 
CA #18 25 10 15 5 352.5 3 611 
JB #19 39 19.5 19.5 3 515.5 8 670.5 
GW #21 31 30 1 10 1892 9 1982 
MO #23 32.5 8 24.5 1 430 7 700 
SJ #24 35.5 22.5 13 6.5 398 5 693 
BB #27 35 18.5 16.5 4 298.5 2 555.5 
EM #28 30 6.5 23.5 2 253.5 1 529 
DB #29 34.5 24 10.5 8 410.5 6 521. 5 
EW #32 44 36.5 7.5 9 2567 10 2708 
s. I. Severity Index 
HOS Hamilton Depression Score 
R. I. Raw Improvement 
TABLE 32 
DMI Patient Pearson Correlations 
X Axis Y Axis y s r 
Raw Improvement Severity Index 23.8 -0.289 -0.218 
Plasma [DMI] Raw Improvement 21.0 -0.017 -0.750 
Plasma ( [DMI] Severity Index 30.9 0.0062 0.359 
Plasma [DMI + 2HD] Raw Improvement 22.8 -0.0176 -0.752 
Plasma [DMI + 2HD] Severity Index 30.1 0.0067 0.379 
RBC [DMI] Raw Improvement 19.1 -0.0062 -0.693 
RBC [DMI] Severity Index 30.7 0.0036 0.524 
RBC [DMI + 2HD] Raw Improvement 20.2 -0.0062 -0.655 
RBC [DMI + 2HD] Severity Index 29.8 0.0038 0.532 
y = y intercept of correlation line 
s = 1 ine slope 
r = correlation coefficient 
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often helpful when a third variable, in this case the Severity Index, 
may have an _effect on the comparison of two variables, in this case drug 
concentration and Raw Improvement. For the DMI data, rank order 
correlations and partial correlations controlling for S.I. did not 
significantly improve correlation coefficient values over those 
calculated by The Pearson correlation. The rank for R.I. was from most 
improvement (number 1) to least improvement (highest number). The rank 
for DMI concentration was from lowest (number -1) to highest 
concentration. These ranks are included in Tables 30 and 31 for plasma 
and RBC data, respectively. The rank order correlation of plasma DMI 
concentration versus R.I. yielded a correlation coefficient of 0.785 
(p<0.01). The rank order correlation of RBC DMI concentration versus 
R.I. yielded a correlation coefficient of 0.488. Partial correlations 
of plasma and RBC DMI concentration versus R.I. were made controlling 
for the initial severity of depression (as measured by the Severity 
Index). The partial correlation coefficient value for plasma DMI versus 
R.I. controlling for S.I. was -0.738. The corresponding RBC value was 
-0.697. 
From these different ways of measuring correlations, it does 
appear that drug concentrations correlate well with Raw Improvement in 
this study. As the drug concentrations increased, the degree of patient 
improvement decreased. 
3. Overdose fatality studies. 
The specimens analyzed in the overdose fatality studies came 
from three Medical Examiner's cases. Two cases were shown to involve 
DMI ingestion and one was an IMP ingestion. Whole blood and brain 
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specimens were analyzed by both HPLC and GC-MS as described in Methods. 
There.was a' time lapse of several months between HPLC and GC-MS analy­
ses. These samples contained more interfering peaks on HPLC than did 
clinical and animal specimens. 
The concentrations in blood and brain for the three cases 
measured by HPLC and GC-MS are shown in Table 33. In the IMP fatality, 
IMP, DMI, DMD, 2HI and 2HD were found in both blood and brain. In the 
two DMI fatalities, DMI, DMD and 2HD were found in all blood and brain 
specimens. One interesting finding in DMI fatality-II was IMP in brain 
by both HPLC and GC-MS. It is noted that the concentration of IMP (0.34 
µg/g by GC-MS) is much lower than that of DMI (51.9 µg/g by GC-MS) and 
is 0.65% of the DMI concentration. 
The concentrations measured by GC-MS were used to derive brain 
to blood ratios of the parent drugs and metabolites. These data are 
shown in Table 34. Generally, the brain to blood ratios decrease from 
parent compounds to the more polar metabolites. The brain to blood 
ratio for DMI divided by the brain to blood ratio for 2HD in IMP 
fatality, DMI-fatality-I and DMI fatality-II, respectively, are 13.3, 
5.86 and 6.15. Therefore, the concentration in brain compared to blood 
in these autopsy cases is much higher for DMI than for 2HD. In the one 
IMP fatality, the brain to blood ratio for IMP divided by the brain to 
blood ratio for 2HI is 2.22. Thus to a lesser extent, the concentration 
in brain compared to blood is higher for IMP than for 2HI in this one 
case. The DMI and 2HI brain to blood ratios are similar in the IMP 
case, 5.31 and 4.59, respectively. The quantities of IMP and DMI in the 
two tissues are greater than for the metabolites. 
l.)0 
TABLE 33 
Overdose Fatality Drug and Metabolite Concentrations 
Determined by HPLC and GC-MS 
IMP DMI DMD 2HI 2HD 
IMP FATALITY 
Blood by HPLC 3.88 3.27 INT 1.55 INT 
Blood by GC-MS 2.87 2.77 0.076 1.54 1.23 
Brain by HPLC 47.7 20.4 INT 8.34 INT 
Brain by GC-MS 29.3 14.7 0.072 7.07 0.49 
DMI FATALITY-I 
Blood by HPLC 42.5 0.96 6.50 
Blood by GC-MS 35.0 0.66 3.96 
Brain by HPLC 50.7 0.87 0.97 
Brain by GC-MS 59.0 0.88 0.87 
DMI FATALITY-II 
Blood by HPLC 5.56 1.95 1.87 
Blood by GC-MS 5.90 1. 70 1.67 
Brain by HPLC 1.27 62.7 4.80 3.85 
Brain by GC-MS 0.34 51. 9 2.68 2.40 
Blood concentrations in µg/ml 
Brain concentrations in µg/g 
INT - unable to measure due to interfering substances 
IMP Fatality 
DMI Fatality-I 
DMI Fatality-II 
TABLE 34 
Overdose Fatality Brain to Blood Ratios 
for Drug and Metabolites 
IMP DMI DMD 
10.2 5.31 0.95 
1.69 0.69 
8.80 1.58 
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2HI 2HD 
4.59 0.40 
0.22 
1.43 
All concentrations used to calculate ratios were determined by GC-MS. 
D. Animal Studies 
L Rabbit 
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Rabbits were used as an experimental model because they had 
been found to hydroxylate IMP and DMI as a major route of Phase I metab­
olism ( 52). The· first rabbit experiment consisted of five male New 
Zealand white animals injected twice daily with 5 mg/kg of DMI. Blood 
was drawn by cardiac puncture, CSF from cisterna magna puncture and 
brain removed by surgery. Plasma, RBCs and brain were analyzed by HPLC 
for DMI and 2HD. In all specimens, no 2HD was detected at a detection 
limit of 5 ng per ml or g. Table 35 shows the DMI concentrations found 
in plasma, RBCs and brain in these five animals. Also included in Table 
35 are the plasma to brain and RBC to brain ratios. 
The dose of DMI was raised to 10 mg/kg twice per day in order 
to increase the blood and brain concentrations and to try to cause accu­
mulation of 2HD. Three animals died within 24 hours of receiving the 
dose. Two of these rabbits had brain tissue removed after death and all 
three had whole blood samples removed by cardiac puncture. Table 36 
contains the DMI and 2HD concentrations found in these specimens. 
Two rabbits were injected with 2HD (7 mg each) and DMI (12.5 
mg each) and sacrificed 20 minutes later. Plasma, RBCs and brain were 
analyzed for 2HD and DMI. One rabbit had low concentrations in all 
specimens (130 ng/g DMI in brain), possibly due to a poor i .p. in­
jection. The other had DMI concentrations of 489 ng/ml in plasma, 1378 
ng/ml in RBCs and 2350 ng/g in brain. The 2HD concentrations were 400 
ng/ml in plasma, 1248 ng/ml in RBCs and none detected in brain. This 
rabbits brain specimen was also analyzed by GC-MS for 2HD. Again, none 
was detected. 
TABLE 35 
DMI Concentrations in Plasma, RBCs and Brain 
in Rabbits Treated Chronically with DMI 
Plasma/ 
Animal Plasma RB Cs Brain Brain 
1 
2 
3 
4 
5 
. 47 22.5 285 
32 96 360 
64 16 189 
237 106 550 
89 109 175 
Mean 93.8 69.9 312 
S.D. 74.1 41.6 13.7 
% S.D. 79% 60% 44% 
Plasma and RBC concentrations in ng/ml. 
Brain concentrations in ng/g. 
0.165 
0.089 
0.339 
0.431 
0.509 
0.307 
0.158 
51% 
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RBC/ 
Brain 
0.079 
0.267 
0.085 
0.193 
0.623 
0.249 
0.200 
80% 
TABLE 36 
·DMI and 2HD Concentrations in Whole Blood and 
Brain from Expired Rabbits 
Animal Identification 
by Date of Death Plasma 
12-15-82 1154 
12-16-82 228 
12-20-82 22 
N.M. = Not measured 
N.D. = None detected 
D M 
Blood concentrations in ng/ml 
Brain concentrations in ng/g 
Brain Plasma 
N.M. 564 
535 348 
165 N.D. 
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2 H D 
Brain 
N.M. 
N.D. 
N.D. 
141 
2. Rat 
Rats were used in a chronic metabolism and distribution study. 
Four groups of five animals were administered IMP or DMI twice daily for 
five days. Plasma, RBCs and brain were analyzed for IMP, DMI, DMD, 2HI 
and 2HD by HPLC. No 2HI or 2HD was detected in any specimen (detection 
limit 5 ng/ml). Table 37 contains the IMP, DMI and DMD concentrations 
found in plasma, RBCs and brain of rats treated with 5 or 10 mg/kg of 
IMP. Table 38 contains the calculated plasma to RBC ratios for IMP, OMI 
and DMD in these animals. Table 39 contains the.brain to plasma and 
brain to RBC ratios of the IMP concentrations calculated for these IMP 
treated rats. Generally, the DMI concentrations are higher than IMP 
concentrations in all specimens. DMD concentrations are the lowest. 
DMI and DMD were measured in the DMI treated rats. These con­
centrations in plasma, RBCs and brain are listed in Table 40. The plasma 
to RBC ratios for DMI and DMD for these DMI treated rats are in Table 
41. The brain to plasma and brain to RBC ratios of DMI concentrations 
for both IMP and DMI treated animals are listed in Table 42. The over­
all mean, and the mean for DMI treated and IMP treated rats is included. 
In order to further study the relationship of brain DMI con­
centrations to plasma and RBC DMI concentrations these concentrations 
were compared in Figures 10, 11, 12 and 13. Brain DMI concentrations (y 
axis) are compared to plasma and RBC concentrations for both groups, IMP 
and DMI treated rats. In each comparison, linear regression was used to 
examine what correlation exists for the data. Included on each figure 
is the y intercept and slope of the best fit line and the correlation 
coefficient. For comparison, they are also listed in Table 43. 
TABLE 37 
IMP, DMI and DMD Concentrations in IMP Treated Rats 
P L A S M A R B C B R A I N 
Animal Dose IMP DMI DMD IMP DMI DMD IMP DMI DMD 
5 54 223 24 39 305 22 50 1505 165 
2 5 83 347 104 69 763 46 155 2845 645 
3 5 27 186 75 79 611 30 100 1080 460 
4 5 50 34 16 14 42 0 615 195 57 
5 5 22 406 36 291 347 0 140 1950 185 
6 10 288 512 147 36 325 80 185 2340 685 
7 10 38 410 69 35 366 6 38 2320 383 
8 10 144 1076 396 40 366 278 115 2660 2810 
9 10 109 1872 131 46 1215 30 400 7460 490 
10 10 51 448 311 100 376 260 295 2000 1430 
Dose in mg/kg B.I.D. 
All concentrations in ng/ml except brain, ng/g. 
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TABLE 38 
Plasma to RBC Ratios of IMP, DMI and DMD 
in IMP Treated Rats 
Animal Dose IMP DMI DMD 
1 5 1.38 0.731 1.09 
2 5 1.20 0.455 2.26 
3 5 0.342 0.304 2.50 
4 5 3.57 0.810 
5 5 0.076 1.17 
6 10 8.00 1.58 1.84 
7 10 1.09 1.12 11.5 
8 10 3.60 2.94 1.42 
9 10 2.37 1.54 4.37 
10 10 0.51 1.19 1.20 
Mean 2.21 1.18 3.29 
Standard Deviation 2.26 0.71 3.26 
Relative S.D. {%) 102% 60% 100% 
Animal 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
TABLE 39 
Brain to Plasma and Brain to RBC IMP Concentration 
Ratios in IMP Treated Rats 
Dose Brain/Plasma Brain/RBC 
5 0.93 1.28 
5 1.87 2.25 
5 3.70 1.27 
5 12.3 43.5 
5 6.37 0.48 
10 0.64 5.13 
10 0.74 0.80 
10 0.80 2.88 
10 3.67 8.70 
10 5.78 2.95 
Mean± Standard Deviation 3.68 ± 3.51 6.92 ± 12.4 
Dose in mg/kg B.I.D. 
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TABLE 40 
DMI and DMD Concentrations (ng/ml) in DMI Treated Rats 
P L A S M A R B C B R A I N 
Animal Dose DMI DMD DMI DMD DMI DMD 
5 376 76 597 5 4275 460 
2 5 279 91 572 59 4,050 1,035 
3 5 266 51 403 0 4,855 510 
4 5 193 161 356 142 2,685 1,760 
5 5 707 61 766 16 4,765 315 
6 10 803 324 1,551 194 7,200 2,120 
7 10 949 319 1,366 245 8,560 2,040 
8 10 962 607 1,439 579 10,370 3,900 
9 10 1,189 251 1,632 99 14,320 1.530 
10 10 1,352 211 1,789 135 12,760 1,340 
Dose in mg/kg B.I.D. 
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TABLE 41 
Plasma to RBC Ratios of DMI and DMD 
in DMI Treated Rats 
Animal Dose DMI DMD 
5 0.630 15.2 
2 5 0.489 1. 54 
3 5 0.663 
4 5 0.541 1.13 
5 5 0.919 3.81 
6 10 0.521 1.67 
7 10 0.694 1.30 
8 10 0.669 1.05 
9 10 0.728 2.54 
10 10 0.757 1. 56 
Overa 11 mean 0.661 3.31 
Standard Deviation ± 0.121 ± 4.28 
5 ng/kg mean 0.648 5.42 
Standard Deviation ± 0.149 ± 5.74 
10 ng/kg mean 0.674 1.62 
Standard Deviation ± 0.082 ± 0.51 
Animal 
IMP-1 
IMP-2 
IMP-3 
IMP-4 
IMP-5 
IMP-6 
IMP-7 
IMP-8 
IMP-9 
IMP-10 
DMI-1 
OMI-2 
DMI-3 
OMI-4 
DMI-5 
DMI-6 
OMI-7 
OMI-8 
DMI-9 
DMI-10 
TABLE 42 
Brain to Plasma and Brain to RBC DMI Concentration 
Ratios in IMP and DMI Treated Rats 
Dose Brain/Plasma 
5 6.76 
5 11. 5 
5 5.81 
5 5.75 
5 4.81 
10 4.56 
10 5.65 
10 2.47 
10 3.98 
10 4.46 
5 11.4 
5 14.5 
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Brain/RBC 
4.93 
3.73 
1.77 
4.65 
5.62 
7 .19 
6.33 
7.25 
6.13 
5.32 
7.14 
7.09 
5 18.2 12. 0 -- _ --
5 13.9 7.52 
5 6.76 6.21 
10 8.98 4.65 
10 9.01 6.25 
10 10.7 7.19 
10 12.0 8.77 
10 9.43 7.14 
Overa 11 mean± S.D. 8.53 ± 4.04 6.34 ± 2.00 
IMP mean± S.O. 5.57 ± 2.27 5.29 ± 1.57 
DMI mean± S.O. 11.5 ± 3.2 7 .40 ± 1.83 
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TABLE 43 
Linear Regression Data for Brain DMI Concentrations 
Versus Plasma or RBC DMI Concentrations Comparisons 
in IMP or DMI Treated Rats 
Comparison 
Brain vs. plasma in 
IMP treated (Fig. 10) 
Brain vs. RBC in 
IMP treated (Fig. 11) 
Brain vs. plasma in 
DMI treated (Fig. 12) 
Brain vs. RBC in 
DMI treated (Fig. 13) 
y 
-83.3 
118 
-4.0 
116 
y y intercept of regression line 
s = line slope 
r = correlation coefficient 
s 
0.261 
0.145 
0.096 
0.126 
152 
r 
0.933 
0.870 
0.932 
0.903 
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A group of ten rats were injected with 2HD and DMI to study 
the distribution of the two compounds. Five animals were sacrificed 30 
minutes after their i nj ecti ons and the other five were sacrificed 60 
minutes after the injections. Plasma and brains were analyzed for 2HD 
and DMI by HPLC. Table 44 contains these concentrations. The brain to 
plasma ratios of the DMI and 2HD concentrations were calculated and 
placed in Table 45. Also included are values in a column labelled: 2HD 
Entry to Brain Relative to DMI. These values for each animal represent 
the 2HD to DMI ratio in brain if the plasma concentrations of the two 
were equal and the same brain to plasma ratios for 2HD and DMI existed 
as found experimentally. These values were calculated by dividing the 
2HD brain to plasma concentration ratio by the DMI brain to plasma 
concentration ratio for each animal as listed in Table 45. The purpose 
of the 2HO Entry to Brain Relative to DMI value is to show the relative 
accessibility of 2HD and DMI from blood into brain found in this experi­
ment. Also included in Table 45 are the overall mean for 10 animals and 
the means for the 0.5 and 1 hour groups for the brain to plasma ratios 
and the 2HD Entry to Brain Relative to DMI data. 
The brain specimen from a rat treated with 10 mg/kg B.I.D. for 
five days (animal No. 9 from Table 37} was analyzed for 2HD by GC-MS. 
This rat was chosen because of the high concentration of DMI found in 
the brain (7460 ng/g). By GC-MS, no 2HD was found above the level of d
0 
2HD present as contamination in the d4 2HD internal standard. 
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TABLE 44 
DMI and 2HD Concentrations in Plasma and Brain 
in DMI-2HD Treated Rats 
D M 2 H D 
Animal Time Plasma Brain Plasma Brain 
0.5 hr 132 624 122 17 
2 0.5 hr 80 376 64 15 
3 0.5 hr 24 92 21 15 
4 0.5 hr 154 403 96 17 
5 0.5 hr 171 372 76 17 
6 1 hr 48 433 53 30 
7 hr 49 460 42 10 
8 hr 85 557 76 23 
9 hr 69 547 58 37 
10 hr 77 641 51 6 
Plasma concentrations are ng/ml. 
Brain concentrations are ng/g. 
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TABLE 45 
Brain to Plasma Ratios for DMI and 2HD 
Concentrations in DMI-2HD Treated Rats 
D M I 2 H D 
2HD Entry to 
Animal Time Brain/Plasma Brain/Plasma Brain Relative 
to DMI 
1 0.5 hr 4.73 0.14 0.030 
2 0.5 hr 4.70 0.23 0.049 
3 0.5 hr 3.83 0.71 0.185 
4 0.5 hr 2.62 0.18 0.069 
5 0.5 hr 2.17 0.22 0.101 
6. hr 9.02 0.57 0.063 
7 1 hr 9.39 0.24 0.025 
8 1 hr 6.55 0.30 0.046 
9 hr 7.39 0.64 0.087 
10 1 hr 8.32 0.12 0.014 
Overall mean± S.D. 5.87 ± 2.49 0.33 ± 0.21 0.067 ± 0.047 
0.5 hour mean± S.D. 3.61 ± 1.05 0.30 ± 0.21 0.087 ± 0.054 
1 hour mean± S.D. 8.13 ± 1.04 0.37 ± 0.20 0.047 ± 0.026 
A. Metabolism 
1. Rat 
DISCUSSION 
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The metabolism of IMP and DMI as shown in the chronic admi.nis­
tration rat studies in this research supports the findings of earlier 
research. IMP is rapidly metabolized via demethylation to DMI, which 
then accumulates in the blood. Table 37 shows that the DMI 
concentration in plasma, RBCs and brain exceeds the IMP concentration in 
IMP treated rats in all instances except for animal Number 4. There is 
demethylation of DMI, also, to DMD. This demethylation of DMI does not 
appear to occur as rapidly as IMP demethylation. In no tissue of IMP 
treated rats (Table 37) or in DMI treated rats (Table 40) is the DMD 
concentration equal to or greater than the DMI concentration. This 
supports the findings of Gillette et al. (50, 51) who noted that IMP is 
more rapidly demethylated than DMI in rat microsome preparations. 
Hydroxylation of IMP and DMI has been found to be a minor met­
abolic pathway in rats (50, 51, 52). In the chronic administration 
studies presented here, very little free 2HI or 2HD could be detected in 
plasma, RBCs and brain. The amounts present could not be differentiated 
from background noise on the HPLC and if they were present they could 
only be small amounts in relation to IMP, DMI, and DMD. 
The metabolism of IMP and DMI in the Sprague-Dawley rats used 
here caused rapid disappearance of IMP from blood and brain with 
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appearance of DMI. The clearance of DMI was slower and DMD appeared as 
the principle metabolite. No accumulation of free 2-hydroxy metabolites 
was found. 
2. Rabbit 
As documented by Gillette et al. (52), rabbits hydroxylate IMP 
and DMI to a greater extent than do rats. They also demethylate IMP and 
DMI. It was found here that the overall metabolism of DMI was much 
faster in the rabbit than the rat. Chronic treatment. with 5 mg/kg of 
DMI in rabbit gave only one animal of five with DMI concentration in 
plasma over 100 ng/ml (Table 35) while the same dose regimen in rats 
caused DMI concentrations over 100 ng/ml in all five animals (Table 40). 
The clearance of DMJ and 2HD from rabbits was rapid enough so that lit­
tle 2HD accumulated in plasma when the DMI was administered twice daily 
and blood drawn six hours after the last dose. However, 2HD was found 
in rabbits injected with 10 mg/kg of DMI who expired some ti me in the 
next 12 hours as shown in Table 36. The presence of 2HD in the plasma 
of two of these three rabbits is evidence of hydroxylation. The ratio 
of 2HD to DMI in these plasma specimens was 0.49 and 1. 53 ( rabbits 
expiring 12-15-82 and 12-16-82, respectively), which indicate a substan­
tial production of 2HD. 
Rabbits clear DMI from their blood more rapidly than do rats. 
They produce 2HD which reaches their blood in much greater concentra­
tions than 2HD that reaches the blood of the rats of these studies. 
Clearance of DMI was too rapid to allow practical distribution studies 
of 2HD in these rabbits. The distribution studies of 2HD in both rat 
and rabbit �,as performed by administering 2HD and DMI together. 
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3. Human 
In 'the studies of rat, rabbit and man the concentrations of 
parent drug and metabolites in the blood were used as an indication of 
the type (i.e. demethylation and hydroxylation) and degree (as indicated 
by the relative concentrations) of metabolism of IMP and DMI which oc­
curs to the greatest extent in the liver (55). Therefore, the actual 
types and rates of metabolism were not studied. It is the concen­
trations of the drugs and metabolites in the tissues, in this case plas­
ma, RBCs and brain, that is of interest in this research. The concen­
trations in the brain (where the receptor sites are thought to be) and 
in the blood, which may be in equilibrium with the receptor sites, were 
determined in order to find the relative amounts of parent drug and 
metabolites. 
In rat and rabbit it was found that qualitatively the same 
metabolites are present in blood and brain with one exception. The ex­
ception was 2HD in the rabbit which was present in plasma but not de­
tected in brain. 
The metabolism of IMP and DMI in human, as indicated by plasma 
and RBC concentrations of IMP, DMI, DMD, 2HI and 2HD, does not directly 
compare to metabolism in rat or rabbit. In patients treated with IMP, 
all or some of these compounds accumulated in the plasma. These results 
compare well to earlier studies (53-57, 77) which have found the same 
metabolites. Table 21 shows the steady state concentrations of IMP and 
DMI and the relative amounts of DMD, 2HI and 2HD. As noted, all 
metabolites were not detected in all patients. For example, patients 
A-2, H-1 and H-4 had no DMD detectable and patients K-1, D-1 and J-3 had 
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no 2HI detectable. All patients had IMP and DMI concentrations greater 
than the defection 1 imit of 5 ng/ml. 
There was variation in the degree of demethylation of IMP to 
DMI. Figure 4 shows the range of the DMI to IMP ratio in plasma. This 
ratio ranged from below 1 to over 10. Half of the 24 patients had more 
DMI than IMP in plasma at steady state and the other half more IMP than 
DMI. This variation in the degree of demethylation of IMP has been 
reported by other investigators (7. 9, 55). 
There was variation in the relative amounts of hydroxylated 
metabolites found in plasma at steady state also. Examination of Table 
21 points this out. There was relatively more 2HD than 2HI in IMP 
treated patients. Figure 3 shows the distribution of the 2HI and 2HD to 
total IMP plus DMI ratios. More patients had ratios greater than 0.20 
for 2HD to total IMP plus DMI than for 2HI to total IMP plus DMI. In 
these patients, 2HD accumulates in plasma to a greater extent than does 
2HI. In fact, 2HI is a minor metabolite in plasma as only one patient 
in 24 had a 2HI concentration greater than 20% of the combined IMP and 
DMI concentrations. 2HD is a more prominent metabolite in plasma as 25% 
of patients had 2HD concentrations of 30% or greater of the combined IMP 
and DMI concentrations. 
From Table 22, it will appear that patients �1ho accumulate 
hydroxylated metabolites (designated as fast hydroxylators) �iill clear 
IMP and DMI more quickly than patients who do not accumulate 2HI and 
2HD. Table 22 shows that "fast hydroxylators" have less than half the 
combined IMP plus DMI concentrations than do "slow hydroxylators" with­
out reg a rd to the DMI to IMP ratio ( the factor used for selecting 
patients as fast or slow demethylators). It appears that the rate of 
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hydroxylation may determine the rate of clearance of IMP and DMI in 
humans, 
In patients in this study taking IMP, both demethylation and 
hydroxylation is evident. The degree of demethylation of DMI appears to 
be low, as little DMD accumulates in plasma (Table 21). The largest DMD 
to total IMP plus DMI ratio is 0.150 and the mean is 0.051. These 
studies are the first to investigate the significance of DMD as a 
metabolite of IMP and DMI. In both cases, DMD is a minor metabolite. 
These plasma concentrations would indicate that based on relative 
concentrations, IMP and DMI are the most prominent compounds and 2HD 
reaches appreciable concentrations in some patients. 
In patients in the DMI study, DMI, DMD and 2HD were detected 
in plasma (Table 27). At a steady state, DMD is a minor metabolite of 
DMI in plasma. The highest DMD to DMI ratio is in patient JB#l9 and was 
0.107. The mean DMD/DMI ratio was 0.067. The variation in this ratio 
was not great as it ranged from 0.022 to 0.107. 
On the other hand, steady state plasma concentrations indicate 
2HD is a major metabolite of DMI. In the 12 patients studied the mean 
2HD to DMI ratio was 0.321 and 8 patients (67%) had ratios greater than 
0.300. In no instance, however, was the steady state 2HD concentration 
greater than the DMI concentration. Other investigators have reported 
2HD plasma concentrations in humans. Potter et al. (57) found mean 2HD 
to DMI ratios of 0.38, 0.23, 0.43 and 0.45 in four study groups. These 
mean values compare very well to the value of 0.321 found here. They, 
however, found ratios greater than one in some patients. Their patient 
population age range (7 to 13 years) was lower than the age range used 
in this DMI study (23 to 51). Perhaps adolescents accumulate more 2HD 
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in plasma due to its increased production or reduced elimination 
compared to' adults. Devane, Savett and Jusko measured 2HD and DMI in 
four subjects. Only a single 50 mg dose was administered so no steady 
state concentrations were measured. They found the maximum 2HD plasma 
concentration to be 76% to 144% of the DMI concentration and the mean 
AUC of 2HD to be 79% of the AUC of DMI. Although not direct comparisons 
with the present study, this data is consistent with the present study. 
The degree of hydroxylation does seem to effect the rate of clearance of 
DMI just as it appears to effect the rate of clearance of IMP. The two 
patients with the highest steady state plasma DMI concentrations, GW#21 
(786 ng/ml) and EW#32 (1123 ng/ml), had the lowest 2HD to DMI ratios 
(0.024 and 0.078, respectively). Low relative accumulation of 2HD in 
plasma may indicate low rates of hydroxylation and low rates of clearance 
of DMI. 
In summary, humans show demethylation and hydroxylation of IMP 
and DMI. There is variation from patient to patient in both demethyla­
tion and hydroxylation. DMD and 2HI are minor metabolites of IMP and 
DMD is a minor metabolite of DMI. 2HD reaches appreciable concentrations 
in some IMP and a majority of DMI treated patients in these studies. 
The rate of clearance of both IMP and DMI is effected by hydroxylation 
and patients with greater relative concentrations of hydroxylated meta­
bolites had lower IMP plus DMI concentrations or lower DMI concentrations 
depending on IMP or OM! treatment, respectively. 
B. Plasma Versus RBC Concentrations 
In twelve IMP patients, ten DMI patients and in 10 rats each treated 
with IMP or DMI, the red blood cells were analyzed for parent drug and 
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some metabolites as well as plasma. Some in vitro studies of DMI, DMD 
and 2HD distribution between plasma and RBCs were performed also. The 
purpose was to determine how the compounds equilibrated between plasma 
and RBC as a basis for comparison of plasma and RBC concentrations ver­
sus clinical response studies. 
The data indicate that the equilibrium ratios for IMP between 
plasma and RBC's differs from the equilibrium ratios for DMI between 
plasma and RBCs in humans. Table 23 contains the DMI/IMP ratios. for 
both plasma and RBCs in IMP patients. The mean RBC DMI/IMP ratio was 
5.14 and the mean DMI/IMP ratio in plasma was 2.03. The mean combined 
IMP plus DMI concentrations in plasma (234.5 ng/ml) and RBCs (283 ng/ml) 
did not differ significantly. The mean plasma IMP concentration to RBC 
IMP concentration 1·1as 1.80 (± 0.80) for the twelve IMP patients. The 
DMI concentration plasma to RBC ratio mean was 0.678 (± 0.285) for the 
same patients. Therefore, in blood the IMP concentration in plasma is 
greater than in RBCs while the DMI concentration in plasma is less than 
in RBCs in these patients. 
The mean steady state plasma concentration to RBC concentra­
tion ratio for DMI in DMI treated patients (Table 29) was similar to 
that found in IMP treated patients. The mean ratio in DMI treated 
patients was 0.742 (± 0.336) and in IMP patients it was, again, 0.678 (± 
0.285). The difference in the two ratios is not significant (p<.001). 
Linnoila, Dorrity and Jobson (83) found similar plasma to RBC ratios for 
DMI concentrations. The mean value for 15 samples was 0.50, which is 
within the range of values found in the present study. The difference 
in the plasma to RBC ratios for IMP versus DMI in IMP patients was 
significant (p<.005). In these patients, IMP and OM! distribute 
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significantly different between plasma and RBCs. DMI has a greater 
affinity for RBCs. 
From Table 29 it can be seen that the plasma to RBC ratios for 
DMD (0.556 ± 0.362) and 2HD (0.673 ± 0.610) do not differ much from that 
for DMI (0.742 ± 0.336). DMI, DMD and 2HD distribute similarly between 
plasma and RBCs in these patients. 
In the in vitro studies of 2HD, DMD and 2HD, it was shown that 
equilibrium between plasma and RBCs was reached in ten minutes or less 
(Table 14). If DMI was added to RBCs first rather than to whole blood, 
the mean plasma and RBC concentrations of DMI did not differ signifi­
cantly (Tables 14 and 15). There were slight variations in those plasma 
and RBC concentrations from week to week (Table 16). It was found that 
the plasma to RBC DMI concentration ratio was constant over a range of 
250 to 3000 ng/ml of DMI in whole blood (Table 17). This means there 
was no saturation of RBCs or plasma in this range causing a shift in the 
ratio. 
The distribution of DMI between plasma and RBCs for 15 normal 
persons is shown in Table 18. The mean plasma to RBC ratio was 0.526 ± 
0.092. No difference for males (0.532) and females (0.519) was noted. 
This mean plasma to RBC DMI concentration ratio of 0.526 is lower than 
that found in DMI patients (0.742) and IMP patients (0.678). For this 
number of patients (15 normals, 10 DMI patients and 12 IMP patients) the 
difference in plasma to RBC ratios for DMI concentrations may be signif­
icant but more patients would need study to confirm it. It is interest­
ing that Linnoila et al. (83) found a ratio of 0.50 in an in vivo study 
of normal volunteers. That ratio, 0.50, is very close to the in vitro 
normal population value found here of 0.525. 
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In rats, the IMP plasma to RBC ratio was greater than the DMI 
plasma to RBC ratio as it was in humans. From Table 38, the IMP ratio 
is 2.21 (± 2.26) and the DMI ratio (for IMP treated rats) is 1.18 (± 
0.71). The DMI ratio for DMI treated rats (Table 41) is 0.661 (± 0.121). 
For DMI treated rats the dose of DMI did not effect the DMI plasma to 
RBC ratios (mean for 5 mg/kg dose is 0.648 and the mean for 10 mg/kg 
dose is 0.674). The DMI plasma to RBC ratio means for IMP treated rats 
(1.18) differed from that for DMI treated rats (0.661). However, the 
large variation in the IMP treated group's ratios (standard deviation of 
0.71) make the difference not significant. 
It appears that IMP and DMI distribute differently between 
plasma and RBCs in both man and rat. In both species, IMP has a greater 
affinity for plasma than RBCs. Also in both species, DMI has a greater 
affinity for RBCs than plasma. 
C. Drug Concentrations Versus Clinical Response 
1. Imi prami ne 
No good correlation between clinical response as measured by 
Hamilton Depression Rating Scores and plasma or RBC drug and metabolite 
concentrations was found for IMP treated patients. Tables 24 and 25 
contain all the data used to calculate the Pearson correlation data in 
Table 26. Raw Improvement Scores indicate the difference in HOS before 
therapy and during therapy. The Severity Index is the HOS at the start 
of therapy and is a measure of the extent of depression. The higher the 
score the worse is the depression rating at the time of testing. Both 
plasma and RBC values for IMP and DMI concentrations,the total IMP plus 
DMI concentrations and the DMI to IMP ratios were compared by Pearson 
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correlation to raw improvement. Table 26 shows that the correlation co­
efficients (r) for all these comparisons were low and no significant (p 
< .01) correlation was found. The highest value for. r was a negative 
0.395. The r = -0.395 was found for RBC DMI/IMP ratio versus raw 
improvement and would indicate that there was greater improvement for 
patients with low DMI/IMP ratios than those with higher ratios. Again, 
this correlation was not statistically significant. 
This data indicates that for this patient population. (24 
patients for plasma studies and 12 for RBC studies) in this particular 
study protocol no clear correlation between plasma and RBC drug concen­
tration and clinical response was found. Other studies using IMP have 
found good correlations (21, 31), while others have not (23, 27). The 
present study of IMP treated patients and clinical response was well 
planned and executed. A placebo washout period was included and IMP was 
administered 1 ong enough to be effi cacous ( 6). Comp 1 i ance with dose 
regimen could not be certain due to the use of out-patients. 
2. Desipramine 
There were some good correlations found between plasma and RBC 
drug concentrations a.nd Raw Improvement in the patients treated with 
DMI. Tables 30 and 31 contain Severity Index Scores, raw improvement 
scores and plasma and RBC drug concentrations for these patients. Table 
32 contains the results of Pearson correlations for this data. The cor­
relations of Raw Improvement versus plasma [DMI] (r = -0.750), plasma 
[DMI + 2HD] (r = -D.752), RBC [DMI] (r = -0.693) and RBC [DMI + 2HD] (r 
= -0.655) are all significant (at least p < 0.05). Figure 9 is a graph 
example of one of these comparisons. In all instances, these correla­
tions indicate that Raw Improvement declines as drug concentrations 
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increase. These patients were treated with a high dose of DMI (300 mg 
per day) sb that high concentrations in blood would generally occur. 
The purpose was to study clinical response at high concentrations. The 
data indicate that response declines (that is, less improvement in 
depression occurs) at high DMI concentrations in blood. There is little 
apparent difference between using RBC and plasma DMI concentrations to 
check correlation to Raw Improvement. The correlation coefficient for 
RBC [DMI] of -0.693 and for plasma [DMI] of -0.750 are not significantly 
different for the number of patients used. The inclusion of 2HD 
concentrations did not significantly change the correlation coefficients 
for the plasma comparison {-0.750 without 2HD and -0.752 with 2HD) or 
for the RBC comparison (-0.693 without 2HD and -0.655 with 2HD). 
In this study using high dose DMI therapy, a negative corre­
lation between drug concentration in blood and clinical response was 
found. At high plasma and RBC DMI concentrations there was less 
improvement in the patient's depression syndrome. This is the first 
report of a decrease in improvement at high steady state DMI concentra­
tions. This phenomenon has been reported for nortriptyline (102) and 
protriptyline (103). 
D. Drug and Metabolite Distribution to Brain 
As noted earlier, IMP patients were found to have IMP, DMI, DMD, 
2HI and 2HD in their plasma. All metabolites were not found in all 
these patients. DMI treated patients had DMI, DMD and 2HD in their 
plasma. Three sets of autopsy specimens consisting of whole blood and 
brain were analyzed for these compounds. Two fatalities were associated 
with DMI ingestion and one with IMP ingestion. In both blood and brain, 
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IMP, DMI, DMD, 2HI and 2HD were detected in specimens from the IMP 
fatality (Table 33). Blood and brain specimens from both DMI fatalities 
were shown to contain DMI, DMD and 2HD. Therefore, there was evidence 
that all metabolites found in clinical patient's plasma could be found 
in human brain after overdose with IMP and DMI. 
The relative amounts of the drugs and metabolites that reach 
the brain from the blood are important when considering relative impor­
tance of drug and metabolites in the pharmacology of IMP and DMI. IMP 
and DMI are considered to be centrally acting drugs (58). The site of 
action or receptors are thought to be in brain (71). The concentrations 
of the drugs and metabolites at the receptors may influence the degree 
of pharmacological response. 
From the plasma concentrations, 2HI and DMD were considered to 
be minor metabolites. 2HD was found in appreciable concentrations in 
both DMI and some IMP treated patients. The relative amount of 2HD that 
reaches the brain may determine whether 2HD is indeed a significant 
metabolite which should then be considered along with DMI in DMI treated 
patients and perhaps with IMP and DMI in IMP treated patients. 
The brain to blood ratios listed in Table 34 for the overdose 
fatality cases are an indication of the entry of each drug and 
metabolite into brain from blood. The degree of entry into brain has 
been theorized to depend on the polarity of a compound (65). The more 
polar the compound, the less the degree of entry into brain. If this 
theory is correct, the more polar metabolites of IMP and DMI would cross 
the "blood-brain barrier" to a lesser amount than IMP and DMI. 
In Table 34, the brain to blood ratio for 2HD is always less 
than the brain to blood ratio for IMP and DMI. In the IMP fatality, the 
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IMP ratio is 10.2, the DMI ratio is 5.31 and the 2HD ratio is 0.40. 
That means ten times as much IMP was found in brain than blood, 5 times 
as much DMI was found in brain than blood but less than half as much 2HD 
was found in brain than blood. 
The brain to blood ratios for 2HD in the two DMI fatalities 
were significantly lower than the brain to blood ratios for DMI. In 
both instances, it is indicated that 2HD enters the brain to a lesser 
extent than does DMI. The overdose fata 1 i ty data must be viewed care­
fully. The conditions of drug administration were not controlled and 
the specimens not collected promptly at time of death. 
A control] ed study using rats was used to better study the 
relative entry of 2HD and DMI from blood to brain. Both DMI and 2HD 
were administered to ten rats. Five were sacrificed at 30 minutes 
post-injection and five after 60 minutes. The brain to blood ratio of 
DMI concentrations was used to judge when distribution had reached equi­
librium. In the chronic DMI administration study, the brain to plasma 
DMI ratio had a mean value of 11.5 (± 3.2) as shown in Table 42. These 
are equilibrium values because this was a chronic study and animals were 
sacrificed at least 10 hours after the last dose. In comparison, the 
brain to plasma ratio for DMI concentrations in the 30 minute group of 
rats was 3.16 (± 1.05) and in the 60 minute group was 8.13 (± 1.04) as 
shown in Table 45. Therefore the 60 minute group was approaching equi­
librium for distribution of DMI to brain from blood. 
Table 44 contains all the 2HD and DMI concentrations in plasma 
and brain from rats administered 2HD and DMI. Table 45 contains all the 
brain to plasma concentration ratios. As distribution approached equi­
librium at 60 minutes, the brain to plasma 2HD ratio was 0.37 (± 1.20) 
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and the brain to plasma DMI ratio was 8.13 (± 1.04). These ratios show 
that 2HD entry into brain is much less than entry for DMI. The DMI con­
centration in brain was an average 8 times the plasma concentration. On 
the other hand, 2HD brain concentration was on average less than one-half 
the plasma 2HD concentration. 
In Table 45, a column labelled 2HD Entry to Brain Relative to 
DMI shows the relative access of 2HD to brain compared to DMI. If blood 
concentrations were equal for 2HD and DMI, the 2HD concentration. in 
brain would be an average of 4.7% of the brain DMI concentration. This 
experiment shows that in the rat, here used as a model, 2HD has poor ac­
cess to brain compared to DMI and 2HD blood concentrations would have to 
be much higher than DMI blood concentrations to yield similar brain con­
centrations. The DMI clinical patient data showed no steady state plas­
ma samples to have 2HD concentrations equal to or higher than DMI con­
centrations. 
Rats were also used as a model to compare plasma and RBC DMI 
concentrations to brain DMI concentrations. The Pearson Correlation da­
ta are shown in Table 43. As can be seen in the correlation coefficients 
(r), the plasma and RBC DMI concentrations correlated well to brain DMI 
concentrations for both IMP treated and DMI treated animals. All r 
values were 0.870 or greater (p < .01). Figures 10 through 13 are 
graphs of each correlation. The brain versus RBC correlations for both 
IMP and DMI treated rats were very similar. IMP treated animals had r = 
0.870 versus r = 0.903 for DMI treated animals. More importantly, the y 
intercepts (118 and 116) and slopes (0.145 and 0.126) of the linear re­
gression line were very similar, indicating that the relationship of 
brain to RBC DMI concentrations 1·1as the same for both groups, IMP and 
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DMI treated animals. It made no difference in these comparisons whether 
the animals' were treated with IMP or DMI. 
However, the plasma versus brain DMI concentration comparisons 
differed for IMP treated versus DMI treated rats. Both had good corre­
lation coefficients (r = 0.933 and r = 0.932, respectively), in fact, 
better than the RBC to brain comparisons. The slopes of the regression 
lines differed substantially. The IMP treated group had a slope of 
0.261 while the DMI treated group's slope was 0.096. The y intercepts 
were -83.3 and -4.0, respectively. These data indicate that the rela­
tionship between the plasma DMI concentration and the brain DMI concen­
tration may be different if the animal is administered IMP rather than 
DMI. IMP in the tissues appears to shift the ratio of plasma to brain 
DMI concentrations but not the ratio of RBC to brain DMI concentrations. 
If other drugs also shifted the plasma to brain DMI ratio but not the 
RBC to brain DMI ratio, RBC concentrations might be a more reliable 
indicator of brain DMI concentrations. However, as noted, in all 
instances plasma and .RBC DMI concentrations correlated well with brain 
DMI concentrations in these rat studies. Further investigation in the 
rat of these relationships might be fruitful. 
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CONCLUSION 
A three step extraction procedure for isolating IMP, DMI, DMD, 
2HI and 2HD from plasma, red blood cells and brain has been developed. 
An HPLC method has been developed to separate the compounds and allow 
quantitation by peak height compared to an internal standard. These 
procedures have been used to accurately and precisely quantitate these 
compounds in human, rat and rabbit blood and brain specimens. Accuracy 
has been shown by comparison to an established GC-MS procedure. 
DMD is a minor metabolite of IMP and DMI. DMD does not accumulate 
in patient plasma samples to above 20% of the combined IMP and DMI con­
centrations in IMP treated patients or to above 20% of the DMI concen­
tration in DMI treated patients. For therapeutic drug monitoring, the 
DMD concentration is probably insignificant. 
2HI is a minor metabolite of IMP. It infrequently accumulates to 
over 20% of the combined IMP plus DMI concentration in plasma. At 
steady state, 2HI was found to be less than 10% of the IMP plus DMI con­
centration in the majority of patients. Measurement of 2HI may be use­
ful in pharmacokinetic and metabolism studies but not for general thera­
peutic drug monitoring. 
2HD is a major metabolite of DMI in plasma of patients at steady 
state. It also reaches appreciable quantities (defined here as greater 
than 20% of IMP plus OM! concentrations) in IMP treated patients. 2HD 
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concentrations reach values large enough in plasma to be potentially 
significant'therapeutically in both DMI and some IMP treated patients. 
The accumulation of hydroxylated metabolites is associated with in­
creased clearance of IMP and DMI compared to patients who have lower 
relative concentrations of hydroxylated metabolites. Patients designat­
ed fast hydroxylators have significantly lower plasma IMP plus DMI con­
centrations than do slow hydroxylators. Hydroxylation may be the rate 
limiting route of metabolism in man for IMP and DMI. 
IMP, DMI, DMD, 2HI and 2HD have been quantitated in the brain of an 
IMP overdose fatality. DMI, DMD and 2HD have been quantitated in the 
brains of two DMI overdose fatalities. The brain to blood ratio of 2HD 
concentrations is much less than the brain to blood ratios of IMP and 
DMI concentrations. This is an i ndi cation that 2HD cannot enter the 
brain as easily as IMP and DMI. 
Rats and rabbits were used as models to study IMP, DMI and 2HD en­
try into brain. In rabbits, no 2HD could be detected in brain despite 
significant amounts in the blood. A larger study in rats showed that 
2HD is, indeed, restricted from entering brain compared to DMI. The 
relative ability of 2HD and DMI to enter brain shows that substantially 
higher blood concentrations of 2HD compared to DMI would be necessary to 
produce equal concentrations in brain. The combined rat data and human 
overdose fatality data indicate that 2HD probably does not reach concen­
trations in brain to be significant pharmacologically compared to DMI. 
It has been shown that IMP and DMI distribute differently between 
plasma and red blood cells. DMI has a greater affinity for RBCs than 
plasma. IMP is the reverse. It has higher concentrations in plasma 
than RBCs. The distribution for both is similar in humans and rats. 
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Both RBC and plasma DMI concentrations correlated well with brain con­
centrations' in the rats. However, the presence of IMP changed the rela­
tionship between plasma DMI and brain DMI concentrations but not RBC DMI 
and brain DMI concentrations. Because IMP shows a greater affinity for 
plasma than RBCs, it may shift the DMI equilibrium between plasma and 
RBCs. 
These quantitative drug studies were performed in conjunction with 
clinical evaluation of patients. Clinical improvement could not be .cor­
related to drug and metabolite concentrations for IMP treated patients. 
Some similar clinical studies have found reasoriably good correlations 
between the two while other studies have not. 
There were found to be good correlations between both plasma and 
RBC DMI concentrations and improvement in the patient's depressive syn­
drome. The DMI study was designed to study the effect of high DMI con­
centrations and clinical response. As the DMI concentration increased 
in this study, the degree of improvement in depression decreased. That 
is, patients with high plasma DMI concentrations (generally, 400 ng/ml 
or greater) showed less improvement than patients with lower plasma DMI 
concentrations (less than 400 ng/ml). Combining the 2HD concentration 
and the DMI concentration did not change the correlations to improvement 
significantly. 
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APPENDIX 1 
American Psychiatric Association; Quick Reference to the Diagnostic 
criteria from Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition, Washington, D. C., APA, 1980, pages 117 to 130. 
MAJOR AFFECTIVE DISORDERS 
Manic Episode 
Differential diagnosis. Organic Affective Syndromes; Schizophrenia, 
Paranoid Type; Schizoaffective Disorder; Cyclothymic Disorder. 
Diagnostic criteria. 
A. One or more distinct periods with a predominantly elevated, expan­
sive or irritable mood. The elevated or irritable mood must be a promi­
nent part of the illness and relatively persistent, although it may al­
ternate or intermingle with depressive mood. 
B. Duration of at least one week (or any duration if hospitalization is 
necessary), during which, for most of the time, at least three of the 
following symptoms have persisted (four if the mood is only irritable) 
and have been present to a significant degree: 
(1) increase in activity (either socially, at work, or sexually) 
or physical restlessness 
(2) more talkative than usual or pressure to keep talking. 
(3) flight of ideas or subjective experience that thoughts are 
racing 
(4) inflated self-esteem (grandiosity, which may be delusional) 
(5) decreased need for sleep 
(6) distractibility, i.e. attention too easily drawn to unimpor­
tant or irrelevant external stimuli 
(7) excessive involvement in activities that have a high potential 
for painful consequences which is not recognized, e.g., buying 
sprees, sexual indiscretions, foolish business investments, reck­
less driving 
C. Neither of the following dominate the clinical picture when an af­
fective syndrome (i.e., criteria A and B above) is not present, that is, 
before it developed or after it has remitted: 
(1) preoccupation with a mood-incongruent delusion or 
hallucination (see definition below) 
(2) bizarre behavior 
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D. Not superimposed on either Schizophrenia, Schizophreniform Disorder, 
or a Paranoid Disorder. 
E. Not due to any Organic Mental Disorder, such as Substance Intoxica­
tion. 
(Note: A hypomanic episode is a pathological disturbance similar to, 
but not as severe as, a manic episode). 
Fifth-digit code numbers and criteria for subclassification of manic 
episode: 
6-In Remission. This fifth-digit category should be used when in the 
past the individual met the full criteria for a manic episode but now is 
essentially free of manic symptoms or has some signs of the disorder but 
does not meet the full criteria. The differentiation of this diagnosis 
from no mental disorder requires consideration of the period of time 
since the last episode, the number of previous episodes, and the need 
for continued evaluation or prophylactic treatment. 
4-With Psychotic Features. This fifth-digit category should be used 
when there apparently is gross impairment in reality testing, as when 
there are delusions or hallucinations or grossly bizarre behavior. When 
possible specify whether the psychotic features are mood-congruent or 
mood-incongruent. 
Mood-congrent Psychotic Features: Delusions or hallucinations 
whose content is entirely consistent with the themes of inflated worth, 
power, knowledge, identity, or special relationship to a deity or famous 
person; flight of ideas without apparent awareness by the individual 
that the speech is not understandable. 
Mood-incongruent Psychotic Features. Either (a) or (b): 
(a) Delusions or hallucinations whose content does not involve 
themes of either inflated worth, power, knowledge, identity, or 
special relationship to a deity or famous person. Included are 
such symptoms as persecutory delusions, thought insertion, and de­
lusions of being controlled, whose content has no apparent rela­
tionship to any of the themes noted above. 
(b) Any of the following catatonic symptoms: stupor, mutism, 
negativism, posturing. 
2-Without Psychotic Features. Meets the criteria for manic episode, but 
·no psychotic features are present. 
0-Unspecified. 
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Major depressive episode 
Differential: Diagnosis. Organic Affective Syndrome, Primary Degenera­
tive Dementia, Multi-infarct Dementia, psychological reaction to func­
tional impafrment associated with a physical illness, Schizophrenia, 
Schizoaffective Disorder, Dysthymic Disorder, Cyclothymic Disorder, oth­
er chronic mental disorders associated with depressive symptoms, Sepa­
ration Anxiety Disorder, Uncomplicated Bereavement. 
Diagnostic criteria. 
A. Dysphoric mood or loss of interest or pleasure in all or almost all 
usual activities and pastimes. The dysphoric mood is characterized by 
symptoms such as the following: depressed, sad, blue, hopeless, low, 
down in the dumps, irritable. The mood disturbance must be prominent 
and relatively persistent, but not necessarily the most dominant symp­
toms, and does not include momentary shifts from one dysphoric mood to 
another dysphoric mood, e.g., anxiety to depression to anger, such as 
are seen in states of acute psychotic turmoil. (For children under sex, 
dysphoric mood may have to be inferred from a persistently sad facial 
expression.) 
B. At least four of the following symptoms have each been present near­
ly every day for a period of at least two weeks (in children under six, 
at least three of the first four): 
(1) poor appetite or significant weight loss (when not dieting) or 
increased appetite or s i gni fi cant weight gain (in children under 
six consider failure to make expected weight gains) 
(2) insomnia or hypersomnia 
(3) psychomotor agitation or retardation (but not merely subjective 
feelings of restlessness or being slowed down) (in children under 
six, hypoactivity) 
(4) loss of interest or pleasure in usual activities, or decrease 
in sexual drive not limited to a period when delusional or 
hallucinating (in children under six, signs of apathy) 
(5) loss of energy; fatigue 
(6) feelings of worthlessness, self-reproach, or excessive or inap­
propriate guilt (either may be delusional) 
(7) complaints or evidence of diminished ability to think or con­
centrate, such as slowed thinking, or indecisiveness not associated 
with marked loosening of associations or incoherence 
(8) recurrent thoughts of death, suicidal ideation, wishes to be 
dead, or suicide attempt 
C. Neither of the following dominate the clinical picture 1·1hen an af­
fective syndrome (i.e., criteria A and B above) is not present, that is, 
before it developed or after it has remitted: 
(1) preoccupation with a mood-incongruent delusion or hallucination 
(see definition below) 
(2) bizarre behavior 
194 
D. Not superimposed on either Schizophrenia, Schizophreniform Disorder, 
or a Paranoid Disorder. 
E. Not due to any Organic Mental Disorder or Uncomplicated Bereavement. 
Fifth-digit code numbers and criteria for subclassification of major 
depressive episode: 
(When psychotic features and melancholia are present the coding system 
requires that the clinician record the single most clinically signifi­
cant characteristic.) 
6-In Remision. This fifth-digit category should be used when in the 
past the individual met the full criteria for a major depressive episode 
but now is essentially free of depressive symptoms or has some signs of 
the disorder but does not meet the full criteria. 
4-With Psychotic Features. This fifth-digit category should be used 
when there apparently is gross impairment in reality testing, as when 
there are delusions or hallucinations, or depressive stupor (the 
individual is mute and unresponsive). When possible specify whether the 
psychotic features are mood-congruent or mood-incongruent. 
Mood-congruent Psychotic Features. Delusions or hallucinations 
whose content is entirely consistent with the themes of either personal 
inadequacy, guilt, disease, death, nihilism, or deserved punishment; 
depressive stupor (the individual is mute and unresponsive). 
Mood-incongruent Psychotic Features. Delusions or hallucinations 
whose content does not involve themes of either personal inadequacy, 
guilt, disease, death, nihilism, or deserved punishment. Included here 
are such symptoms as persecutory delusions, thought insertion, thought 
broadcasting, and delusions of control, whose content has no apparent 
relationship to any of the themes noted above. 
3-With Melancholia. 
A. Loss of pleasure in all or almost all activities. 
B. Lack of reactivity to usually pleasurable stimuli (doesn't feel much 
better, even temporarily, when something good happens). 
C. At least three of the following: 
(a) distinct quality of depressed mood, i.e., the depressed mood is 
perceived as distinctly different from the kind of feeling experi­
enced following the death of a loved one 
(b) the depression is regularly worse in the morning 
(c) early morning awakening (at least two hours before usual time 
of awak;ening) 
(d) marked psychomotor retardation or agitation 
(e) significant anorexia or weight loss 
(f) excessive or inappropriate guilt 
2-Without Melancholia 
0-Unspecified 
BIPOLAR DISORDER 
296.6x Bipolar Disorder, Mixed 
Diagnostic criteria. 
Use fifth-digit coding for manic episode. 
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A. Current (or most recent) episode involves the full symptomatic pic­
ture of both manic and major depressive episodes intermixed or rapidly 
alternating every few days. 
B. Depressive symptoms are prominent and last at least a full day. 
296.5x Bipolar Disorder, Depressed 
Diagnostic criterion. 
Currently (or most recently) in a manic episode. (If there has been a 
previous manic episode, the current episode need not meet the full 
criteria for a manic episode.) 
296.5x Bipolar Disorder, Depressed 
Diagnostic criteria. 
A. Has had one or more manic episodes. 
B. Currently (or most recently) in a major depressive episode. (If 
there has been a previous major depressive episode, the current episode 
of depression need not meet the full criteria for a major depressive 
episode.) 
MAJOR DEPRESSION 
296.2x Major Depression, Single Episode 
296.3x Major Depression, Recurrent 
Diagnostic criteria. 
A. One or more major depressive episodes. 
B. Has never had a manic episode or hypomanic episode. 
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OTHER SPECIFIC AFFECTIVE DISORDERS 
301.13 Cyclothymic Disorder 
Differential Diagnosis. Bipolar Disorder, major depressive episode, 
manic episode. 
Diagnostic criteria: 
A. During the past two years, numerous periods during which some symp­
toms characteristic of both the depressive and the manic syndromes were 
present but were not of sufficient severity and duration to meet the 
criteria for a major depressive or manic episode. 
B. The depressive periods and hypomanic periods may be separated by pe­
riods of normal mood lasting as long as months at a time, they may be 
intermixed, or they may alternate. 
C. During depressive periods there 
is depressed mood or loss of interest 
or pleasure in all, or almost all, 
usual activities and pastimes, and at 
least three of the following: 
(1) insomnia or hypersomnia 
(2) low energy or chronic fatigue 
(3) feelings of inadequacy 
(4) decreased effectiveness or pro­
ductivity at school, work, or 
home 
(5) decreased attention, concentra­
tion, or ability to think clearly 
(6) social withdrawal 
(7) loss of interest in or enjoyment 
of sex 
During hypomanic periods 
there is an elevated, 
expansive, or ·irritable mood 
and at least three of the 
following: 
decreased need for sleep 
more energy than usual 
inflated self-esteem 
increased productivity, 
often associated with 
unusual and self-imposed 
working hours 
sharpened and unusually 
creative thinking 
uninhibited people-seeking 
(extreme gregariousness) 
hypersexuality without 
recognition of possibility 
of painful consequences 
(8) restriction of involvement in 
pleasurable activities; guilt 
over pa�t activities 
(9) feeling slowed down 
(10) less talkative than usual 
(11) pessimistic attitude toward the 
future, or brooding about past 
events 
(12) tearfulness or crying 
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excessive involvement in 
pleasurable activities with 
lack of concern for the high 
potential for painful 
consequences, e.g., buying 
sprees, foolish business 
investments, reckless 
driving 
physical restlessness 
more talkative than usual 
overoptimism or exaggeration 
of past achievements 
inappropriate laughing, 
joking, punning 
D. Absence of psychotic features duch as delusions, hallucinations, in­
coherence, or loosening of associations. 
E. Not due to any other mental disorder, such as partial remission of 
Bipolar Disorder. However, Cyclothymic Disorder may precede Bipolar 
Disorder. 
300.40 Dysthymic Disorder (or Depressive Neurosis) 
Differetial Diagnosis. Major Depression; normal fluctuations of mood; 
chronic mental disorders, such as Obsessive Compulsive Disorder or Alco­
hol Dependence, when associated with depressive symptoms. 
Diagnostic criteria. 
A. During the past two years (or one year for children and adolescents) 
the i ndi vi dua 1 has been bothered most or a 11 of the time by symptoms 
characteristic of the depressive syndrome that are not of sufficient se­
verity and duration to meet the criteria for a major depressive epidode. 
B. The manifestations of the depressive syndrome may be relatively per­
sistent or separated by periods of normal mood lasting a few days to a 
few weeks, but no more than a few months at a time. 
C. During the depressive periods there is either prominent depressed 
mood (e.g., sad, blue, down in the dumps, low) or marked loss of inter­
est or pleasure in all, or almost all, usual activities and pastimes. 
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D. During the depressive periods at least three of the following symp­
toms are present: 
(1) insomnia or hypersomnia 
(2) low energy level or chronic tiredness 
(3) feelings of inadequacy, loss of self-esteem, 
or self-deprecation 
(4) decreased effectiveness or productivity at school, 
work, or home 
(5) decreased attention, concentration, or ability 
to think clearly 
(6) social withdrawal 
(7) loss of interest in or enjoyment of pleasurable 
activities 
(8) irritability or excessive anger (in children, expressed 
toward parents or caretakers) 
(9) inability to respond with apparent pleasure to praise 
or rewards 
(10) less active or talkative than usual, or feels slowed 
down or restless 
(11) pessimistic attitude toward the future, brooding about 
past events, or feeling sorry for self 
(12) tearfulness or crying 
(13) recurrent thoughts of death or suicide 
E. There are no psychotic features, such as delusions, hallucinations, 
or incoherence. 
F. If the disturbance is superimposed on another mental disorder or a 
preexisting mental disorder, such as Obsessive Compulsive Disorder or 
Alcohol Dependence, the depressed mood, by virtue of its intensity or 
effect on functioning, can be clearly distinguished from the individu­
al's usual mood. 
ATYPICAL AFFECTIVE DISORDERS 
296.70 Atypical Bipolar Disorder 
This is a residual category for individuals with manic features that 
cannot be classified as Bipolar Disorder or a Cyclothymic Disorder. For 
example, an individual who previously had a major depressive episode, 
now has an episode of illness with some manic features (hypomanic epi­
sode), but not of sufficient severity and duration to meet the criteria 
for a manic episode. Such cases have been referred to as "Bipolar!!." 
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296.82 Atypical Depression 
This i-s a residual category for individuals with depressive symptoms who 
cannot be diagnosed as having Major or Other Specific Affective Disorder 
or Adjustment Disorder. Examples include the following: 
(1) A distinct and sustained episode of the full depressive syn­
drome in an individual with Schizophrenia, Residual Type, that de­
velops without an activation of the psychotic symptoms. 
(2) A disorder that fulfills the criteria for Dysthymic Disorder; 
however, there have been intermittent periods of normal mood last­
ing more than a few months. 
(3) A brief episode of depression that does not meet the criteria 
for a Major Affective Disorder and that is apparently not reactive 
to psychosocial stress, so that it cannot be classified as an Ad­
justment Disorder. 
NOTE: five-digit codes, such as 296.2x Major Depression, Single Episode, 
are used as a classification scheme for the diagnosis of patients. 
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Period O O O O O 0 
(Check One) 10011 (0021 (0031 (0041 toos1 10001 
'80 8/80 PART 1 
4 R. P. PURPURA, M.D. 
PATIENT'S NAMI!: 
R. 0. FRIEDEL, M.D. 
4 5 0 6 
18--21 
PATIENT'S I.D. NO. 
PATIi!: Of" THlfl 
REPORT 
31-33 
FOR EACH ITEM 
1. DEPRESSED 
MOOD 
(Sadness, 
hopeless, helpless, 
worthless) 
2. FEELINGS 
OF GUILT 
3. SUICIDE 
L INSOMNIA 
EARLY 
INSOMNIA 
MIDDLE 
INSOMNIA 
LATE 
WORK AND 
ACTIVITIES 
RETARDATION 
(Slowness of 
thought and speech; 
impaired ability to 
concentrate; de­
creased motor 
activity) 
AGITATION 
O.NXIETY 
'SYCHIC 
,.-!--I-..-
CHECK THE BOX NEXT TO THE RESPONSE THAT BEST CHARACTERIZES THE PATIENT 
oO Absent 
1 D These feeling states indicated only on questioning. 
20 These feeling states spontaneously reported verbally. 
(40) 30 Communicates feeling states non-verbally - i.e., through facial expression, posture, voice and 
tendency to weep. 
4 0 Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non­
verbal communication. 
oO Absent 
1 0 ?elf-reproach, feels he has let people down. 
(41 I 20 Ideas of guilt or rumination over past errors or sinful deeds. 
3 D Present illness is a punishment. Delusions of guilt. 
(42) 
{43) 
(44) 
(45) 
(46) 
(471 
(48) 
{49) 
4 D Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations. 
oO 
,o 
20 
oO 
,o 
20 
oO 
,o 
20 
oO ,o 
20 
30 
Absent 
Feels life is not worth living. 
Wishes he were dead or any thoughts of possible death to self. 
Suicide ideas or gesture. 
Attempts at suicide (only serious attempt rates 4). 
No difficulty falling asteep. 
Complains of occasional difficulty falling asleep - i.e., more than 1 /2 hour. 
Complains of nightly difficulty falling asleep. 
No difficulty. 
Patient complains of being restless and disturbed during the night. 
Waking during the night - any getting out of bed rates 2 (except for purposes of voiding). 
No difficulty. 
Waking in early hours of the morning but goes back to sleep. 
Unable to fall asleep again if gets out of bed. 
No difficulty. 
Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies. 
Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect 
in listlessness, indecision and vacillation (feels he has to push self to work or activities). 
Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if 
patient does not spend at least three hours a day in activities (hospital job or hobbies), exclu-
sive of ward chores. 
4 D Stopped working because of present illness. In hospital, rate 4 if patient engages in no activi­
ties except ward chores. or if patient fails to perform ward chores un9ssisted. 
0 D Normal speech and thought. 
1 D Slight retardation at interview. 
2 0 Obvious retardation at interview. 
3 0 Interview difficult. 
4 0 Complete stupor. 
oO None 
1 0 "Playing with" hands, hair, etc. 
2 0 Hand-wringing. nail-biting, hair-pulling, biting of lips. 
0 D No difficulty. 
1 0 Subjective tension and irritability. 
2 D Worrying about minor matters. 
3 D Apprehensive attitude .:ipparent in face or speech. 
4 D Fears expressed without questioning. 
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Treatment 
Period 
(Check One) 
Base-
� 
End of Weck M Screen line 1 2 3 4 0 0 0 0 0 0 
(001) (002) (003) (004) (006) (008) 
1 •ATO<NT. O.O. NO. - - - -
FOR EACH ITEM CHECK THE BOX NEXT TO THE RESPONSE THAT BEST CHARACTERIZES THE PATIENT 
oO Absent Physiological concomitants of anxiety, such as: 
,o Mild Gastro-intestinal - dry mouth, wind, indigestion, diarrhea, cramps, belching 11. ANXIETY 
(SO) 20 Moderate Cardio-vascular - palpitations, headaches 
SOMATIC 30 Severe 
Respiratory - hyperventilation, sighing 
40 Incapacitating 
�:;:��:req� 
12. SOMATIC oo None 
SYMPTOMS 
(51) ,o Loss of appetite but eating without staff encouragement. Heavy feelings in abdomen. 
GASTRO- 20 Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels 
INTESTINAL or medication for G.I. symptoms. 
13. SOMATIC oO None 
SYPMTOMS (52) ,o Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy or fatigua-
GENERAL 
bility. 
20 Any clear-cut symptom rates 2. 
14. GENITAL oO Absent Symptoms such as: Loss of libido 
SYMPTOMS 
(53) ,o Mild Menstrual disturbances 
20 Severe 
oO Not present 
15. HYPOCHON- ,o Self-absorption (bodily) 
(54} 20 Preoccupation with health. DRIASIS 30 Frequent complaints, requests for help, etc. 
40 Hypochondrical delusions. 
A. WHEN RATING BY HISTORY: 
oO No weight loss. 
16. LOSS OF 
(55) ,o Probable weight loss associated with present illness. 
WEIGHT 20 
Definite (according to patient) weight loss. 
(Answer only B. ON WEEKLY RATINGS BY WARD PSYCHIATRIST, WHEN ACTUAL WEIGHT CHANGES 
ARE MEASURED: 
AorB) oO Less than 1 lb. weight loss in week. 
(56) ,o Greater that 1 lb. weight loss in week. 
20 Greater that 2 lb. weight loss in week. 
oO Acknowledges being depressed and ill. 
17. INSIGHT (57) ,o Acknowledges illness but attributes cause to bad food, climate, overwork,virus,need for rest,etc. 
20 Denies being ill at all. 
{58} (59) 
AM PM 
18. DIURNAL oO oo Absent If symptoms are worse in the morning or evening note which it is and rate 
VARIATION ,o ,o Mild severity of variation. 
20 20 Severe 
19. DEPERSONAL· oO Absent 
IZATION AND ,o Mild Such as: Feelings of unreality 
DEREALIZA-
(60) 20 Moderate Nihilistic ideas 
TION 30 Severe 40 Incapacitating 
oo None 
0. PARANOID ,o Suspicious {611 
SYMPTOMS 20 Ideas of reference 
30 Delusions of reference and persecution 
1. OBSESSIONAL oO AND Absent 
COMPULSIVE 
(62) ,o Mild 
SYMPTOMS 20 Severe 
TIGATOR'S SIGNATURE: 
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